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Abstract

THE IMPACT OF IMPRECISION IN HCV VIRAL LOAD TEST RESULTS ON
CLINICIANS’ THERAPEUTIC MANAGEMENT DECISIONS AND ON THE ECONOMIC
VALUE OF THE TEST
By Roberta Marie Madej, MS, MBA
A dissertation submitted in partial fulfillment of the requirements for the degree of
Doctor of Philosophy at Virginia Commonwealth University
Virginia Commonwealth University, 2013
Major Director: William J. Korzun, Ph.D., Associate Professor
Department of Clinical Laboratory Sciences

Clinical laboratory test results are integral to patient management. Important aspects of
laboratory tests’ contributions are the use of the test information and the role they have in
facilitating efficient and effective use of healthcare resources. Methods of measuring those
contributions were examined using quantitative HCV RNA test results (HCV VL) in therapeutic
management decisions as a model. Test precision is important in those decisions; therefore, the
clinical use was evaluated by studying the impact that knowledge of inherent assay imprecision
had on clinicians’ decisions.
A survey describing a simulated patient at a decision point for HCV triple-combination
therapy management was sent to 1491 hepatology clinicians. Participants saw HCV RNA results
at five different levels and were asked to choose to: continue therapy, discontinue therapy, or
repeat the test. Test results were presented both with and without the 95% confidence intervals

(CIs). Three of the VLs had CIs that overlapped the therapeutic decision level. Participants saw
both sets of results in random order. Demographics and practice preferences were also surveyed.
One-hundred-thirty-eight responses were received. Adherence to clinical guidelines was
demonstrated in self-reported behaviors and in most decisions. However, participants chose to
repeat the test up to 37% of the time. The impact of the knowledge of assay imprecision did not
have a statistically significant effect on clinicians’ decisions.
To determine economic value, an analytic decision-tree model was developed. Transition
probabilities, costs, and Quality of Life values were derived from published literature. Survey
respondents’ decisions were used as model inputs. Across all HCV VL levels, the calculated test
value was approximately $2600, with up to $17,000 in treatment-related cost savings per patient
at higher HCV VLs. The test value prevailed regardless of the presence or absence of CIs, and
despite repeat testing.
The calculated value in cost savings/patient was up to 100 times the investment for HCV VL
testing. Laboratory tests are investments in efficient uses of healthcare resources. Proper
interpretation and use of their information is integral to that value. This type of analysis can
inform institutional decisions and higher level policy discussions.

Chapter One: Introduction

Clinical laboratory test results are integral to patient care and management. At times the
information provided by test results is pivotal in the choice or evaluation of a clinical strategy.
Laboratory results are also used in developing, implementing and measuring the outcomes of
clinical practice and evidence based medicine. Whether a clinician is screening individuals to
determine disease risk, testing to inform diagnosis or prognosis, monitoring disease states,
managing chronic health conditions, or individualizing therapeutic interventions, laboratory test
information contributes to shaping the utilization of other medical services. Laboratory test
results are used in quality measures of healthcare, objective clinical outcome measures, pay-forperformance measures, and as factual evidence in therapeutic clinical trials (The Lewin Group,
2005, 2008). While those who use laboratory test information may consider test results
unconditionally robust, laboratory professionals understand that they are produced by assays,
instruments, processes and people, all of which contribute to imprecision in that information.
Clinicians and policy makers may not recognize the limitations of test results that can arise from
the variability in the three phases of laboratory testing (pre-examination, examination and postexamination phases). These limitations should be considered when interpreting the results.
Furthermore, they may not appreciate the strategies laboratory professionals develop to mitigate
test result variability. Even for tests where little imprecision exists, research shows that
laboratory test information is not always interpreted or used correctly. The concepts of disease
probability are difficult, and management plans derived from test results may not be followed
1

optimally (Bramwell, West, & Salmon, 2006; Cahan, Gilon, Manor, & Paltiel, 2003; Gosh,
Gosh, & Erwin, 2003; Steurer, Fischer, Bachmann. Koller & der Reit, 2002). This adds another
facet to the quality and consistency of laboratory tests; the quality of the outcome of test
information is dependent on the correct and optimal use of the results.
Conversely, laboratory professionals, whose customary focus are implementing the strategies
to produce the most precise and accurate result, may not be aware of the broadest use of the test
information by clinicians and policy makers. Evaluations of clinical laboratory tests have
traditionally centered on the analytical characteristics of assay methods. The conventional
laboratory test implementation plan includes verification or validation of sensitivity, specificity,
precision, accuracy, reproducibility, and reportable range of the examination phase by best
practice (Clinical and laboratory Standards Institute [CLSI] EP5A2, 2004; CLSI EP15A2, 2005)
and in the United States, by law (Clinical Laboratory Improvement Act, 2003; Medical Device
Quality Systems Regulation, 2008). The adoption of broader quality systems practices now
necessitate consideration of the pre and post examination phases as part of the total testing
process (CLSI GP26A3, 2004). In the fullest scope of practice, laboratory professionals are
moving beyond the focused analytical evaluations to consider the applicability of the measurand
to the disease process. However, there is little formal work assessing how the information
generated from laboratory testing is interpreted and incorporated into the medical decisionmaking process. This is becoming more necessary as the field of companion diagnostics grows,
and constraints in healthcare resources demand that the most effective, informative and efficient
services and interventions be used.
Medical providers have the responsibility to evaluate and employ those interventions and
services that will provide the best outcome for their patients and for the healthcare system
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(Huninck et al., 2006; Price & Christenson, 2007). Clinical laboratory tests can be valuable tools
in this effort, and are also subject to the same standard. The ultimate value of a laboratory test is
more completely determined by its informative impact in medical decisions. The proper test
must be ordered, and the information interpreted in context of the limitations of the tests and of
the specific characteristics of the patient (Lundberg, 1998; Price & Christenson, 2007; Van
Walraven & Naylor, 1998). The analytical characteristics of the test, the implementation of the
test, and the actual performance of the test, added to its interpretation and application by the
medical decision maker, define the utility and value of the results. It is important then as part of
an assessment of a laboratory test’s clinical utility, to understand the uses of that test’s
information, particularly when those uses are integrated in clinical practice guidelines.
With the increasing scrutiny on the most effective use of healthcare resources, it is also
important to understand the economic value that laboratory tests have in the healthcare system.
In most cases, they are used as information to reduce the uncertainty in medical decisions.
Growing demands on expanding technological choices and resources require prudent utilization
of healthcare dollars, and provoke increasing demands for evidence-based information as well as
for the evaluation of how that information is used (Drummond & Sculpher, 2006; Tunis, 2004).
Health economics has been employed for nearly two decades in some countries for the selection,
pricing and reimbursement of therapeutics, and it is now being applied to a broader scope of
health care services and programs (Drummond & Sculpher, 2006). In the United Kingdom, the
National Health Service’s (NHS) National Institute for Clinical Excellence (NICE) describes the
process for evaluating healthcare technologies in three guidance documents: Updated guide to
the Methods of Technology Appraisals (NICE, 2008), Guide to Single Technology Appraisal
Process (NICE, 2010) and Guide to the Multiple Technology Appraisal Process (NICE, 2010).
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Clinical effectiveness and cost effectiveness are aspects of the appraisals for those technologies
approved by the NHS. An important aspect of technology assessment in the United Kingdom
now includes the projected financial impact on healthcare resources. It is incumbent on the
sponsor of a drug, intervention or device to demonstrate its cost effectiveness. There are now
various types of Health Technology Assessment (HTA) requirements, which include clinical and
economic evaluations in over 30 countries. A European collaborative project, the European
Network for HTA (EUnetHTA) has been established in response to the need for developing a
sustainable network to define and refine practices in this area (Minshall, 2008; Kristensen, 2008).
The United States is also playing a role in these developments. The Agency for Healthcare
Research and Quality (AHRQ) is a partner organization to EUnetHTA and guidelines for
submission of economic assessments of therapeutics are already established (Fry, Avery, &
Sullivan, 2003). As a part of the American Recovery and Reinvestment Act, the United States
committed billions of dollars for comparative effectiveness research (CER), measuring costs and
clinical utility of interventions, technologies, and services (Gaba, 2009). As one of the 12
agencies within the U.S. Department of Health and Human Services, the Agency for Health
Research and Quality funds and disseminates comparative effectiveness and technology
assessment research (http://www.ahrq.gov/about/).
Clinical laboratory testing, which has provided benchmark and experimental endpoint data to
many health economic studies of therapeutics, devices and services, is now becoming the subject
of these types of analyses; and its importance is growing. For example, while concerned with
providing broader access to the appropriate use of genetic test results, the Secretary’s Advisory
Committee on Genetics Health and Society (SACGHS) made its first recommendation that
evidence based information to drive coverage policies for that access (SACGHS, 2006).
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Pharmacoeconomic experts criticize the lack of utility and value evidence for diagnostics
(Ramsey et al., 2006). Because non-laboratory clinical interventions are different from
laboratory information services, it is essential that methods to evaluate the clinical and economic
utility of laboratory tests be appropriate to in vitro diagnostics.
HCV Viral Load Testing: A Model
The laboratory tests that drive the decisions for Hepatitis C disease management provide one
model to examine the value of those tests in the decision-making process. Hepatitis C viral load
assays (HCV VL) quantitatively measure the amount of HCV RNA in patients’ plasma by
nucleic acid testing (NAT), and the test results are a surrogate marker for the disease burden.
HCV VL was integral to research on the natural history of the disease and is used in the clinical
trials of therapeutics to treat it. The test now has a role in determining the management path of
HCV patients. The American Association for Liver Diseases (AASLD) Clinical Practice
guidelines and the American Gastroenterological Association recommend quantitative HCV
RNA testing for viral load at several points during the diagnosis and management of the disease
(Dienstag & McHutchinson, 2006; Ghany, Strader, Thomas, & Seeff , 2009; Ghany, Nelson,
Strader, Thomas, & Seeff, 2011). HCV Viral load is considered one of the main sources of
information for tailoring therapy and monitoring compliance (Chevaliez & Pawlotsky, 2009;
Mangia et al., 2008; Paxton, 2011; Terrault et al., 2005; Zeuzem et al., 2003). The latest triple
combination therapies for HCV genotype 1 patients include specific treatment recommendations
based on absolute values of HCV VL (Ghany et al., 2011; Merck Sharp & Dohme Corporation,
2011; Vertex Corporation, 2011). Though HCV VL results are used as absolute values or
relative value changes, there is little discussion of the inherent variability in viral load results
except the published recommendations that patients be monitored with the same test throughout
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their course. Global proficiency test assessments and shared-sample studies have demonstrated
the variability in NAT (Best, Gust, Johnson, McGavin, & Dax, 2000; Schirm, van Loon,
Valentine-Thon, Klapper, Reid, & Cleator, 2002; Yen-Lieberman et al., 1996). Practicing
clinicians and laboratory professionals have published their observations regarding the variability
of the assays and their possible impact on the decisions being made (Laperche et al., 2007,
Pawlotsky, 1997). There are few professionals who serve in both capacities, and as VL testing
becomes more mainstream, clinicians’ understanding of this variability and its resulting impact
on their decisions have not been studied.
Statement of Problem
Conventional assessments of diagnostic tests are technically oriented and focus on the
performance characteristics of the analytical process and technologies. Diagnostic tests,
however, are tools that produce information which is used in medical decisions. As it informs a
decision, there are two significant variables to the contribution of a diagnostic test: 1) the overall
test performance and 2) the use of the information. These are interdependent and contribute to
the assessment of the utility and resulting value of a clinical laboratory test. An example of this
is found in HCV VL testing to determine and direct treatment strategies. The test and methods
have been technically validated and clinical trials support the basic utility of the results.
Understanding the limitations, the use of the information resulting from these tests by clinicians,
and the influence that knowledge of the limitations may have on their decisions have not been
evaluated. Additionally, the value that the test information brings to specific healthcare
situations and, if this value changes with the quality of the test, have not been assessed.
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Research Questions
Will knowledge of the imprecision in quantitative laboratory test results affect clinicians’ use
of the information in managing patients? Can this be measured?
Can health economic tools (decision analytic models) be used to determine the value of
laboratory test information?
Will changes in the use of test information result in changes in the value of the laboratory
test?
Research Hypotheses and Objectives
This research studied the decisions made by clinicians using the viral load results from
quantitative HCV RNA tests, with and without knowledge of the test imprecision (expressed as
the 95% confidence intervals). In addition to determining if there were changes in decisions
associated with the knowledge, the value of the test information was calculated using a decision
analytic model. The overall objective was to determine if the clinical utility (CU), measured as
patient management decisions of clinicians using the results and the value of the laboratory test
information measured by cost savings, will change if clinicians are aware of the imprecision of
the results.
Null Hypotheses
The hypotheses for this research were:
H1 null hypothesis: The presentation of HCV VL results with 95% confidence intervals will
have no impact on the treatment decision for HCV genotype 1 patients.
H2 null hypothesis. There is no difference in the impact of awareness of CIs on the treatment
decisions between different levels of HCV VL.
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H3 null hypothesis. Clinicians’ experience and demographics will have no impact on
treatment decisions using HCV VL results presented with and without confidence intervals.
The Value of Clinical Laboratory Test Information in Healthcare
In addition to testing the hypotheses, the impact of these decisions on the economic value of
the test information was evaluated through the use of decision analytic model outcomes.
Study Design
A non-experimental design using a survey targeted to a specific cohort of decision makers
was employed. The survey was developed for clinicians who use HCV VL test results in the
management of their chronic HCV patients. A defined clinical scenario was used describing a
simulated HCV genotype 1 patient who had just completed 12 weeks of triple combination
therapy with telaprevir, pegylated interferon-alpha and ribavirin. Different levels of quantitative
HCV RNA results for the patient were presented to survey participants in the traditional manner,
without confidence intervals, and also with the range of results that represent the 95% confidence
intervals, which is an expression of the imprecision of the test. The order of presentation of
these two sets of results was randomized. Participants were asked to decide whether to continue
the patient onto double combination therapy, to discontinue therapy, or to repeat the test. The
distribution of responses was analyzed for differences in the likelihood of using the test
information (not repeating the test) as well as differences in the ultimate therapy decision made
by those who used the test result. Further, the proportions of clinicians selecting each of the
possible options were used to populate a decision analytic model of the case. Through the model,
the expected value of the test results at each VL level and in a population of mixed VL levels,
with and without corresponding confidence intervals was calculated.
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Rationale for this Study
This research evaluated some of the interrelated factors in the provision and use of quality
laboratory test results. In order for laboratory test information to be effective, the result must be
robust and it must be interpreted and used appropriately in the correct context. As information
providers, laboratory professionals make assumptions about the understanding and application of
the information by the receivers of it without really knowing if those assumptions are accurate.
This research examined whether the knowledge of the inherent imprecision of VL assays
changes the decisions clinicians will make from those test results. There are recommendations to
routinely report or make available on request the imprecision budgets with laboratory test results
(CLSI C51A, 2011); yet there is no research to show that this addition would provide quality
information to the clinician or to the patient. In addition, because the survey in this study was
based on a well-defined clinical path where the use of the test is recommended to drive a specific
treatment management decision, intended adherence to these guidelines was also evaluated.
The quality of a laboratory test result and its use in practice influences its value. Current
health economic publications use clinical pathways and decision analytic models, assuming that
clinicians invariably make the most suitable patient management choice based on the information
received. Research has shown that this presumption is simplistic (Bramwell et al., 2006; Steurer
et al., 2002), and that the consequences of misinterpretation and misuse of test results are not
well understood or appreciated (Gandhi et al., 2006). Additionally, the actual use of information
by clinicians, is rarely considered in health economic analyses.
In addition to patient diagnosis, prognosis, and medical management, the results of laboratory
tests are inputs and endpoints in clinical trials and shape health economic assessment models;
however, the value of the test information itself is not routinely measured or discussed. When
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economic analyses of laboratory tests are undertaken, tools commonly used such as cost-benefit,
cost-effectiveness and cost-utility analyses may not fully define the true impact of the
information. Therefore, exploring the use of value calculations and clinical utility measures to
evaluate the contributions of laboratory tests is important to the field of clinical laboratory
science, health economics research, and healthcare resource assessment.
This study examined elements of the assumptions in current clinical research: the
development of clinical decisions based on laboratory test information, compliance with
guidelines in the face of test limitations, and the appropriateness of current methodologies to
study laboratory test contributions to healthcare. The objective is that the outcome of this work
provides insight, strategies, and tools specific to the assessment of laboratory test information’s
utility and value. If successful, these tools could be applied to other value analyses of laboratory
tests in diverse healthcare situations.
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Chapter Two: Literature Review

Clinical Laboratory Testing in Healthcare
Clinical laboratory testing is pervasive in most aspects of healthcare. Approximately 6.8
billion laboratory tests are performed annually in the United States. Over 4,000 different tests are
available for clinical use, and approximately 500 of the over 1,162 tests reimbursed by Medicare
are performed on a regular basis. In addition to being used as indicators of wellness, disease and
patient treatment management, the results from testing are used in public health surveillance, in
clinical trials, and in research. (The Lewin Group, 2008.)
Laboratory testing contributes to health management decisions from birth. Approximately
four million newborns are screened by tests for congenital and metabolic disorders annually
(Little & Lewis, 2008). For the 5,000 infants with severe disorders, more specific testing, and
for some, life-long monitoring by laboratory tests will follow. Adults are accustomed to periodic
screening tests such as cholesterol, fasting blood glucose, fecal occult blood, urinalysis,
Papanicolaou (Pap) testing and prostate specific antigen (PSA) tests. Not only are test results
incorporated into specific guidelines (America Diabetes Association [ADA], 2010; Nelson,
Moser, Gaffey, & Waldron, 2009), but a majority of adults expect and desire these as part of
their routine physical examinations (Oboler, Prochazka, Gonzales, Xu, & Anderson, 2002).
Advancements in treatment modalities, technological progress, and easy access to rapidly
disseminated research information have facilitated the implementation of a growing number of
new applications for medical laboratory testing. A relevant example of this is the establishment
11

of molecular tests to direct, monitor and manage patients with serious viral infections such as
human immunodeficiency virus (HIV), hepatitis B virus (HBV) and hepatitis C virus (HCV).
The role of quantitative molecular assays for viral load testing has been the subject of
investigation and debate in several viral diseases since technological improvements made this
type of measurement feasible and more robust. The precision and reproducibility of these tests
continues to be discussed, particularly as they are integral to therapeutic management decisions
(Chevaliez & Pawlotsky, 2009; Pisani et al., 2009).
Nucleic acid quantification for viral load was first applied in AIDS research to estimate the
extent of HIV infection by measuring the number of RNA genome copies in the plasma (Ho,
1996). As molecular techniques were further refined, greater understanding of the pathogenicity
of the virus, disease prognosis, and treatment success indicators developed (Mellors et al., 1996).
Viral load measurements became surrogate markers of disease clearance in therapeutic trials; and
the data gathered from those trials were applied to patient management guidelines when the
agents were approved for therapy. Quantitative HIV RNA testing used with CD4+ counts for
therapy initiation and serial quantitative HIV RNA tests for monitoring viral load during therapy
are now part of standard practice in the management of AIDS (Hammer et al., 2008). Similar
strategies have been applied to other viral diseases and several quantitative molecular assays
have become integrated into patient management protocols. Examples include quantitative HBV
DNA with genotyping assays which are integral to the selection of appropriate therapeutic
regimens for hepatitis patients (Valsamakis, 2007). Quantitative HCV RNA tests are used to
monitor patients on therapy, detect drug resistance, and follow patient compliance (Ghany et al.,
2009; Paxton, 2011). Further, human cytomegalovirus (HCMV) viral load results distinguish
between viral disease and organ rejection in transplant patients, facilitating the appropriate
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choice between conflicting management strategies (Griffiths, Whitley, Snydman, Singh, &
Boeckh, 2008).
The adoption of molecular viral load markers is one example of similar scenarios utilizing test
results as evidence in clinical practice guideline development and in patient management
decisions. The expanding recognition of companion diagnostics and the utilization of laboratory
test results in all aspects of healthcare present the medical community with the challenge of
determining their most effective and efficient applications. Consequently, when evaluating new
laboratory tests, investigations of clinical utility and economic value will become as necessary as
assessing analytical performance and clinical outcomes (Ramsey et al., 2006).
Clinical Utility: How Clinicians Use and Value Laboratory Test Information
Today the comprehensive assessment of necessary medical services includes an evaluation of
clinical utility. The term clinical utility is used throughout healthcare but remains subjectively
interpreted. First appearing in medical literature in 1961, its use has increased steadily, though a
single consensus definition has not been developed (Smart, 2006). The characterization of
clinical utility often reflects the perspective of the stakeholder; and the outcomes measured
delineate the scope. For a laboratory test, clinical utility encompasses more than just the ability
of the result to define a clinical state or disease. It is a multidimensional parameter in which the
stakeholders are patients, clinicians, and others in healthcare. Evidence that a test result
facilitates improved patient outcomes or that it is useful to those making medical decisions have
been offered as definitions (The Lewin Group, 2009). Broader descriptions include economic
and social outcomes (Grosse & Khoury, 2006).
A search of the term clinical utility in the medical literature identified several common
attributes synonymous with clinical effectiveness. From the clinician’s perspective, four main

13

characteristics are considered: appropriateness, acceptability, practicability and accessibility. For
a service or an intervention to be appropriate, clinical evidence should demonstrate its impact on
treatment and its importance to clinical decision making. To be acceptable, the effect on a
patient’s course, quality of life, and on the clinician’s practice, are considered. The training and
knowledge needed to implement the service and to maintain the functionality of using it are
characteristics of practicability. Accessibility incorporates availability, costs, cost effectiveness
and resources (Smart, 2006).
For laboratory tests, characteristics of appropriateness and acceptability, as defined here, are
normally assessed when new tests are established. By regulation, manufacturers who sell in vitro
diagnostic tests in the United States must submit data supporting the safety and effectiveness of
their tests, either by showing substantial equivalence to pre-existing tests or demonstrating it
through studies. The intended use of the test in question, the relative risk of the test and its
placement in the healthcare system all impact the type of submission and the data needed to
support it (USFDA 21CFR807, 21CRF814, 21CFR860). This is accomplished through clinical
trials, where the new tests are validated analytically and evaluated according to clinical
outcomes, or compared to other tests for which clinical outcomes have been established.
Depending on the test and the scientific environment, intended use statements, clinical and
professional guidelines, and marketing or post-market studies may incorporate the medical
decisions to be made and the impact the test may have on patient care. Less well studied are the
practicability and accessibility characteristics of clinical utility, those that incorporate clinician
behaviors and economic effectiveness.
Clinicians are the gatekeepers to medical care and are the predominant prescribers and users
of laboratory tests. It is appropriate then, to evaluate clinical utility from their perspective.
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Clinicians interpret and utilize laboratory test results as one of their criteria in tailoring available
treatment strategies to the medical and quality-of-life needs of their patients. The clinical utility
of a laboratory test depends on the clinician’s ability to prescribe it appropriately and to use the
information derived from it effectively and correctly. This in turn depends on their
understanding of the clinical information provided by the test and the limitations of the method.
These are elements of the practicability aspect of clinical utility.
There is some published research regarding clinicians’ understanding and use of diagnostic
information, but less on the specific subject of laboratory test information interpretation and use.
Because laboratory test results inform varied clinical states and stages, it is difficult to generalize
the depth and breadth of understanding needed to apply them with only a few studies. Some test
applications are a one-to-one correlation of result and disease state, while others demand a
working knowledge of probability and risk, and still others require interpretation along a
quantitative continuum. What has been demonstrated, though, is that many clinicians have
difficulty with the practical applications of the concepts used to fully apply diagnostic
information. Some examples follow.
Fifty practitioners in Australia completed self-assessment questionnaires where they rated
their ability to understand and describe evidence-based medicine terms such as relative risk,
absolute risk, sensitivity, specificity and positive predictive value (PPV). For each of the terms,
there were only 14-30% positive responses to the question of whether they could understand and
explain the term to others. In post-survey assessment interviews where the same physicians were
asked to explain the terms, only three of the practitioners met some of description criteria: two
partially explained the term, numbers needed to treat (NNT), and one satisfactorily explained
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sensitivity. This study illustrated the practitioners’ difficulty with the terms and also their
inability to realistically assess their shortcomings (Young, Glasziou, & Ward, 2002).
In another study, researchers in Switzerland surveyed 263 general practice physicians to
evaluate which types of additional test information would most effectively aid physicians’ in
correctly determining the probability of a patient having a disease. Their study also gave insight
to physicians’ ability to practically apply sensitivity and predictive values (Streurer et al., 2002).
They designed a two-part survey, the first part consisting of multiple choice selections of
definitions for sensitivity and PPV. In addition to answering the multiple choice questions,
subjects were asked to calculate the probability of disease in a patient with a positive test. They
were given the test characteristics of 95% sensitivity, 95% specificity, a population prevalence of
1%, and a range of choices for answers. Though 76% and 61% of the physicians chose the
correct definitions for sensitivity and PPV, respectively, only 22% made the correct selection of
less than or equal to 25% for the probability of disease in the presence of a positive test result
(56% selected the choice of “nearly 100 %”). On first examination, the results seem more
encouraging than the Australian group’s findings, even with a large proportion of subjects
selecting the grossly wrong PPV of near 100%. However, there are key differences. In this
study, the participants were given a choice of definitions, as opposed to having their own
definition scored against expected terms. Also, answers for the probability calculation were split
into ranges and presented as selections. The large difference in percent correct for the definitions
versus the percent correct for the PPV calculation illustrates a deficit in the ability to apply the
information, even though the definitions could be memorized or reasoned.
In the second part of the survey, the participants were asked to estimate the probability of
endometrial cancer in a 65 year old woman with abnormal uterine bleeding and were given 10%
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as the prevalence of endometrial cancer in women with abnormal bleeding. The original group
was split into three sub groups and each third received the results of a positive transvaginal
ultrasound test in a different manner. One sub group received only the result (“pathological
result compatible with cancer”). The second group received the result plus the sensitivity and
specificity of the test; and the third received the result plus simple wording of the likelihood ratio
of a positive test: “A positive test is obtained twice as frequently in women with an endometrial
cancer than in those without the disease.” In this phase of the study, the group that had only the
positive test result grossly overestimated the probability of disease; those given numerical values
for sensitivity and specificity gave a significantly lower estimate; and those for whom the test
characteristics were described in simple words, gave an estimate of likelihood closest to that
found in literature based groups. However, in a later analysis of the data, it was determined that
the “simplified language” approach may have provided an opportunity to incorrectly apply a
mathematical calculation that coincidently resulted in a number close to the correct one. In the
amended analysis, it was still concluded that the added quantitative information regarding the
test characteristics moderated the physicians’ tendencies to overestimate the probability of
disease (group one vs. group two plus group three). However, the comparison between the type
of information provided, or comparing group three alone with group one in a stricter analysis
were no longer statistically significant (Bachmann, Steurer, & ter Reit, 2003). The impact to the
patient of overestimating or underestimating the probability of disease is specific to each clinical
case and was not addressed by this study. It does raise the question of clinicians’ expectations of
the diagnostic utility of tests and the possibility that prejudicial expectations could lead to the
incorrect application of the information. Inaccurate high expectations of utility can lead to
inappropriate overuse of tests.
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Of concern is that physicians’ over-estimation of the pre-test probabilities of medical
conditions in their patients could lead to improper test usage and bias of interpretations test
results in support of the original assessments. To understand clinicians’ ability to ration the
probabilities of possible clinical conditions for a single patient, physicians and residents in
another study were presented with a patient scenario and five possible clinical conditions for the
symptomology and evidence. They were asked to estimate the probabilities of each condition for
the patient in the scenario. Of the 84 physicians tested, 65% of them determined probabilities for
each condition such that the total exceeded 100% (Cahan et al., 2003). This finding is not
uncommon. Misapplying pre-test probabilities and baseline risks, as well as incorrect PPV
calculations were recurrent findings in several other studies on this topic (Bramwell et al., 2006;
Ghosh & Ghosh, 2004; Heller, Sandars, Patterson & McElduff, 2004).
The research discussed thus far focuses on qualitative tests, pre-and post-test probabilities and
analysis of patient risk. There are few studies focused on the topic of the impact that clinicians’
awareness of quantitative test imprecision will have on their decisions. A rare number of clinical
guidelines exist that specify the use of tests with defined criteria for precision, such as those for
cholesterol in lipid management and troponin in the assessment of cardiac arrest (National
Cholesterol Education Program Laboratory Standardization Panel, 1988; Thygessen et al., 2012).
Clinical specialists and physicians associated with laboratory practice have published their
observations of test variability, examining analytical and biological sources; discussed the
possible impacts, and have made recommendations for mitigation in laboratory practice, but not
in medical practice (Fraser, 2003; Plebani, 2004). One example is an examination of the
variability of creatinine measurements on the calculations of estimated glomerular filtration rate
(eGFR) and the impact it has on the classification of renal disease (Klee, Schryver, Saenger, &
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Larsen, 2007). Consecutive blood samples from patients were used to analyze the within-subject
variance of creatinine testing, and mathematical simulation was used to create scenarios of
different creatinine levels with varied levels of imprecision. It was determined that a 20 µmol/L
negative shift in creatinine nearly doubled the percentage of patients classified as having
decreased renal function, and the same positive shift nearly halved the percent.
Recommendations for stringent control of the laboratory methods were made, but there was no
mention of the need to understand or mitigate the influence of the variation on physicians’
interpretations. In addition there was no recommendation to assess what physicians’ actual
interpretation would be for results very near the decision breakpoints.
Observations of imprecision in molecular viral load assays have led some practicing
specialists to question patient monitoring results and recommend further comparative studies
(Pawlotsky, 1997). However, no studies such as those described previously, addressing
practicing clinicians’ understanding of pre and post-test probability, PPV and likelihood ratios,
or their understanding of the variation in the quantitative test results could be found in the
literature, nor were they recommended by any of the researchers.
The clinical laboratory and regulatory communities have recognized the importance of the
variability surrounding quantitative results and the possible implication this could have on the
clinical utility of laboratory tests. This is most evident in the International Standards
Organization’s (ISO) requirements for determining and reporting the uncertainty for test methods
in the 2012 standards for quality and competence in medical laboratories, and in guidelines
developed to help laboratories provide this information (ISO, 2012 ; CLSI C51A, 2011). Studies
of clinicians’ understanding and application of these potentially confusing issues are necessary.
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The provision of such information, along with quantitative results and reference ranges, could
impact the clinical utility of current and future laboratory tests.
Optimal use of laboratory tests depends intrinsically on physicians’ abilities to correctly apply
the information derived from them in practice. This requires that they understand more than the
results, the reference ranges, and the diagnostic conditions supported, but also the limitations of
the test producing the results, and the robustness of that result in the context of clinical practice.
When developing tests, calibrating the result with clinical outcomes may provide correct answers
and have analytic value, making the test appropriate and acceptable; but it may not have
complete clinical utility as used in routine practice. Studies measuring clinicians’ interpretation,
understanding, and use of quantitative information (i.e., the practicability aspect of clinical
utility) are necessary.
Health Economics and the Assessment of Value
Growing demands for healthcare resources, escalating utilization and expanding technology
options, require judicious allocation of those resources. Choosing appropriate services and
interventions amid technology abundance and resource constraints is difficult. Yet physicians in
their role as gatekeepers to healthcare services, must consider the most efficient and effective use
of interventions and tools. Policy leaders also need clear, concise, and commutable data to
inform their debates and decisions as they determine standard practice protocols and
reimbursement strategies. To evaluate laboratory tests in this environment, the accessibility
aspect of clinical utility must be considered in addition to analytical and clinical performance
characteristics. This includes how the test augments or replaces conventional practices, the costs
to the system, the benefits generated, and the resources needed to maintain the testing services.
Laboratory tests are vehicles that provide information to reduce uncertainty in medical decisions.
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New tests can be categorized as those that provide completely new information (as in a new
analyte), refine existing diagnostic information, or provide similar information to what is
available through the use of new technology. When evaluating the accessibility of a test, the
information provided by the test as well as the resources needed to establish, maintain and
effectively utilize the results from the test should be considered.
Evaluating the accessibility of a health care intervention or service includes demonstrating its
value to the system in communicable terms. Led by the Australians in the 1990s, several
countries have adopted a range of methods in the field of health economics (HE) to substantiate
the utilization and reimbursement of therapeutics (Drummond & Sculpher, 2006). These
methods are now incorporated into more expansive Health Technology Assessments (HTA) and
are being applied to a broader scope of health care services and programs. HTA covers an
expanded analysis of health technologies using the information from technical and clinical costeffectiveness research and evidence based medicine (EBM) to evaluate where to place the
technology relative to current practice and resources. In a global survey by the HTA principles
working group of the International Society for Pharmacoeconomics and Outcomes Research
(ISPOR), the term is defined as “the careful evaluation of a medical or health technology for
evidence of its safety, efficacy, cost, cost-effectiveness and ethical and legal implications, both in
absolute terms and in comparison with other competing technologies.” (Stephens, Handke, &
Doshi, 2010).
In the United Kingdom, the National Health Service’s (NHS) National Institute for Clinical
Excellence (NICE) lays out the process for evaluating healthcare technologies in three guidance
documents: Updated Guide to the Methods of Technology Appraisals (NICE, 2008), Guide to
Single Technology Appraisal Process (NICE, 2010) and Guide to the Multiple Technology
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Appraisal Process (NICE, 2010). Clinical effectiveness and cost effectiveness are key parts of
the submissions for approval by the NHS. The assessment includes the projected financial impact
of the new technology on national healthcare resources. It is incumbent on the sponsor of a drug,
intervention or device to demonstrate its cost effectiveness. Over 30 countries now employ some
type of HTA. The majority of stated purposes for these HTAs are for coverage decisions and
clinical guidance. Though the evaluation of costs is unpopular in many jurisdictions, a little over
half of HTAs formally include cost and cost effectiveness (Stephens et al., 2010).
In response to the rapid adoption of HTA, a European collaborative project, the European
Network for HTA (EUnetHTA) was established to develop a sustainable network defining and
refining practices in this area (Kristensen, 2008; Minshall, 2008). Though HTAs vary among
countries and even within countries, guiding principles to improve their conduct have been
published by key experts in the field. The principles cover the structure of HTAs, the methods
used, the processes for conduct, and the use of the HTA in healthcare decisions. The common
threads in all the principles are: defining specificity in purpose, equal application to all health
care goods and services and establishing processes for maintaining objectivity and transparency
(Drummond et al., 2008).
The United States is active in the global debate and in forming its own policies. The Agency
for Healthcare Research and Quality (AHRQ) is a partner organization in EUnetHTA. As a part
of the American Recovery and Reinvestment Act, the United States committed billions of dollars
for comparative effectiveness research (CER), measuring costs and clinical utility of
interventions, technologies, and services (Gaba, 2009). As one of the 12 agencies within the
U.S. Department of Health and Human Services, the Agency for Health Research and Quality
(AHRQ) funds and disseminates comparative effectiveness and technology assessment research
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(http://www.ahrq.gov/about/). The importance of these evaluations is growing and discussions
continue to develop the structure, methods, and metrics of these programs (Avron, 2009; Garber
& Tunis, 2009; Naik & Petersen, 2009). CER and HTAs are included in coverage with evidence
development (CED) programs that are used by the Centers for Medicare and Medicaid Services
(CMS) and large insurers for coverage and reimbursement decisions (Drummond et al., 2008).
With respect to testing, the Secretary’s Advisory Committee on Genetics Health and Society
(SACGHS), while concerned with providing broader access to the appropriate use of genetic test
results, listed as its first recommendation that evidence-based information drive coverage
policies to ensure access (SACGHS, 2006). Since guidelines for the submission of economic
assessments for therapeutics have already been established (Fry et al., 2003), health economists
criticize the lack of utility and value evidence for diagnostics and recommend the same standards
be applied to this field (Drummond et al., 2008; Ramsey et al., 2006).
New discoveries and rapid dispersion of information provide more options in a field of limited
resources. It is important then to assess the impact of applying economic methods developed for
pharmaceutical interventions on valuing diagnostic tests. These tools have not been used to
appraise laboratory tests in the past, so there are few specific guidelines with which to compare
the clinical and economic value of new tests and technologies. Pharmaceuticals are
interventions; their delivery, function and outcomes are essentially different from laboratory
tests, which supply information. From a laboratory test, there is usually an indirect and
interdependent path leading to the final patient outcome. The laboratory test result must be
recognized, understood, and used correctly in an intervention decision. The medical intervention
must then be applied (or not) to the patient, and must work as predicted to produce the intended
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outcome. It is essential to understand how current health economic methods can be suitably
applied to isolate the value of the laboratory test in this complex relationship.
Economic Assessments in Healthcare
Three elemental types of economic analyses permeate the literature for the appraisal of
therapeutics and interventions and are now being applied to evaluate laboratory tests: Costbenefit analyses (CBA), Cost-effectiveness analyses (CEA), and a specific type of CEA: Costutility analyses (CUA) (Bloom, 2004; Neumann, Greenberg, Olchanski, Stone, & Rosen, 2005;
Tunis, 2004). These assessments can provide information for decision making, but like
diagnostic tests in patient management, they should not be the sole source of the decision. The
elements of CBA, CEA and CUA are categorized in Table 1. Further detail is described in the
following sections.
Table 1
Types of Health Economic Analyses
Type of
Analysis
Cost Benefit
Analysis
(CBA)

What is it
asking?
What is the
added cost
for an added
benefit?

Identification Costs
Benefits
of Outcomes
Single or
Monetary Monetary
multiple
outcomes.

Report

Considerations

Benefit
/Cost
ratio
or NPV

Determine
monetary value
of intangibles

Cost
Effectiveness
Analysis
(CEA)

What is the
cost per unit
of outcome?

Single and
common
outcome.
Varying
degrees.

Monetary Natural
units

Cost /
natural
unit
selected

Determine the
threshold value
of the natural
units

Cost Utility
Analysis
(CUA)

What is the
cost per
desired unit
of outcome?

Single or
multiple
outcomes.
Varying
degrees.

Monetary Value:

Cost/
QALY
or
DALY

Threshold
values for cost
per QALY/
DALY

combination
of quant and
qual of life
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Cost-benefit analysis. In CBA all the costs and the benefits from the programs being
evaluated are converted to monetary terms. This method is employed in situations where market
indicators are not useful or they are non-existent (such as health care policy); and where
decisions must be made on projected future benefits. An investment can be considered favorable
if the money derived from benefits exceeds that of the costs. Many times this is expressed as a
ratio between the discounted net benefits (B) over the discounted net costs (C); if the benefit to
cost ratio (BCR) is greater than one, a test or medical intervention has value (Folland, Goodman,
& Stano, 1997). In theory, this statement is simple. However in reality, determining all costs,
sourcing appropriate data for them, and quantifying the benefits in monetary terms from the
proper perspective are challenges.
In CBA for clinical laboratory diagnostics, the costs include more than just the reagents and
personnel, or as often presented in pharmacoeconomic studies, the list price or reimbursement
price of the tests. The perspective of the analysis is an important issue in all health economic
studies; in CBA this will determine the inputs used. If the study perspective for a CBA is at the
institutional level, the costs to the institution beyond the clinical laboratory service, as well as the
benefits gained by the whole institution are quantified. For example, if analyzing the
introduction of a new test from the sole perspective of the laboratory, reagents, personnel,
training, and comparisons to the charges for sending the test to reference labs might be made.
The opportunity costs of using the space and resources for other laboratory tests might also be
considered. But when assessing the impact at the institutional level, inputs to the costs and the
benefits extend beyond the horizon of the laboratory and parameters such as patient length-ofstay, patient level of service, or physician utilization would be considered. CBA can be useful in
different scenarios such as decisions whether or not to order a test, methodology comparisons,
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and testing site comparisons (main laboratory vs. satellite or point-of-care service). The direct
and indirect costs and benefits, and opportunity costs are relatively tangible and straightforward
to measure in these narrowly focused CBAs.
Challenges emerge when clinical laboratory tests are discussed in the realm of total health
care services and where competing, non-test intervention options might exist. For example,
policy makers may compare the option of implementing a laboratory test or a different method of
diagnosis to direct patients to specific types of care; or compare the implementation of a testand-treat strategy to population vaccination for an infectious disease. In these situations, the
societal perspective is used; the scope is broadened and other types of costs, unfamiliar to
clinical laboratory professionals must be considered. In addition to capturing a broader scope of
direct and indirect costs and benefits, some may be intangible, requiring a transformation to
monetary value. This can be particularly challenging when intangibles, such as the value of a
service or the value of a life, must be determined. Methods to derive the willingness to pay can
be used for services, and several methods to estimate the value of an individual life are
continually assessed and calibrated (Johansson, 2003; Messonnier & Meltzer, 2003).
CBA for diagnostic testing should carry further considerations based on the performance
characteristics of the tests. Many past economic analyses of clinical programs assume that
testing is 100% correct. This may be appropriate when the test information is a small part of a
very large and complex study and its role is minimal. In more recent studies, where diagnostics
are the central focus of the analysis, or the test information is pivotal in determining or assessing
patient outcomes, the test performance characteristics play a key role in assessing the BCR.
Costs associated with false negative and with false positive results must be added to the
equations.
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CBA facilitates the comparison of different types of programs because it strips them down to
monetary measures, and when the net present value (NPV) of the BCR is calculated, CBA can
provide data to compare options with different time horizons. When deciding to implement
laboratory tests or programs surrounding the implementation of tests, when confronted with a
choice between different options, or when ranking priorities within a set budget, CBA can be
useful. Distilling options down to identical monetary units is in contrast to the other two
common tools used in health economics, Cost-effective analysis and Cost-utility analysis, where
the options compared are presented in terms of costs per unit of health outcome (Messonnier &
Meltzer, 2003).
Cost-effectiveness analysis. Cost-effectiveness analyses systematically consider alternative
approaches to an issue by comparing the costs and the consequences of each approach as they
impact an appropriately selected health-related outcome unit. What distinguishes CEA is that the
outcomes of all the alternatives are measured in the same unit and must be relevant to the clinical
objective (Berger, Bingefors, Hedblom, Pashos, & Torrance, 2003). Examples are life-years,
symptom free-days, and cases prevented. These are described as “natural units” (Drummond &
Sculpher, 2006). Compared to CBA, which assesses programs with different objectives (and
perhaps different outcomes); CEA evaluates programs with different approaches to the same
objective. The costs to obtain that objective are compared. Therefore, a single, measurable,
natural-unit outcome must be selected (Fos & Fine 2003).
CEAs are growing in popularity and are becoming the predominant method for evaluating the
costs and effects of alternative strategies in health care (Messonnier & Meltzer, 2003). The
programs and interventions being compared can be ranked, or several interventions can be
studied, each for their incremental cost effectiveness. The perspective in CEA is usually from a
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patient or public health view; and in CEA this perspective determines the outcomes measured.
When a laboratory test is being evaluated, the impact that the test has on extending patients’
lives, averting disease, or changing a specific state of health of patients is considered. The
challenge for laboratory testing is to demonstrate the direct impact of the test on the patient state.
An example of this is a new or more sensitive marker that informs the definitive treatment of
patients, such as a marker for stroke or acute myocardial infarction. By using the new marker,
the number of appropriately treated cases may increase. For this example, calculating the
positive or negative balance of all the costs and consequences, as in CBA, may not be useful. A
cost-effectiveness ratio (CER), the cost per life saved or the cost per complication averted, more
appropriately conveys the value of the outcome. When compared against the standard test, or no
test at all, an Incremental Cost Effectiveness Ratio (ICER) can be calculated illustrating the
incremental cost per life saved (or other natural outcome) of the program under consideration.
An issue for interpretation is assessing whether the value of the CER or the ICER is acceptable.
Few countries and jurisdictions have established thresholds for cost effectiveness.
Cost-utility analysis. Because CEA expresses costs per a specific biological unit,
interventions with different natural outcomes cannot be compared. In addition, there can be a
range of interpretations that decision makers may have regarding the comparative value of the
outcomes (e.g. determining the relative priority of blood pressure control compared to
cholesterol management or to a year of life). A further refinement in CEA is the Cost-utility
analysis. In CUA, the benefits or outcomes are expressed in parameters that account for quality
as well as the quantity of the benefit in Quality Adjusted Life Years (QALY) or Disability
Adjusted Life Years (DALY). QALYs are measures of mortality and the quality of life. The
quality of life is measured on a scale from 0 (death) to 1 (full health) and the time gained in the
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CEA is adjusted by the quality weight depending on the state of health (Gold et al., 1996 p. 88).
The QALY has become a standard currency in health economic evaluations. QALYs are most
useful when evaluating individual benefits in longer term outcomes. The values for QALYs
encompass the preferences of individuals for specific states of health, and they can be
determined in several ways. The important characteristic of these methods is that preference
weights are not subjectively assigned but are determined through individual surveys and are
published for use by researchers.
Less often used is the DALY. A DALY is defined as one year of healthy life lost due to death
or disability from the disease or condition in question. It is the sum of the years of life lost
(YLL) and the years of life with a disability (YLD) and thus, incorporates the time lost to death
at each age, disability weights, age weights and time preference (Fos & Fine, 2005). DALYs
provide a relative scale to compare different diseases and conditions, both physical and mental.
Since DALYs are calculated from a theoretical maximum life span, that maximum must be
carefully ascertained. For every subject studied, an individual life span should be calculated
based on health and risk factors for each (minus the condition in question). Because this is
impractical, actuarial data for specific populations are utilized. This makes the DALY a gross
measurement at best and comparable among studies only when all the conditions used in the
DALY calculation are transparent and pertinent. In addition to actuarial-determined life spans,
the quality of life ratings are assigned by health professionals, not the individuals suffering with
the disability. For these reasons, the DALY is considered less relevant.
CUA facilitates the comparison of programs producing different outcomes, as each is
translated into directly comparable QALYs or DALYs. For example, if policy makers are
deciding whether to institute a community smoking cessation or weight loss program, outcomes
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from a CUA would be presented as the cost per QALY for each option. For laboratory services,
a clinic might utilize CUA to decide between establishing a point-of-care cholesterol or a
prothrombin-time testing service for their outpatient community. The question being addressed
by CUA does not necessarily have to be a direct comparison of one or more options. Some
jurisdictions have explicit or implicit values for the reasonable cost of a QALY or DALY. In
those cases, if the analysis of a single option results in the cost/QALY less than the threshold, the
program can be considered economically viable.
An example of interpreting the relevance of a CER derived from a CUA is in an analysis of
Chlamydia trachomatis testing performed in The Netherlands. The impact of a systematic
screening-treatment program that included partner treatment for young Dutch adults was
evaluated for its impact on preventing the serious sequelae associated with the infection, pelvic
inflammatory disease (PID) and sterility (de Vries, van Bergen, de Jong-van den Berg, &
Postma, 2006). The calculated CER was €373 per major outcome averted (MOA). The only
benchmark available in The Netherlands at the time was a threshold of €20,000 /life-year gained
or QALY. In order to discuss the comparative relevance of their numbers, the researchers
applied recently published quality adjusted weights from the United States to each of the disease
states into their mathematical model to convert the events averted into QALYs. By this method,
the calculated overall cost was €1000 per QALY. Since this was far below the policy threshold,
they concluded that the program was cost effective.
Decision analysis and mathematical models. Health economic evaluations are commonly
performed by constructing and populating mathematical models. The models may extrapolate
data from clinical trials, or extract data from several sources including literature and public
records. As models, they cannot duplicate life situations, so this limits applicability to the
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assumptions made in building them. However, it can also be argued, that randomized clinical
trials, considered the gold standard scientific in evidence gathering, also can have limitations in
scope and applicability. In clinical trials, well-controlled patient selection criteria, strict
operational management, and finite timelines, result in a representative sample and conditions
that may not necessarily be generalize able to an entire population for a longer horizon.
Mathematical models can incorporate the results from several trials, meta-analyses of
publications, and numerous databases and can represent many scenarios. The assumptions in
models, though limited, are transparent, and the impact of key assumptions can be tested in
sensitivity analyses. Neither represents the total solution in healthcare policy analysis. Both
should be used alone or in combination, with knowledge of the limitations and as appropriate for
the situation analyzed (Cohen & Reynolds, 2008; Lang, Lopert, & Hill, 2003; Weinstein et al.,
2001).
A framework for these analyses that is useful to health economics is decision analysis. Prior
to use in healthcare, analytic modeling had demonstrated its utility in situations when investment
choices had to be made in uncertain situations and the major downstream decisions and
outcomes were considerations in the decision (Gallant, Kieffel, & Chatwin, 1997; Weinstein et
al., 2001). Designing models for decision analysis gives structure to the question and the
options, demands evidence, provides a format to evaluate uncertainty and variability within the
assumptions, and can reveal a path to future research (Drummond, Sculpher, Torrance, O’Brien,
& Stoddart, 2005). The nature of this discipline is a systematic approach to outline and quantify
the options in decisions to be made under conditions of uncertainty (Goldie & Corso, 2003; Scott
& Rafferty, 2007). A primary purpose of diagnostic testing is to provide information that
reduces uncertainty in healthcare decisions; in some situations, a single diagnostic test can be
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placed directly in the clinical decision path. In these cases, decision analytic modeling could be
used to quantify the role of that test. Decision analysis can be particularly useful in healthcare
because the expected value of different strategies can be compared after recording the relevant
events with their probabilities and associated costs. When enough information exists, the
modeling can be performed before resources are invested in long term trials. In
pharmacoeconomics, decision modeling, first described for use in healthcare in 1980 (Fineberg,
1980; Weinstein & Fineberg, 1980) has become useful for analyzing data from many sources to
better inform decisions in actual practice (Sanchez & Lee, 2000). The elements of a simple
analytic decision model are shown in Figure 1. The first point in the tree is the decision node,
represented by the square. A decision informed by a laboratory test will stratify the patients to
different management schemes based on the results of the test. The next point of dispersion is
the chance node (filled circle) that illustrates which of the several events beyond the control of
the decision maker may occur. There may be several different branches; but, symmetry around
each node is not required. The branches represent the natural sequence of consequent events,
and each must be mutually exclusive. Collectively they must exhaust all possibilities. Two are
shown in the figure for simplicity. The probabilities of each of these chance events are recorded
along the branches. The final nodes are the terminal nodes which represent the end of each
sequence along with the outcome of the events (life years/ QALYS/ length of stay). Value is
assigned to the outcomes. The expected value of each branch can be compared by calculating
from right to left, multiplying the probabilities by the cost of the outcomes for each decision
alternative.
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Costs of outcomes
Probability of Outcomes

P Outcome A1
Pt. Management Scheme A
P Outcome A2

Test

Pt. Management Scheme B
P Outcome B1

(Decision nodes)

P Outcome B 2
(Chance nodes)
(Terminal nodes)

Figure 1. Example of a simple decision tree analytic model. This example describes a laboratory
test informing patient management strategy (adapted from Weinstein & Fineberg, 1980).
The purpose of decision analytic modeling, according to an International Society for
Pharmacoeconomics Outcomes Research (ISPOR) guideline, is to “structure evidence on clinical
and economic outcomes in a form that can help to inform decisions about clinical practices and
health-care resource allocations” (Weinstein et al., 2003). It is important that models are not
mistaken for truth but instead used as tools to facilitate information gathering for disciplined
analyses. Because a model has the ability to reveal logical connections between inputs and
outputs in the form of valued consequences and costs, the model should be transparent and
follow commonly accepted practice guidelines (Weinstein et al. 2001; Weinstein et al., 2003).
Technological advancements expand the options in healthcare services, and increase the
utility of analytic modeling to inform research, clinical practice and policy decisions. Placing a
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laboratory test in the clinical decision path and illustrating its impact on succeeding events, may
be particularly suitable for the evaluation of pharmacogenomics and companion diagnostics,
where test information is the gating item that guides therapy choices. The value of making the
therapeutic decision with and without the test information can be calculated. An example is in
the management of warfarin therapy, where genetic variants in metabolic enzymes have been
associated with variations in the efficacy of the drug.
Researchers evaluating the use of genetic test information to modify doses of warfarin therapy
have used decision modeling and cost effectiveness in their assessments. In one such study,
You, Chan, Wong and Cheng (2004) employed decision analytic modeling to assess the costbenefit of pharmacogenomics-oriented management of warfarin dosing. Their goal was to
evaluate the potential clinical and economic outcomes of using CYP2C9 genotype data for
patients receiving anticoagulant therapy. Patients with CYP2C9 polymorphisms are associated
with reduced warfarin dosing requirements and higher risk of a major bleeding event from
warfarin overdosing during the first three months of therapy. Using CYP2C9 polymorphism
prevalence, event rates, and cost data from clinical trials and provider data, they constructed a
decision tree to simulate the events of two theoretical cohorts initiating warfarin therapy: one
with genotyping data prior to the institution of therapy and one without genotyping. Patients
with at least one CYP2C9 variant (in the genotyped group) received intensified anticoagulation
service while those without the significant polymorphisms and those not genotyped received
standard care. Through the model outputs, it was determined that major bleeding events would
be averted in the genotyped group; however, the total costs of care for this group would also be
greater. The incremental cost of averting a bleeding event was $5778 per event. Using the CER
benchmark of less than $50,000 per QALY as a goal (from Panel on Cost Effectiveness in Health
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in Medicine), they converted their outcomes to this measure by estimating one month of illness
at a utility score of 0.39 for events averted, resulting in 0.05 QALY. For those patients who
hypothetically averted death from a major bleed, they conservatively estimated a life expectancy
of one year and calculated one QALY. To be cost effective by the benchmark, they calculated
that the genotyping scheme would have to show a gain of greater than 0.1 QALY per event
averted ($5778/ $50,000); their results were between 0.05 and 1 QALY. One of the difficulties
in the interpretation of this study is the projected infrequency of bleeding events. Though
potentially devastating, the number of events in these patients was small, approximately eight per
100 patient years. This is weighed against the risk of delaying therapy (to wait for genotyping)
and risking stroke; approximately two events per 100 patient years. Another issue is the 12month time horizon of the model, appraising an intervention that is most useful in the initial
three months. Specific to testing, a third challenge is measuring the impact of the laboratory test
using conventional health economic tools. It is hard to prove that the test alone has a direct
effect on the patient outcome. As in this study, the test result can lead to a more expensive
health management path. However, the CUA and the information from this model are useful.
Since the infrequency of the bleeding events is prohibitive to the trials needed to prospectively
demonstrate the utility of the intervention, recommendations for more focused clinical trials can
be made. In this case, limiting prospective clinical trials to the induction period of three months
and examining the costs of the intensified anticoagulation service, perhaps as standard of care,
could be pursued.
Analytic models can also be used to understand how best to focus technology investments to
optimize patient outcome. Meyers et al. (2000) utilized a Markov model for the analysis of cost
effectiveness of specific improvements in tests for cervical cancer screening. Figure 2 illustrates

35

a simple Markov model; an analytic tool used to represent disease progression states and events
that recur over a specified period of time (Lang et al., 2003). In Figure 2, each mutually
exclusive health state is in a circle, and the transitions between each of the states are represented
by arrows (state transitions). The probabilities of moving from one state to another or staying in
the same health state are assigned.
Probability
of
remaining
in state

Probability
of
remaining
in state

Probability of
transition

Disease

Well

Probability of

Probability of

transition

transition

Dead
Probability
of
remaining
in state

Figure 2. Example of a simple Markov model (adapted from Goldie & Corso, 2003).
In the Meyers study, researchers were able to provide insight into the marginal cost of
performance specification improvements for new cervical cancer screening tests. Using the
Papanicoloau (PAP) test as the base case, they modeled several levels of sensitivity and
specificity of hypothetical screening tests with the downstream costs of the future events. While
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they increased levels of sensitivity in the hypothetical test, they only altered the specificity by
making it equal or poorer than the base case, assuming that a new technology would increase
sensitivity at the expense of maintaining or decreasing specificity. They also examined different
screening frequencies of the new versus hypothetical test. Improved sensitivity led to
substantially greater costs than the health benefits obtained, mainly due to the magnified number
of low grade lesions with the consequent increased resources needed to evaluate them. Findings
such as these can help policy makers focus on the attributes that new technologies should present
as they assess them. They can also influence the direction of future development of new tests.
New screening tests for cervical cancer might only be viable if, in addition to sensitivity
improvements, specificity is also improved or if the downstream procedures for evaluating all
patients with positive test results became less expensive.
The optimal placement of a new test among conventional tests for hereditary
hemochromatosis (HH) has been studied through analytic modeling in Canada (Gagne, Reihnarz,
Laflamme, Adams, & Rousseau, 2007). Researchers built a modular simulation program to
generate a virtual population of one million people with demographic, genetic and phenotypic
characteristics specific for HH. They used this “population” to evaluate all screening algorithms
that were practically possible using the available biochemical and genetic tests. In addition, they
altered the population by varying HFE gene frequencies and penetrance. Using their model they
were able to analyze the outcomes of 165 different screening algorithms in 91 different virtual
populations. Among the top cost-effective strategies for most permutations of prevalence and
penetrance was a combination of conventional biochemical tests: unbound iron-binding capacity
plus transferrin saturation. The genetic test was optimally cost-effective as a confirmatory test.
Additionally, analysis of population screening was also performed and was shown not to be cost-
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effective when only hepatic complications were considered. This analytic model can be
continually refined and used to provide insight on several research and policy questions
regarding effective HH management.
For viral molecular tests, economic studies have focused on screening strategies for blood
borne viruses such as HIV, HCV and HBV. In blood-donor screening, HE analyses have
forecasted costs of up to $11.2 million per QALY using the combination of HCV, HIV and HBV
NAT tests to avert infection and subsequent disease in blood-product recipients. Despite the
high cost /QALY, the outcomes have not influenced policy makers to recommend against their
adoption. However, the information has helped support the discontinuance of other non-essential
or repetitive tests, such as anti-hepatitis B core and p24 antigen testing (Jackson, Busch, Stramer,
& AuBuchon, 2003).
For individual diagnosis and patient management of these viral diseases, there is a paucity of
health economic literature. Most work has focused on assessing the cost effectiveness of
screening populations for the early detection and early intervention of HCV disease. The United
Kingdom’s National Health Service (NHS) published an HTA report on the cost effectiveness of
actively screening former injecting drug users (IDUs) for HCV. They built a decision analytic
model to evaluate the impact of case-finding (a proactive search of a targeted population) and
treatment on a hypothetical cohort of 1000 IDUs. They compared the targeted, screened and
treated cohort to one that spontaneously presented for testing. Clinical and epidemiological
experts were used to inform the structure of the model and parameter estimates were populated
through literature and electronic database searches. Their model consisted of a simple decision
tree for the testing schemes, with a Markov model for the treatment and outcomes. The model
ran for the life of the cohort cases; all entered at 37 years of age. For each 1,000 subjects in the
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case-finding cohort, three cases of decompensated cirrhosis, three deaths (from HCV disease),
and one case of hepatocellular carcinoma were averted. One liver transplant for each 10,000
cases would also be averted. Twenty-five more subjects in the case-finding cohort than in the
spontaneous testing cohort would be prescribed combination therapy. In terms of cost-utility,
£16,514 per QALY would be invested, below the £30,000 per QALY benchmark used by NHS
policy makers. Though it resulted in higher absolute costs, £760,000 due to targeting, testing
and treatment resources, the case-finding strategy in this scenario was within the acceptable NHS
criteria (Castelnuovo et al., 2006). This type of study is used by NHS commissioners to adopt
strategies, set policy or design further research.
An Italian group evaluated the cost effectiveness of screening in IDUs and patients who
received major and minor surgery (potential exposure risk) for the Veneto region, using the
demographic and public health records from this population of 4,750,000. They hypothesized
that the socioeconomic burden of disease could be reduced by screening and early intervention in
asymptomatic, at-risk groups. They further stratified the analysis by HCV genotype, which
impacts treatment success. Both IDU and surgery patients’ analyses were very sensitive to the
prevalence of the more difficult to treat genotypes 1 and 4. However, only the IDU population
screening was shown to be below the cost per QALY threshold of €30,000. Screening IDUs
actually had a negative cost per QALY in those with genotypes 1 and 4 (€ -5.14). For cases with
genotypes 2 and 3, the cost per QALY was €9,659. In the surgery patients, all costs per QALY
were far above the threshold: €699,991 for genotypes 1and 4 and €2,324,471 for genotypes 2 and
3 (Tramarin et al, 2008). These outcomes could reflect the relative risks of these two
populations. The surgery patients were not limited to only those that would receive blood
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products. Even so, the adoption of HCV screening of blood products has significantly reduced
the risk of infection for recipients.
The type of population, the risk of developing disease, and the prevalence of disease have
been important modifiers in other studies. The results of an analysis in France showed that
screening for HCV was the dominant (more-cost effective) strategy only in IDUs, when that
group, transfusion patients, and the general population were compared (Loubiere, Rotily, &
Moatti, 2003). An earlier US study using the prevalence of the 3.8% for the general population,
also found that screening the average risk group in a relatively low prevalence setting was not
cost effective as a general health policy (Singer & Younossi, 2001).
These examples illustrate some of the opportunities and difficulties in applying traditional
economic analyses to studying the cost effectiveness of laboratory tests. Diagnostics are usually
a new cost, unless one is replacing another. Understanding how to structure an analysis in
specific populations with differing prevalence rates, or states of health and with different test
performance characteristics is challenging.
Another way to consider the value of diagnostic tests is to regard the costs of laboratory tests
as investments in information which will reduce uncertainty in specific medical decisions.
Directing resources and investments towards developing and refining tests that provide the most
clinically valuable information could result from these analyses. Value of information (VOI)
analytical tools are becoming useful in clinical trial design to identify and evaluate the benefit of
proposed additional research. Reducing uncertainty and the calculated clinical and economic
value of that reduction are instructive in determining clinical trial strategy (Yokota & Thompson,
2004). Laboratory tests provide information which reduces uncertainty in health and patient
management. In this regard, VOI might be applied to ascertain the value of diagnostic tests.
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This idea is not new. In 1988, Phelps and Mushlin suggested methods to calculate the
Expected Value of Diagnostic Information (EVDI) and the Expected Value of Clinical
Information (EVCI) using CUA and decision analytic models as the analytical foundation. The
probabilities of a patient being sick or well, and being treated or not in each of those states, with
and without the diagnostic information to guide the treatment decisions, were illustrated in
models that look very much like current analytical decision trees. While the publication was a
theoretical description, it presented several principles. The most important was the view that
diagnostic tests are information and their value should be measured in that regard. The base case
analysis is then a specific clinical path without the diagnostic information, and it is compared to
the clinical path utilizing the test results. The importance of understanding that diagnostic tests
do not deliver perfect information and the costs and consequences of choosing the “incorrect
path” based on that imperfect information were also described. Several applications for this type
of analysis were proposed, including determining the range of disease probabilities over which
devices may be used, and comparing one device against another without the expense of
randomized controlled trials.
Methods calculating VOI have rarely been applied to analyses of laboratory tests. Recent
work to determine the value of epidermal growth factor receptor (EGFR) in non-small-cell lung
cancer (NSCLC) second-line treatment with (EGFR) tyrosine kinase inhibitors (TKI’s) illustrates
some of the challenges in measuring the value of laboratory testing and provides one use of VOI
(Carlson, Garrison, Ramsey, & Veenstra, 2009). Two different test methods, a protein
expression and a gene copy number test were evaluated. Sensitivity analyses of the model
revealed that effectiveness was most sensitive to changes in disease-progression free and overall
survival states. The CUA of pathways with and without the test results demonstrated that the
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pathway without the testing was more “cost-effective” up to a threshold of $150,000 cost per
QALY, after which, the gene copy number test was more cost effective. Testing for EGFR by
gene copy number produced an added three weeks quality-adjusted life expectancy and a 1.4
month overall survival difference at the cost of $9200. (Test costs were $320; most of the
additional costs were treatment costs associated with extended survival). The ICER of adding the
test, and the outcomes associated with the testing was $162,000. It is not surprising that a test
providing information that extends life by only a few weeks would produce a costly outcome. In
addition to the CE analyses, the Expected Value of Perfect Information (EVPI) at a threshold of
$US 100,000/ QALY was calculated. Over a five-year period, the EVPI was $31.4 million,
representing the upper bound of opportunity costs that the added test information would
contribute in appropriately triaging patients during that time. Currently, there is no agreed upon
benchmark for information investment; therefore, the EVPI merely supports recommendations
for further study into the role of this test, particularly if the efficacy of the treatment is improved.
The expense of NSCL cancer treatment, the increased response of those testing positive for
EGFR, and the necessity of selecting only those patients that could respond provided a rationale
to demonstrate the clinical and economic utility for a test to select these patients. However, the
benefit of the intervention in the population was marginal, and the benefit added further health
care costs to the economic outcome. Calculating the EVPI, however, demonstrated the value
that the information itself could impart in the clinical scenario. While investing in healthcare
costs and services, is it worth investing up to $31.4 million over five years to decrease the
uncertainty with which patients are chosen for this therapy? Though there are no policy
thresholds at this time, it is conceivable that clinicians and patients might be able to use this type
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of information at the individual level or a cost per test basis if there was enough research around
the VOI parameter.
The EGFR study calculated the VOI assuming the results derived from the tests were always
correct; therefore, the value calculated was the upper limit of any contribution by the test.
Combining more realistic technical characteristics of tests with the VOI derived from them, is
the basis of a synthesis of analytical tools proposed in “ROTS analysis” (Laking, Lord, &
Fischer, 2006). ROTS analysis combines two linear schools of thought: the ROC or Receiver –
Operator Curve analysts and the VOI analysts. This multidimensional model links changing test
thresholds and the cost-effectiveness of different interventions. Within the stated changing
parameters, ROTS analysis provides a method to answer questions regarding the justification for
doing a test, a test’s optimum operating point, and comparison to competing tests or
methodologies. However, the graphical representation and interpretation in ROTS may be
beyond the current scope of CE discussions, particularly since the current HE methods were not
specifically optimized to analyze laboratory tests. A subset of the conclusions in ROTS could be
obtained by appropriate sensitivity analyses of more standard CE evaluations, though ROTS
provides more interpolation and dimension. ROTS seems to be optimized for qualitative results,
utilizing sensitivity and specificity as principle parameters. The results of quantitative tests
would have to be translated into clinical sensitivity and specificity for the intended outcome, if
the method were to be employed to assess quantitative results.
Among the methods surveyed, cost-benefit and cost-effective analyses are being applied to
diagnostic testing, and used by policy makers and academics. Laboratory professionals utilize
CB to justify new tests, methods, or instruments for their particular organization, but usually do
not initiate more strategic CEA and CUA analyses. Conversely, health economists rarely
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represent the performance characteristics of diagnostic tests in their analytical models. For
laboratory professionals, the reasons may be that the analyses are too complex, require too much
input, or have received too little exposure. Because of discreet institutional budgets, the
relevance of developing CE models for health policy may have little perceived relevance to the
operations of clinical laboratories. For academics and health economists, including test
performance characteristics and their subsequent impact on the clinical pathways modeled may
be too complex, or may be considered trivial in the scheme of the larger analyses. Most of the
examples of HE analyses for laboratory tests in the research discussed here have been focused on
diagnostics with a yes/ no result of disease states carrying different probabilities, which is only
one use of laboratory test results. There is no work examining the value impact of the variation in
quantitative tests which are used to monitor and adjust clinical therapies. Viral disease
management depends on quantitative viral load test information for triaging patients to the
proper therapy, for monitoring patients on therapy, and for determining clearance of the virus.
For HCV, where a change in quantitative test results can catalyze an alteration in therapy, it is
relevant to examine the clinical and economic value of those results and the impact that
imprecision has on the decisions made by them.
Hepatitis C and Viral Load Testing
Hepatitis C imposes a major disease burden on the world (Sy & Jamal, 2006). The global
prevalence of HCV has been estimated by WHO to be approximately 3%, affecting 170 million
people (http://www.who.int/csr/disease/hepatitis/whocdscsrlyo2003/en/index3.html ). This is
considered an underestimate due to reporting inefficiencies, underreporting, and the fact that
many of the rates are derived from disease prevalence in the blood donor population. Depending
on the country and area surveyed, the prevalence of HCV can range from below 1% to above
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20%. In the United States, underreporting and asymptomatic infections add to the recording
challenges. Approximately 3.2 million people in the US have chronic HCV
(http://www.cdc.gov/hepatitis/HCV/HCVfaq.htm#section1). The National Institutes of Health
project 35,000 new cases per year and cautions that since most chronic infections have not yet
been diagnosed, a fourfold increase in the number of infected adults is predicted from 1990 to
2015 (NIH, 2002).
HCV is the leading cause of liver transplantation in the United States, one of the principal
causes of cirrhosis, and a common cause of hepatocellular carcinoma. It is the primary reason
for death from liver disease in the United States. Between 1999 and 2007, HCV related deaths
outpaced HIV and HBV related deaths and accounted for approximately 4.58 deaths per 100,000
persons per year (Ly et al., 2012). With an estimated prevalence of at least 1.8%, HCV is the
most common chronic blood-borne infection in the United States (NIH, 2002).
The virus, transmission and course of disease. The hepatitis C virus is a small enveloped
RNA virus constituting its own genus within the Flaviviridae family (Op De Beeck &
Dubuisson, 2003). There are six genotypes of HCV, each having implications on viral
persistence and patient management (Simmonds et al., 2005). Genotype 1 is predominant in the
US, accounting for 70– 75% of all HCV infections. It is also associated with a lower response to
current treatment regimens (NIH, 2002).
HCV is transmitted primarily through contact with infected blood or blood products. This is
the main source of infection in several countries. In the US, the blood supply has been routinely
tested for HCV antibody since 1992. For those who received transfusions, blood products or
organ transplants prior to 1992 the risk is high. Since then, the risk from this source has been
minimized and injection drug users currently have the highest risk. Other possible sources of
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infection include exposure to an infected sexual partner, perinatal exposure, and occupational
exposure to infected blood by healthcare workers (Ghany et al., 2009; & NIH, 2002; Sy et al.,
2006).
Many individuals infected with HCV remain symptomless. For those that do develop clinical
symptoms, the incubation period ranges from 15-150 days. Approximately 15-25% of infected
individuals will spontaneously clear the virus. The remaining 75-85% will maintain chronic
infections. These individuals are at risk for further, serious sequelae. Approximately 60-70% of
those chronically infected will develop chronic liver disease. Of these, 5-10% are expected to
develop cirrhosis and 1-5% will die from the consequences of the cirrhosis which includes
hepatocellular carcinoma (Ghany et al., 2009; Seeff, 1999). A review of several natural history
studies in the 1990s concluded that approximately 20% of infected individuals progress to
cirrhosis, fibrosis and serious end-stage liver disease. The serious consequences of HCV
infection usually manifest after approximately 20 years (Seeff, 1999). Figure 3 provides an
illustration of HCV disease pathways.
Treatment and patient management. Because the symptoms of HCV infection can be
inconspicuous while the virus remains transmissible, diagnosis is important. In addition, because
the disease manifests slowly, early diagnosis provides a window of opportunity to intervene and
prevent the more serious consequences associated with progression. For genotypes 2-6, the most
common treatment strategies for chronic HCV infection employ combinations of long-acting
pegylated interferon-alpha, and ribavirin (Ghany et al., 2009; Sulkowski, 2008). While there are
several treatment protocols approved by the US Food and Drug Administration (FDA), the
strategy that has demonstrated the highest rates of sustained viral response (SVR) and is the
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Figure 3. The natural course of HCV infection. Adapted from Seeff, 1999; Ghany et al., 2009;
and CDC.gov 2012.
current standard of care, is a combination of peginterferon-alpha administered in weekly
subcutaneous injections with daily oral ribavirin (Ghany et al., 2009). Besides the treatment
inconvenience, the side effects of this combination therapy are not trivial. The management of
the side effects is particularly frustrating for non-symptomatic individuals diagnosed with HCV.
Adverse effects include profound fatigue, headache and other pain, neutropenia,
thrombocytopenia, hypothyroidism and hyperthyroidism, visual disturbances, nausea, fever,
depression, irritability, suicidal tendencies, and cognitive impairment. Other complaints include
insomnia, inability to exercise, and the loss of motivation. The addition of concomitant
medications and interventions to manage these adverse events impact patients’ quality of life and
productivity (Ghany et al., 2009; Hopwood, Treloar, & Redsull, 2006).
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In 2011, a new class of therapeutics was added to the dual therapy for the treatment of HCV
genotype 1, the most common and difficult to treat of the HCV viruses in the US. The use of one
of the protease inhibitors, telaprevir (Incivek ™) or boceprevir (Victrelis™), with the dual
combination therapy, increases the response rate, but rates of anemia are also increased and
hemoglobin levels must be monitored closely (Ghany et al., 2011; Merck Sharp & Dohme
Corporation, 2011; Vertex Corporation, 2011). There are several other therapeutics for HCV in
development and for which HCV VL measurements will be critical in the assessment of their
success (Cox, 2013).
Adverse events and inconvenience can also impact patients’ compliance to therapy. Because
of the associated debilitating events and the observation that not all infections are eliminated by
therapeutics, a goal of many clinical research studies has been to find the most effective and
shortest regimen. HCV viral load (VL) testing has played a key role in these studies; and as
therapeutic strategies are individualized to patients, VL testing utilization will increase. Current
treatment protocols require administration of therapy for a minimum of 12 weeks up to 72
weeks, depending on viral genotype, and the HCV VL test results at specified intervals during
the treatment. The goal is to treat the patient aggressively, but humanely, to eradicate the virus.
Through research, opportunities to remove patients from further therapeutic discomfort when VL
results indicate therapy is not effective have been identified (Chevaliez & Pawlotsky, 2009;
Ghany et al., 2009; Ghany et al., 2011).
Chronic HCV disease management and laboratory testing. Laboratory testing is
integrated into all phases of hepatitis C patient care: diagnosis, therapy selection and
management, and the determination of failure or sustained cure. Patients are usually first
diagnosed by means of positive HCV antibody tests that are confirmed by qualitative or
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quantitative (viral load) HCV RNA tests. Serum aminotranferase levels and liver biopsy
histology help establish the severity of the disease and any sequelae present. Quantitative HCV
RNA and HCV genotype tests along with biopsy results and patient data are used to plan the
most appropriate and potentially effective treatment strategy (Chevaliez & Pawlotsky 2009;
Ghany et al., 2009; Ghany et al., 2011; Sulkowski, 2008). A newer biomarker, IL28B has been
added to the testing menu. Knowledge of mutations in this gene provides a probability of
successful response for therapies using interferon in HCV genotype 1 infected patients.
However, HCV VL reduction and clearance are still the definitive targets. (Ge et al., 2009;
Sharifi & Alavian, 2011).
The goal of therapy is to avoid the future complications of HCV, which can only be achieved
with certainty if the virus is eradicated. The most powerful predictor of treatment response and
the definitive indicator of treatment outcome is HCV VL. When treatment begins, a viral load
determination is made. Depending on the genotype, the severity of liver disease, the likelihood
of a sustainable response to treatment, the probability of adverse events, and the presence of
comorbid conditions, the length of treatment is individualized. The key information for
adjusting the length of treatment is the succeeding HCV VL results. The best evidence of the
eradication of the virus is provided by quantitative HCV RNA nucleic acid testing (NAT) of
patients’ blood throughout the course of therapy and continuing after therapy (Ghany et al.,
2009; Sulkowski, 2008).
The American Association for the Study of Liver Diseases (AASLD) publishes datasupported recommendations for the diagnosis, treatment, and management of patients with
hepatitis C disease. In the newly revised guidelines for HCV genotype 1, the predominant
genotype in the United States and the most refractive to therapy, clinicians are recommended to
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initiate their treatment-naïve HCV patients with one of the new protease inhibitors plus the
standard dual combination therapy. After the initial treatment period using the three
therapeutics, quantitative HCV RNA testing is performed to determine the viral load. If the
HCV RNA level is not below a specified number (100 IU/ml for boceprevir or 1000 IU/ml for
telaprevir) therapy can be discontinued (Ghany et.al, 2011). Clinical studies have demonstrated
that there is virtually no probability of a sustained viral response (SVR) for patients that do not
achieve this milestone (Chevaliez & Pawlotsky 2009; Ghany et al., 2011, Terrault et al., 2005;
Zeuzem et al., 2003). For patients where the initial phase of therapy has been successful,
treatment should continue with interferon-alpha and ribavirin for 12 to 36 additional weeks,
depending on HCV VL results within that period. At the end of therapy, another viral load
measurement is taken with the anticipation that the patient has achieved a “less than detectable”
value. Twenty four weeks after therapy completion, an HCV VL test is performed to confirm the
patients SVR status. AASLD guidelines also differentiate the treatment management for patients
with genotype 2 or 3. These patients receive an HCV VL test at the beginning of their treatment
and are scheduled for 24 weeks of interferon-alpha and ribavirin therapy. At the end of 24 weeks
another viral load determination is made and then again at 48 weeks to determine the
sustainability of the response (Ghany et al., 2009). Figure 4 illustrates these clinical pathways.
Clinical management guidelines illustrate the integral and essential role of quantitative HCV
testing in HCV patient care. Considering the length of treatment, potential morbidity, and costs
associated with current therapy, studies continue to focus on altering regimens specific to patient
and disease characteristics. Newer clinical studies are exploring even more individualized
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Figure 4. Treatment strategies for chronic hepatitis C infection. Derived from Ghany et al, 2009; and Ghany et al., 2011.
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treatment strategies, from shortening treatment based on the first time HCV is undetectable, to
lengthening it in other situations. The results of these studies are proposals that recommend
shortening therapy when a rapid viral response (RVR) is established, halting therapy when it has
been demonstrated to be ineffective, or lengthening it when prolonged therapy increases the
chance of SVR (Chevaliez & Pawlotsky, 2009; Mangia et al., 2007; Poordad, Reddy, & Martin,
2008; Zeuzem et al., 2005). In all cases, the decisions are predicated on the HCV VL
measurement. Establishing SVR by means of HCV VL was the surrogate endpoint for the
clinical trials that led to the approval of the two new protease inhibitors for HCV genotype 1
patients (Jacobson et al., 2011). While the dependence on this measurement is essential, there is
little technical discussion in the clinical literature on the imprecision of the assays and the
clinical consequence of acting on such information, and no studies demonstrating how
differences in the precision of the results will affect clinicians’ decisions.
Quantitative HCV RNA viral load testing. The hepatitis C Virus was discovered in 1989;
one of the first organisms to be linked to disease by molecular techniques alone (Choo et al.,
1989). Establishing hepatitis C virus as the etiologic agent of one of the forms of non A/ non B
hepatitis was accomplished by identifying and sequencing the viral RNA; without actually
isolating or culturing the virus. Despite the newness of the molecular techniques used to isolate
and quantify the virus, by 1995 viral load testing for HCV was being used regularly for
prognosis and disease therapy management (Gretch et al., 1995; Martinot-Peignoux et al., 1995).
By 2001, it was considered one of the most common tests performed in many molecular
laboratories (Podzorski, 2001).
Early researchers demonstrated the discrepancies within and between the different available
commercial and laboratory developed assays. There were no formal proficiency testing
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programs for HCV VL at the time, so the discrepancies were observed by comparing the results
of multi-center studies distributing shared samples. The earliest of these compared qualitative
results on undiluted samples and on dilution series of samples. One early European study found
that only five of the 31 participating laboratories from Europe, the US and Japan performed
flawlessly on a panel of four HCV positive, six HCV negative and a dilution series with two
samples (Zaaijer et al., 1993). The earliest College of American Pathologist (CAP) proficiency
test panels demonstrated 13 – 95% correct results on the HCV RNA qualitative samples
distributed in the first year to approximately 50 laboratories in the United States (Gretch, 1997).
The Quality Control for Molecular Diagnostics (QCMD), a European Union supported
proficiency testing effort, was the first to provide globally available qualitative and quantitative
HCV proficiency testing panels. Two consecutive panels in 1999 and 2000 showed an
improvement in qualitative testing where over 80% of global laboratories reported correct
results. For those laboratories reporting quantitative results on the first panel, 60% were within
the acceptable range of the geometric mean +/- 0.5 log10 and for the second panel in 2000, 73%
were within this range (Schirm et al., 2002).
In addition to the differences in technologies and asynchronous states of development for
available assays, there were no globally accepted standard reference materials, primarily because
the virus could not be propagated. As a consequence, quantitative assays were developed with
different reporting units: copies, genome equivalent units, and relative light units (Schirm et al.,
2002). In 1996, the World Health Organization (WHO) in a global collaborative study with 22
laboratories established the first WHO International Standard for HCV RNA, expressing the
quantity in International Units (IU) (Saldanha, Heath, Lelie, & the WHO collaborative study
group, 1999). International units are assigned to biologic material WHO International Standards
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and have no reference other than in relation to that standard material and the testing that
quantified it (WHO, 2002). The difference in quantification among the global laboratories that
tested the first standard, using either quantitative tests or limiting dilutions with qualitative
testing, was greater than 2 log10. Although the inter laboratory imprecision was large, this was
viewed as providing a step towards reducing the variability in the results of future tests.
Despite the establishment of the WHO International standard, assessment of proficiency
testing for quantitative tests continued to be difficult. Participating laboratories still reported
historical units, so conversion factors were used for multi-assay comparisons (Pembrey et al.,
2003). Adding to the complexity was a technology shift to real time polymerase chain reaction
(RT-PCR) which expanded the reportable range span from barely 5 log10 IU/ml to greater than 6
log10 IU/ ml (Barbeau, Goforth, Caliendo, & Nolte, 2004). Bias continues to exist between
methods and among the genotypes in HCV VL, to the extent that it could influence treatment
decisions. The recommendation to follow serial patient samples with one test method, and
preferably through one laboratory, throughout the treatment experience of the patient, is still
relevant (Caliendo et al., 2006; Laperche et al., 2007). In practice, however, this
recommendation may not be easy to follow, and there is no information regarding actual
compliance.
Even if clinicians had the ability to direct patients’ serial samples to one laboratory using one
method, there would still be reason for concern. Depending on the technology and the laboratory
used, the inherent imprecision may make it difficult to determine the changes in viral load
necessary to guide treatment decisions. At the time when therapy management decisions were
made based on the detection of a 2 log10 reduction in viral load, the Instituto Superiore di Sanità
in Italy conducted a multi-center study with 58 laboratories and two manufacturers using a panel
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of samples designed to reflect the performance of this intended use. In addition to one panel
sample at the sensitivity limit, six samples of the eight member panel were designed to test the
ability of the tests to accurately detect a 2 log10 change. Three replicates each of two samples
that were at 5.68 log10 and 3.61 log10 were distributed to the participants in each of two panel
sets. In the data analysis, all combinations of the results between these two samples were
calculated and the percent of unacceptable result-combinations was reported. The range of
unacceptable results (less than 2 log10 IU/ml difference between the two samples) among the four
methods tested was 30% to 66% with an overall rate of 40% of all the results. It was calculated
that this could have led to the unnecessary discontinuation of therapy in up to 40% of patients.
The researchers noted that if an uncertainty of 2 SD was considered in the evaluation of the
results, the hypothetical incorrect decisions would have been reduced to 2% (Pisani et al., 2009).
With the exception of the HCV VL results from the laboratories, the work that determined these
conclusions was accomplished by mathematical modeling. The new therapeutic regimens for
HCV genotype 1 incorporate the achievement of absolute reduction of viral load for the therapy
management decision; the 2 log10 IU/ml change is no longer used. Though the limit of detection
for the acceptable assays to determine the VL are specified in pharmaceutical labeling and
clinical guidelines, the precision specifications are not, and there is variance around those
absolute values in even the most reproducible tests. Whether or not physicians consider the
imprecision in HCV VL tests as they are making therapeutic management decisions with these
quantitative results is untested.
Justification for the Research
HCV Viral load testing is essential to the diagnosis and management of patients infected with
the virus. The previous section discussed the recommendations for using HCV VL in clinical
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decisions and some of the clinical research that demonstrated its utility. Based on research, the
collective opinions of experts, and FDA submissions for therapeutics, HCV VL testing is
standard practice to inform decisions in treatment of the disease. The efforts to understand and
decrease the imprecision in HCV quantitative testing has also been discussed, as well as opinion
leaders’ views of the residual variation and the impact that could have on patient care. The
research and discussion of these complex issues have been conducted among experts in
laboratory testing, virology and hepatology. It is unknown if all treating physicians have
integrated this knowledge into their practice. As new treatment regimens are introduced, it is
important to understand where indecision, confusion, or non-adherence to recommended
practices exist.
The current research regarding physicians’ integration of test results in medical decision
making illustrates a broad, inconsistent, and sometimes incorrect understanding of the precise
meaning and application of the intended information supplied by laboratory testing. The types of
laboratory tests that have been addressed in the studies discussed are primarily those informing
the physician of the probable presence or absence of disease. There are no studies measuring
physicians’ understanding of continuous quantitative information, nor are there studies
addressing the impact of integrating the knowledge of the imprecision in quantitative testing in
their decisions.
It is appropriate to use HCV disease management as a model to study the implications of
quantitative test variation on clinicians’ decisions. The global impact of the morbidity and
mortality on society has been discussed; but added to that is a growing body of publications
outlining the costs of chronic HCV disease, cost-benefit impacts of intervention, and cost
effectiveness of specific therapies. In the United States, the direct costs of HCV infection in
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1998 were calculated to be one billion dollars (Wong, 2006). The extended incubation time
before complications manifest will result in a calculated economic burden of $US 86.2 billion of
direct and indirect medical expenses during 2010-2019. Adding quality of life, productivity and
societal costs increases the estimate to $US 184 billion (Shah & Wong, 2006). The seriousness
of the economic impact and the possibility of reducing that impact with suboptimal interventions
drive studies to demonstrate the cost effectiveness of specific and comparative therapeutic
regimens (Hornberger et al., 2006; Rajenrda & Wong, 2007). Paired with those studies and
subsequent disease management strategies are the HCV VL tests that direct patients into the most
effective therapeutic plan, but the monetary value of those tests is rarely studied. For example,
the ability to cease treatment at 12 weeks for non-responding patients was calculated to save $US
15,000 per patient (Wong, 2006). Though HCV VL results drive the decision, there is no
analysis of the contribution to savings the test may have. Further, there is no discussion of how
the variation in the results might impact the decision and alter the utility and value of the pivotal
determinant.
In the research presented here, these two important questions were studied. Referring to
Smart’s proposed model of clinical utility (2006), this study first examined the practicability, the
knowledge and training needed to support HCV VL testing, by evaluating the understanding and
impact the test results presented with imprecision information have on clinicians’ use of the
information. A survey presenting a specific scenario of a simulated patient completing 12 weeks
of therapy and that patient’s initial and 12 week HCV VL results at different levels was offered
to clinicians (survey participants) who treat patients with chronic hepatitis C. In random order,
each participant saw the test results with and without disclosing the imprecision, expressed as the
95% confidence intervals. The participants were asked to choose their course of action based on
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the two different types of reports. The accessibility, or the economic and cost effectiveness
consequences of using HCV VL results as “perfect” information, and as information with
imprecision were then evaluated using decision analytic modeling and value of information
calculations.
The purpose of this study was to test the hypothesis that clinician awareness of the expected
imprecision in pivotal test results will impact their medical management decisions. The data
from their responses were also used in decision analytic models to measure the changes in the
value of the information provided by laboratory tests as clinicians alter their use of them. The
work consisted of an observational study utilizing a clinician survey that presented a scenario
where laboratory results provide the determining factor for the subsequent step in a patient’s
medical care.
The treatment of chronic hepatitis C using quantitative HCV RNA results was chosen for this
study for several reasons: AASLD practice guidelines recommend the consideration of an action
based on the results of the quantitative HCV RNA molecular tests. The guidelines and several
publications recommend the use of a single test methodology by a single manufacturer
throughout the care of the patient. It is unknown if clinicians comply with this recommendation
and purposefully choose the same laboratory and method for their patient testing. Finally, there
is an increasing reliance on both absolute and relative values derived from molecular viral load
testing in the personalization of therapy regimes for several viral diseases. It is important to
investigate the clinician mitigation and responses to the variation in this type of testing.
Contribution of the research. The hypothetical impact that the variation in VL testing could
have on the ability to assess a 2 log10 reduction of HCV for patients on therapy was
mathematically demonstrated (Pisani et al., 2009). However, whether or not clinicians would
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have acted on the information as predicted in the European study was not tested. The new
therapeutics and new guidelines for HCV genotype 1 patient management present an opportunity
to analyze what physicians will do given the imprecision of the test results when making a
decision around an absolute threshold. Physicians’ abilities to appropriately utilize test results
impact the value of those results, and consequently the tests from which the results are produced.
Appraising the value of tests as information with realistic performance characteristics, as well as
with data on the use of the information, is an approach not commonly employed in clinical utility
discussions of laboratory tests. Additionally, the value of information as a measure of laboratory
test value has not been published. It may provide additional information for the assessment,
development and direction of future investment in clinical laboratory tests.
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Chapter Three: Methods

The purpose of this research was to study if presenting imprecision information with
laboratory test results impacts patient management decisions and the use of healthcare resources.
The study utilized the quantitative test for HCV viral load (HCV VL), a pivotal test in clinical
practice, as a model. The impact that knowing the imprecision, an inherent characteristic of the
test, has on the decisions of those who use HCV VL for therapeutic management was measured
in this study. Further, the test’s economic value and the changes to that value based on the
recorded decisions were calculated. For the first part of this research, a survey was developed to
evaluate decisions made when the HCV RNA (HCV VL) results were provided with and without
the 95% confidence intervals (CIs) that describe the imprecision. Using HCV VL results for a
simulated HCV genotype 1 infected patient on triple-combination therapy, the survey was
designed to compare the responses to VL results reported in the customary manner, without
imprecision information, to responses to the same results reported with their 95% confidence
intervals. Each survey participant was presented with both types of HCV VL presentations (with
and without CI), but in random order. The characteristics of the simulated patient and the
expected confidence intervals for the HCV RNA levels were derived from literature. It was
expected that responses made viewing results with imprecision information would be different
from the responses made viewing results in the conventional presentation.
Survey data were analyzed for differences in responses to the HCV VL results with CI and
those without CI. The respondents’ patient management decisions were then used as inputs to a
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decision analytic model developed to calculate the value in cost savings and changes to that
value based on changes in responses from the different presentations.
Survey Design
The survey was designed to focus on the decision made after 12 weeks of triple combination
therapy for patients infected with HCV genotype 1 virus: telaprevir (Incivek™), alpha interferon
and ribavirin. The selection of the decision point for the survey was based on information in the
labeling of Incivek (Vertex Pharmaceuticals, 2011) and the updated American Association for
the Study of Liver Diseases (AASLD) guidelines that incorporate treatment and evaluation
guidelines for these therapeutic regimens (Ghany et al., 2011).
For treatment naïve patients without cirrhosis (the simulated patient in the survey), the
following treatment recommendations are stated in the AASLD guidelines. (Class and levels
refer to the strength of evidence supporting the recommendation):
“ The recommended dose of telaprevir is 750 mg administered with food (not
low-fat) three times per day (every 7-9 hours) together with peginterferon alpha
and weight-based ribavirin for 12 weeks followed by an additional 12-36 weeks
of peginterferon alpha and ribavirin (Class 1, Level A).
Patients without cirrhosis treated with telaprevir, peginterferon, and ribavirin,
whose HCV RNA level at weeks 4 and 12 is undetectable should be considered
for a shortened duration of therapy of 24 weeks (Class 2a, Level A).
Treatment with all three drugs (telaprevir, peginterferon alpha, and ribavirin)
should be stopped if the HCV RNA level is >1,000 IU/ml at treatment weeks 4 or
12 and/or detectable at treatment week 24 (Class 2a, Level B).”
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The survey was designed according to the clinical path in Figure 5. The decisions that
participants made based upon the HCV VL results after 12 weeks of therapy, with and without
confidence intervals, were recorded and analyzed.
Participants were presented with a description of a simulated patient with HCV genotype 1
disease who had been on triple combination therapy for 12 weeks. The initial HCV VL for this
patient, as well the description of that patient’s tolerance to the therapy over the 12 week course
were also described. Five different levels of HCV VL results were presented to the survey
participants with and without the 95% confidence interval for each result. The order in which
these were presented was randomized. The HCV VL levels in the survey included results for
which the patient management choice made according to practice guidelines would be relatively
clear, as well as results for which the choice could be equivocal. Participants were asked to
consider each result individually and choose one of three patient management decisions: to
continue therapy, to discontinue therapy, or to repeat the HCV VL test. The survey was hosted
on Survey Monkey®, an internet based, secure survey service. (Appendix A contains the
complete survey text.)
Although the HCV VL result can be pivotal in the 12-week treatment management decision
for HCV patients on triple combination therapy, other patient variables are considered by
clinicians, such as age, weight, sex, degree of cirrhosis, and tolerance to therapy (Ghany et al.,
2009; Sulkowski, 2008). The survey was designed to reduce as many of these variables as
possible by presenting one patient with average demographics and a moderate set of adverse
events. Since professional practice, judgment, and experience can also influence the decisions,
questions relating to the participants’ demographics and practice were incorporated into the
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Figure 5. Clinical path for HCV genotype 1 patients after 12 weeks of triple combination therapy. The three shaded boxes represent
the choices following the presentation of different HCV VL results with and without confidence intervals in the survey.

survey. These included professional credentials, the number of years the participant has been
treating HCV, the average number of HCV patients seen per month, the area of practice specialty
and the geographic region in which the participant practiced. Other items in the survey queried
preferences regarding the prescription and use of laboratory tests, such as the ability to direct
patient testing to a single testing laboratory or method, the desire to have confidence intervals
reported with results, and the preferred guidelines used for managing patients with HCV disease.
Selection of HCV VL test results and imprecision ranges. One set of quantitative HCV
RNA test results presented to the participants represented typical HCV VL results. From most
laboratories these results are reported without information regarding the imprecision of the
assays. The other set of results reported the identical test values, but with the 95% confidence
intervals for those values, as well.
The 95% confidence intervals for the HCV VL results in the survey were based on published
literature. Imprecision statistics are published from multi-site trials, assay studies and
proficiency test summaries, and they provide insight to the expected confidence intervals within
a laboratory. However, these are usually focused experiments, sometimes with artificial or
pooled samples (Caliendo et al., 2006; La Perche et al., 2007; Pisani et al., 2009). The
confidence intervals used in the survey for this research were calculated according to a
recommendation by the Virology Quality Assurance Laboratory Program (VQA). The VQA
program, formed by the virology committee of the AIDS Clinical Trials Group uses an intralaboratory SD criterion of 0.15 log10 SD for viral load assays (Yen-Lieberman et al., 1996). It
was first established for HIV assays, however, laboratory directors producing results for other
VL assays recognize it as a goal (Caliendo et al., 2006). Though the recommendation was made
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in 1996, later published studies either refer to this recommendation or their data demonstrates
that 0.15 log10 = 1SD is still a reasonable estimate (Table 2).
Table 2
Three Studies with Published Intra-laboratory Reproducibility Statistics
Study

Year

Replicates
0-2.9 log10
SD log10

VL ranges:
3-4.9 log10
SD log10

> 5 log10
SD log10

Foreman
&Valsamakis

2004

20

0.2

0.2

0.1

Caliendo et al.

2006

7

Approx.
0.15

Approx.
0.15

Approx.
0.15

Chevaliez et al.

2009

6

0.8

.04

0.21

For the imprecision budget of 1SD = 0.15 log10 used for the HCV VL results in the survey,
the calculated 95% CI ranges were determined as shown in Table 3. They were rounded for the
survey presentation.
Table 3
95% CIs for HCV VL Results in Survey. Based on 0.15 log10 =1SD
HCV VL IU/ml
Test Result
562,000
31,620
1,950
1,000
562
100

Low 95%
286,000
16,060
991
508
286
51

High 95%
1,107,000
62,230
3,837
1,968
1,107
197

Using the information in Table 3, if patients are managed according to absolute test values
and clinical guidelines alone, without consideration of test imprecision and other factors, the
responses in Table 4 could be predicted at each HCV VL level for the 12-week result.
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Table 4
Predicted Decisions Based on HCV VL Test Result and Clinical Guidelines
Baseline
(IU/ml)
562,000

Post 12 wk Rx
HCV VL (IU/ml)

Decision according to guidelines

31,620
1,950
1,000
562
100

Discontinue therapy
Discontinue therapy
Continue/Discontinue therapy
Continue therapy
Continue therapy

Selection of the Study Sample
Clinicians who treat patients with chronic HCV disease were the intended population for this
survey. Access to these clinicians was through the member directory of the AASLD-American
Association for the Study of Liver Diseases. Members with physician (MD or DO), physician’s
assistant (PA), nurse practitioner (NP) or nurse (RN) credentials who did not indicate a pediatric
specialty were invited to participate through a personally addressed e-mail containing a link to
the survey.
Sample size. To compare the decisions made with and without the presentation of confidence
intervals, it was determined that a sample size of 99 would be needed for an effect size of .1
(showing a 10% difference in responses across the three decisions) with 2 predictors (the level of
the viral load and the presence/ absence of confidence intervals) an alpha of .05 and power of .8.
(On-line sample size calculator (http://www.danielsoper.com/statcalc/calc01.aspx). Adding
demographic and clinician practice variables, with up to 12 predictors, a sample size of 184
would be required for the same power and alpha. Invitations to join the survey with an enclosed
link were sent by the primary researcher to 1491 selected AASLD members. The first page of
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the survey contained an explanation and consent form. The study received approval by Virginia
Commonwealth University IRB #HM14538.
Variables in the Survey
The decision to continue or discontinue treatment (therapy decision) is a function of the
information presented to the clinician (patient and test result information), clinicians’ judgment
and experience (clinician variables), and standard or accepted clinical practices. The survey was
designed to test many of these variables. The variables are listed in Table 5.
Testing a Draft Version of the Survey
Prior to the release of the final survey, a draft version of survey (HCVVL Survey- Draft 3)
was sent via e-mail link to three physicians, one laboratory director and a clinical trials manager.
Instructions to review the survey and send comments were provided in the e-mail with the
internet link and PDF attachment of the survey. Some recipients of the e-mail chose to complete
the survey and in addition to their comments, their survey responses were recorded.
For those that actually completed the survey, the responses were “analyzed” as a test of the
survey and the internet hosted service. There were four recorded responses: two from physicians
and two from clinical research managers (one was also a medical student). Three of the four
respondents stated they managed HCV patients. The time to complete the survey was less than
11 minutes for all respondents.
All respondents chose integer values for the test results but one of three that answered the
question stated that their laboratory reports are provided results both in integer and log values.
For the four that answered the main question, there was a difference in the decision choices
made using the test values without the confidence intervals (No CI) and those results with the
confidence intervals (with CI). The pairs where the decision was different between the two
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Table 5
Variables in the Survey
Variable
All participants
Retest
Discontinue Therapy
Continue Therapy
Result presentation with or without
95% CI (intervention)
HCV VL
Contribution of CI results
Desire to have CI results
HCV Pt management professionals
Years of experience
No. of patients per month
Guidelines used for managing HCV
patients
Use of HCV VL for Rx management
HCV Pt management professionals utilizing
HCV VL
Send tests to same testing lab
HCV VL test method specified
Type of VL test results received from
testing lab
Guidelines used in treating HCV
patients
Physicians
Field of practice

Variable
Type

Source

Analytical
type

Dependent
Dependent
Dependent
Independent

Survey
Survey
Survey
Provided

Categorical
Categorical
Categorical
Categorical

Independent
Independent
Independent

Provided
Survey
Survey

Categorical
Categorical
Categorical

Independent
Independent
Independent

Survey
Survey
Survey

Continuous
Continuous
Categorical

Independent

Survey

Categorical

Independent
Independent
Independent

Survey
Survey
Survey

Categorical
Categorical
Categorical

Independent

Survey

Categorical

Independent

Survey

Categorical

presentations are highlighted in yellow in Table 6. The survey instrument appeared to be able to
elicit and record responses and the data was retrievable in a manner that could be used for the
planned analyses.
Final Survey Version
The final version of the survey distributed for the study was changed based on the reviews by
this pilot group, and research committee members. Changes included:
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Table 6
Responses to Patient Management Questions from Draft HCV VL Survey
Test Result
(IU/ml)

100,000
5,623
1,950
1000
562
100

% Response
Continue Rx with Dual
Therapy
No CI
With CI
0
0
0
0
0
0
25
0
100
75
100
100

DC Rx
No CI
100
100
100
0
0
0

Retest
With CI
100
100
75
0
0
0

No CI
0
0
0
75
0
0

With CI
0
0
25
100
25
0

1) The order of presentation of the HCV VL results with and without CIs was
randomized. (In the pilot version, the order was constant: without CI presented first,
with CI presented second.)
2) HCV RNA test result numbers were only presented as integers in the final survey. In
the pilot survey, participants were given a choice between integer and log10 values.
This choice was sacrificed on the final survey for the ability to randomize the
question order. All those participants completing the pilot survey chose integers, and
in discussions with laboratory directors on the subject, integer presentation was the
predominant form for laboratories not providing both.
3) The pilot version included a question about the importance of other non- HCV VL test
considerations for therapy management. All participants rated each of items at least
moderately important. In view of the length of the survey and consideration that this
did not contribute to the aim of the survey, this question was eliminated.

69

Other feedback from participants included questions regarding the drug of choice, suggestions
to randomize the presentation of results with and without CIs and a request to simplify the
survey. The three adjustments described above were made in response to their feedback.
The Decision Analytic Model
The treatment decision responses from the survey were used in an economic model to assess
if changes in the treatment decisions influenced the value of the test. A development decision
analytical model was constructed in Microsoft Excel 2007 to calculate the changes in test value
as the use of the information changed.
The key assumptions in the development model were:


The entry point in the model was at the HCV VL test following 12 weeks of triple
combination therapy (Incivek, interferon –alpha and ribavirin); the point where AASLD
guidelines recommend patients with HCV VL above 1000 IU/ml be removed from
further treatment.



The initial choice of decisions at the entry point was: Discontinue therapy, Continue
therapy or to Repeat the test. (The same decisions as in the survey).



Parameters and disease states were for HCV genotype 1 patients. For the development
model, the health states were: Response, SVR, Chronic HCV, Cirrhosis, Hepatocellular
Carcinoma, and Death.



The time horizon of the development model was 72 weeks. This encompasses the length
of influence of the HCV VL test in this clinical pathway, allowing the possibility of two
weeks delay for re-testing, an additional 36 weeks of continuing therapy plus 24 weeks
post therapy and testing to evaluate an SVR (SVR is defined as undetectable HCV RNA
24 weeks post the completion of therapy.) Sixty two weeks were needed to
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accommodate the two week repeat-test decision, but since the model was in 12-week
cycles, 72 weeks were used.


The development model employed Markov chains to map the probabilities of moving
through health states after the treatment management decisions had been made and
entered.



With the exception of the first two cycles, each time cycle was 12 weeks.



In the first cycle, the population of patients entered in the “repeat test” decision remained
in a chronic HCV state on dual combination therapy for two weeks and then were “reentered” back into the population for 10 weeks based on the percent decision to
discontinue or continue therapy from those that did not choose to re-test. This was
designed to simulate the time for a new sample to be drawn, tested, and reported with
subsequent clinician interpretation and decision.



There were no Quality of Life (QoL) values calculated in the development model.

Parameters for the development model. The purpose of the development model was to test
functionality and sensitivity to inputs. For the development model, transition probabilities and
cost parameter values were derived from literature and bureau of statistics tables where
accessible, however, estimations were made for several of the parameters. After testing the
development model for functionality, all parameter values were sourced from literature and
documented for the final model.
Testing the development model. The model was checked for mathematical accuracy by
visually checking each equation, assuring all populations were 100% at each state, and after
running the model, by analyzing the outputs for consistency with expected results.
A minimum of 235 scenarios were tested in the development model. Included were:
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•

All patients continuing on therapy (as if there were no test)

•

All patients removed from therapy (therapy failure with no test)

•

Using the response/ no-response population percentages cited in the clinical trials for
Incivek (telaprevir)

•

All combinations of the three decisions: Repeat the test/ Discontinue therapy and
Continue therapy in 5% increments. (Simulating increased indecision based on test
imprecision.)

The model output for a patient without therapy costs and without testing was $4,917 per
person during this period. These patients continued on a path of chronic HCV and subsequent
disease management cost consequences for the entire 72 weeks.
The total costs for remaining on therapy in the development model were $14,474 per patient.
This represented the costs if there was no HCV VL testing at week 12 and therapy was continued
for all patients, including those patients with VL greater than 1000 IU/ml (who should be
removed from therapy). HCV VL testing saves medical costs and quality of life loss due to
medication adverse events. The value of perfect test information was calculated to be the value
of the savings from discontinuing a therapy regimen that was not appropriate (up to $9557) for
the individual patient with a true HCV VL above 1000 IU/ml. However, the development model
had no consideration of penalties for incorrectly removing a patient from therapy. There were no
quality of life values for health states, and the costs of disease progression were not fully
developed.
To test a scenario duplicating the expected population response rates in the clinical trials for
telaprevir, inferences from the clinical trial literature were made. Though a cutoff of <1000
IU/ml for continuing therapy is given in literature and guidelines, there is no data in the studies
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showing the percent of patients with HCV VLs greater than 1000 IU/ml at week 12. The
telaprevir clinical trial reported that 58% of patients had an extended Rapid Virological
Response (eRVR), defined as an undetectable HCV VL at week 4 and 12. Among the 42% of
patients who did not have an eRVR, a Sustained Virological Response (SVR), which is the
treatment goal, was achieved in 60%. Therefore, it was assumed that approximately 17% (42% x
.40) of total patients starting therapy could be expected to have an HCV VL at week 12 that
would indicate that they are non-responsive to the therapy.
In a population where approximately 17% would have an HCV VL that would dictate
removal from therapy at week 12, the average per-patient cost would be $6542. Therefore,
testing on a population basis, and removing patients with HCV VL’s > 1000 IU/ml from
unproductive therapy, should save approximately $7932 (14,474-6542) per patient, provided the
test is reliable, and not repeated.
To model the consequences of imprecision, increasing retest rates were used as a surrogate.
The percent retest population was started at 0% (completely accurate, precise and reliable
information) and was increased up to 100% in 5% increments. Each of these were tested with all
combinations of decisions to continue or discontinue therapy; also varied in 5% increments. The
relative changes in total costs as the percent of decisions to repeat the test increased, were plotted
from the model outputs and are shown in Figure 6.
Conclusion of development model testing and final model. Through the development
model studies, it was concluded that mechanistically, the outputs from the model produced
changes in total costs as a result of different percentages of each decision entered. For the final
model used in the research, values for transition probabilities, costs and QoL were sourced from
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Figure 6. Percent change in costs as a function of percent retest rate.
literature. The dual therapy costs were adjusted for inflation. Table 7 lists the parameters used in
the model and their source.
Costs for health states were derived from Pyenson, Fitch, and Iwasaki (2009). Commercial
and Medicare costs (for those above and below 65years of age) were provided in their analysis.
From that publication, the Medicare costs for those less than 65 years of age were used in the
final version of the model. For several of the health states, they were more conservative than the
commercial costs. The health state costs derived from Pyenson et al. were not inflation-adjusted.
In the review of other literature, including an analysis of a large managed care organization
claims database from July 2001 to March 2010, the variability of reporting costs of each health
state for HCV disease was revealed (McAdam-Marx et al., 2011). Monthly costs at published
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Table 7
Decision Analytic Model Parameters
Parameter (12 weeks)
Triple combination therapy responses
Undetectable HCV VL p 12 wks
dual Rx
Undetectable HCV RNA at Rx end
Continued Response
Health state transition probabilities
Progression: Chronic HCV to
cirrhosis
Progression: Cirrhosis to
Decompensated Cirrhosis
Progression: Decompensated
Cirrhosis to HepCA
Costs
Cost of HCV viral load test
Cost of 12 wks dual therapy
(interferon and ribavirin)
12 week period costs for patients
with SVR1
12 week costs for patients with
Chronic HCV1
12 week costs for patients with
Cirrhosis1
12 week costs for patients with
Decompensated Cirrhosis1
12 week period costs for patients
with Hepatocellular Ca1
QoL Values
Chronic hepatitis

Value

Source

0.58

Jacobson et al., 2011

0.87
0.75

Jacobson et al., 2011
Jacobson et al.,2011

.006

Pyenson et al., 2009

.010

Pyenson et al., 2009

.010

Pyenson et al., 2009

$58.88
$5,721

CMS, Laboratory Fee Schedule,
April 2013
Piwko et al, 2005
Adj to 2013 via
http://www.bls.gov/cpi/cpicalc.htm

$0
$1545

Pyenson et al., 2009

$2345

Pyenson et al., 2009

$21,300

Pyenson et al., 2009

$7200

Pyenson et al., 2009

0.82

Cirrhosis – diagnosed

0.74

Decompensated cirrhosis

0.32

Hepatocellular carcinoma

0.10

1

Excludes HCV dual therapy and HCV test
costs. Includes other medical costs associated
with health state
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Australian Government, Dept of
Health and Aging, 2002
Australian Government, Dept of
Health and Aging, 2002
Australian Government, Dept of
Health and Aging, 2002
Australian Government, Dept of
Health and Aging, 2002

and inflation adjusted values were compared (Table 8). The values as published in Pyenson et al.
were higher in some cases than McAdam-Marx et al. and lower in others. Therefore, the values
as published in Pyenson et al. were used in the model as published (first column of costs in Table
8). A sensitivity analysis of the impact of cost variation was performed with the model and is
reported in the results section.
Table 8
Comparison of Published and Inflation Adjusted Costs for HCV Health States
Monthly Costs ($)
Pyenson et al.
adjusted*
556

McAdam-Marx et al.,
2011
488

McAdam-Marx et al.
adjusted*
529

437

474

2295

2488

3616

3919

HCV Health State Pyenson et al., 2009
Chronic HCV
515
Compensated
772
833
Cirrhosis
Decompensated
4200
4536
Cirrhosis
HCC
2400
2592
* Adjusted for inflation to 2013 costs per http://www.bls.gov/cpi/cpicalc.htm

Other changes made to the final version of the model used in this research were: removal of
death as a health state, removal of SVR as a separate health state from Response, and reduction
of the time from 72 to 60 weeks (more appropriately reflecting the time span over which the test
has influence; that needed to evaluate SVR). In addition, the health state “Decompensated
cirrhosis” was added and Quality of Life (QoL) values were accumulated at each state.
In addition, because the clinically prescribed decisions are not identical for all VL levels,
different inputs and patient flow strategies were used for each VL level when testing the inputs
from the survey at each distinct VL level.
For each viral load level, the model was run with at least three separate sets of inputs.
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1. Inputs reflecting all patients on therapy for the duration of therapy, reflecting a situation
where no test is available to guide removal of non-responders. (For this situation the
model had to be adjusted to remove the 24-week HCV test cost and subsequent routing
based on the results.)
2. Inputs according to AASLD guideline-directed decisions (e.g. no repeats and using the
percent distribution of the population VLs at that level, based on the imprecision used in
the survey 1SD =0.15 log10)
3. Inputs according to the proportion of decision choices by respondents in the survey.
Only data from the first presentation of HCV results to the respondents were used. These
data were used, as opposed to combining all responses, because clinicians normally are
provided with a single presentation of results to review.
The decision proportions were entered into health states at time zero (review of HCV results
post completion of 12 weeks of triple combination therapy) according to the following strategies:
1. For the Discontinue therapy arm, all decision proportions were entered in the Chronic
HCV health state as no further therapy would be given.
2. For the Continue therapy arm of the model:
a. The Repeat test decisions were combined with the Continue therapy decisions for
entry. After a cycle of two weeks, this proportion of responses was re-distributed
among the discontinue therapy and continue therapy arms according to the percent at
in the original entry.
b. For decisions recorded at a HCV VL=1950 IU/ml, proportions were entered into the
health states based on the distribution of the VL, using the CIs in the survey. At an
HCV VL =1950 IU/ml, the lower 95% confidence limit is 990 IU/ml. Approximately
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2.7% of the HCV VL values would be at 1000 IU/ml or below. Therefore, in the
Continue therapy arm, 2.7% of the decisions were entered in the Response health
state and 97.3% were entered in the Chronic HCV health state. For guidelinedirected decisions, the proportions used for each arm were: 0% Repeat test/97.3%
Discontinue therapy/ 2.7% Continue therapy.
c. For decision choices recorded at HCV VL1000 IU/ml proportions in the Continue
therapy arm were split equally between the Chronic HCV state and the Response
state. For guideline-directed decisions, the proportions used for each arm were: 0%
Repeat test/50% Discontinue therapy/ 50% Continue therapy.
d. For decision choices recorded at HCV VL 560 IU/ml proportions were entered into
the health states based on the distribution of the VL using the CIs in the survey. At
an HCV VL of 560 IU/ml the upper 95% confidence limit is 1110 IU/ml. If 97.5% is
at 1110 IU/ml or below, then 95.2% is at 1000 IU/ml or below. Therefore, in the
Continue therapy arm 95.2% of the decisions were entered in the Response state and
4.8% in the Chronic HCV health state. For guideline-directed decisions, the
proportions used for each arm were: 0% Repeat test/4.8% Discontinue therapy/
95.2% Continue therapy.
e. For decision choices recorded at HCV VL 100 IU/ml decisions for the Continue
therapy arm were entered in the Response health state. For guideline-directed
decisions, the proportions used for each arm were: 0% Repeat therapy/0%
Discontinue therapy/100% Continue therapy.
As with the development model analyses, inputs representing a population of diverse HCV
VL levels were also analyzed. The decision inputs were designed so that the therapy response
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outcomes of the model reflected the telaprevir trial outcomes as closely as possible. The inputs
are described in the results section.
Each decision set (proportions for Continue therapy, Discontinue therapy or Repeat test) was
used for the initial inputs to a model run. The resulting total costs and the average QoL ratio
from all branches of the model, each time the model was run, were recorded and compared. The
total costs of the survey-recorded decision choices with and without CI were compared against
the total costs of the guideline-directed decisions at each VL level. In addition, the total costs
resulting from the removal of non-responders from therapy were subtracted from the total costs
of keeping all patients on therapy for a determination of the value of the quantitative HCV RNA
test information. Sensitivity analyses of the model to costs, QoL values and retest rates were
also performed.
Hypothesis Testing
The recorded responses from the survey were analyzed using Chi-square, bivariate and
multinomial logistic regression techniques to test the first three hypotheses defined for this
research.
H1 null hypothesis: The presentation of HCV VL results with 95% confidence intervals will
have no impact on the treatment decision for HCV Genotype 1 patients.
It was presumed that the presentation of results with CI would result in different decisions
when compared to the decisions made with results presented in the conventional manner. For the
HCV VL load levels immediately below the threshold, at the threshold, and immediately above
the threshold it was expected that there would be increased ambiguity between the Discontinue
and Continue therapy choices, and higher repeat testing decisions for the results presented with
CI. Since the CI’s for the HCV VL immediately above the threshold crossed slightly below the
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threshold, it was also thought that there might be an increased proportion of clinicians deciding
to continue therapy when compared to decisions made viewing the same HCV VL result without
CI. Anticipating these findings, the second hypothesis was formed to further characterize the
differences in decisions that might be observed.
H2 null hypothesis. There is no difference in the impact of awareness of CIs on the treatment
decisions between different HCV VL levels.
H3 null hypothesis. Clinicians’ experience and demographics will have no impact on treatment
decisions using HCV VL results presented with and without confidence intervals. If there were
differences in the decisions made viewing results with and without the presentation of CI, it was
thought that differences in experience and practice might correlate with the ability to apply the
information correctly.
In addition to testing these hypotheses, the recorded responses from the survey were used as
inputs to the decision analytic model to evaluate the economic impact of the clinicians’
decisions. It was proposed that the value of the HCV VL test at the 12- week decision point in
therapy could be determined by calculating the cost of treatment and disease progression, leaving
all patients on therapy throughout the course and comparing them to the costs in the scenario
where patients who would fail therapy, revealed by the HCV VL test results, did not continue the
dual-combination treatment.
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Chapter Four: Results

The purpose of this research was to examine methods of measuring the contribution of
laboratory tests to healthcare. Important aspects of a laboratory test’s contribution are the
clinical utility of the test information, and the role of that information in facilitating efficient and
effective use of patient management resources. The use of quantitative HCV RNA test results
(HCV VL) to decide whether to continue or discontinue antiviral therapy after 12 weeks of
treatment was used as a model for this research. For the clinical utility of the HCV VL test,
precision is crucial; therefore, the clinical utility was evaluated by studying the impact that the
knowledge of the inherent assay imprecision might have on patient management decisions. To
measure the test’s economic contribution, a Markov decision-tree model was developed to
determine the cost differences in leaving all patients on therapy versus removing those who
would not respond given their HCV VL result. Further, the cost differences resulting from
removing patients from therapy as directed solely by clinical guidelines and those resulting from
removing patients according to the clinicians’ decisions from the survey were determined and
compared.
Impact of Test Imprecision on Clinician Decisions
A survey was designed to elicit clinicians’ decisions when HCV VL results were provided
with the 95% confidence intervals around five different levels of HCV viral load results. An
invitation e-mail with the survey link was sent by the primary researcher to 1491 members of the
American Association for the Study of Liver Diseases. At the close of the survey, 138 responses
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were recorded (9.3%). Of those responding, 14 accepted only the consent and progressed no
further, six of the respondents answered only one of the two questions with the HCL VL results,
and the remaining 118 answered both. Though respondents could exit the survey at any point,
114 answered demographic and clinician preferences questions as well. Respondents used an
average of 8.3 minutes to complete the survey. Recorded times greater than 60 minutes were
removed from the data. It was assumed that these respondents had been interrupted or left their
computers with the survey open and that the elapsed time was not reflective of time spent
answering the questions.
Sample. The sample of respondents consisted of health care professionals who would utilize
HCV VL results in their clinical practice. Physicians comprised 89% of respondents and 92% of
respondents answered that they managed the treatment of hepatitis C patients. Responders were
in practice an average of 20.5 years and saw an average of 47 patients per month. Ninety-one
percent claimed their field as hepatology, gastroenterology or both. All respondents indicated
they use HCV RNA results in the management of their patients with hepatitis C. Of those,
84.2% indicated they send their samples to the same testing lab for the pre-treatment and the 12week test points most of the time. The remaining 15.8% responded it was not within their
control. Sixty-one percent specified that the identical test method be used for the pre-treatment
and the 12 week test points; while 28.9% responded it was not within their control. Of the 114
respondents to the question of practice guidelines used, 96% indicated the use of the AASLD
guidelines. EASL guidelines were utilized by 15.8%, and information from pharmaceutical
companies was utilized by 13.2%. These responses indicate knowledge of the current clinical
practice guidelines for the management of hepatitis C disease, and the intent to comply. Table 9
contains the responses to the questions regarding practice preferences and logistics.
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Table 9
Respondent Preferences and Patient Management Practices
____________________________________________________________________
Preferences and Practices

Percent of Responses

Preferences regarding presentation of CI:
The results with CI
n=118
Neither added to nor detracted from the test result
Provided relevant added information to the test result
Detracted from or confused the test result

44.9
38.1
16.9

Desire to receive the 95% CI with patient results? n=114
No
Yes
Not decided
Already do receive them

46.5
43
7.9
2.6

Practices regarding HCV RNA testing:
Send tests to the same lab for Pretreatment and 12-wk HCV RNA. n=114
Yes
84.2
Not within respondents control
15.8
No
0
Specify that identical methods be used for pre-treatment and 12-week HCV RNA. n=114
Most of the time
61.4
Not within respondents control
28.9
Not at all
8.8
Sometimes
0.1
Type of VL results received from laboratory. n= 114
Integers and Log10
Integers
Log10
Unsure

71.9
20.2
6.1
1.6

Guidelines used for patient management. (Non-exclusive choices.) n=114
AASLD
96.5
EASL
15.8
Pharmaceutical Company
13.2
Institutional
7
Others
Less than 7
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Descriptive statistics of the sample demographics are in Table 10. The responses were
analyzed in total and then were split, based on whether the respondents saw the results presented
without CI first (No CI) or with CI first (With CI). For categorical data, the chi-square test was
used to test the independence of the observed versus expected frequencies in each of the two
population samples (Microsoft Excel 2007). For continuous data, the TTEST function
(Microsoft Excel 2007) was used to test for significance. The two groups, separated by the order
of the presentation of results with confidence intervals, were demographically similar; no
statistical differences were determined. They could be used be used as two separate sample
groups for future comparisons.
Hypothesis testing. Different groupings of the data were used in the following analyses for
hypothesis testing. Analyses of multiple decisions and variables employed Pearson’s chi-square,
logistic regression, and multinomial logistic regression (IBM SPSS version 20). Analyses at
each VL level, comparing each of the three decisions made without CI (NoCI) and with CI (With
CI) were performed by chi-square tests (Microsoft Excel 2007). Figure 7 outlines the different
data groupings.
H1 null hypothesis. The presentation of HCV VL results with 95% confidence intervals will
have no impact on the treatment decision for HCV Genotype 1 patients.
H2 null hypothesis. There is no difference in the impact of awareness of CIs on the treatment
decisions between different levels of HCV VL.
These two hypotheses are interdependent. In a thorough analysis of H01, H02 is included as
the data was analyzed for the impact of CI on the three decisions in total and separately at each
VL level.
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Table 10
Sample Population Demographics
Seen First
No CI

With CI

Total
124

Percent

Number
65

Percent
52.4

Number
59

Percent
47.6

p

101
6
5
2
2
8

81.5
4.8
4.0
1.6
1.6
6.5

52
3
4
2
1
3

80.0
4.6
6.2
3.1
1.5
4.6

49
3
1
0
1
5

83.1
5.1
1.7
0.0
1.7
8.5

0.98
0.99
0.66
0.61
0.99
0.58

110
1
1
1
1
10

88.7
0.8
0.8
0.8
0.8
8.1

59
0
1
0
1
4

90.8
0.0
1.5
0.0
1.5
6.2

51
1
0
1
0
6

86.4
1.7
0.0
1.7
0.0
10.2

0.97
0.77
0.82
0.78
0.82
0.87

Manage hepatitis C patients
Yes
114
No
4
No response
6

91.9
3.2
4.8

61
2
2

93.8
3.1
3.1

53
2
4

89.8
3.4
6.8

0.88
0.99
0.82

91.9

61
2-300
35
54.1
61.4

93.8

53
0-300
30
38.8
49.8

89.8

61
1-40
20
20.7
9.8

93.8

53
4-45
20
20.3
10.3

89.8

53
41
16
4
2
1
0
1
1
6

89.8
69.5
27.1
6.8
3.4
1.7
0.0
1.7
1.7
10.2

Participants*
Location of practice
US
Europe
Canada
AUS/NZ
LATAM
No response
Profession
Physician
Nurse Practitioner
Nurse
Physician's Assistant
Other
No response

Number of patients per month
Responses
114
Range
0-300
Median
30
Avg
47.0
SD
56.6
Number of years in practice
Responses
Range
Median
Avg
SD

114
1-45
20
20.5
10.0

91.9

Field of practice
(Non-exclusive multiple choice)
Responses
114
91.9
61
Hepatology
88
71.0
47
Gastroenterology
34
27.4
18
Infectious diseases
9
7.3
5
Internal Medicine
4
3.2
2
Pediatric Hepatology
1
0.8
0
Virology
1
0.8
1
Pathology
1
0.8
0
Research
1
0.8
0
Blanks
10
8.1
4
*Answering at least one question
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93.8
72.3
27.7
7.7
3.1
0.0
1.5
0.0
0.0
6.2

0.15

0.82

0.99
0.99
0.99
0.99
0.77
0.82
0.77
0.77
0.88

Surveys Sent
N=1491

Responses
n=138
Declined consent or
did not answer:
n=14
Answered 1 or both
HCV Result questions:
n=124

Analyzed all responses ,
irrespective of order
seen:
n=124

Analyzed all responses ,
based on order seen
order seen:
n=124

Analyzed all responses ,
split population on first
question:
n=124
NoCI results : n=65
WithCI results: n=58 -59

Analyzed responses
only answering BOTH
HCV result questions:
n=118

Changed response from
one question to next
n=24

Figure 7. Groupings of data for analysis of survey responses.
The strategies used to analyze the responses in relation to the presentation of results with and
without CI were (Figure 7):


Analysis of the decisions from all respondents as one group.



Analysis of the decisions between two groups, based upon whether the respondents saw
HCV VL results with CI first or without CI first.



Analysis of the impact of the presentation order of results with and without CI on the
decisions made.
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Analysis of the impact of the presentation order of CI on individuals whose decisions
were different between the first and second questions.

Analysis of decisions from all respondents independent of order seen. Data from 124
respondents were used, and decisions based upon the results with CI and the results without CI
were compared.
Multinomial logistic regression was used to analyze the impact of CI on choosing one of the
three possible decisions: Discontinue therapy, Continue therapy or Repeat the test. Through
logistic regression methods (bivariate and multinomial) the probability of an outcome can be
predicted based on the known values or frequencies of occurrence of the predictor variables. For
the first analysis, the sole predictor variable was the presence or absence of CI with the
quantitative HCV VL results. Table 11 lists the impact of the variable CI on the decision
outcomes. Multinomial logistic regression uses one of the outcomes as a reference and returns
one less than the number of outcomes as models. In this research, there were three outcomes so
two models in relation to the reference are returned. The Repeat test outcome was the reference
in these regressions. Separate analyses of the likelihood of repeating the test was performed by
binomial logistic regression and is presented later. In logistic regression, the coefficients for
each variable (B) are selected through maximum likelihood estimation, fitting the parameters to
the observed data. They represent the change in the logit of the outcome variable (the natural
logarithm of the odds of the outcome happening) associated with a one-unit change in the
predictor variable. The Wald statistic denotes whether the coefficient is significantly different
from zero, the strength of that predictor variable. It is a z-statistic with a chi-square distribution;
therefore its significance can be reported. Exp B is the exponential of the predictor coefficient, B
(natural logarithm) and as such indicates the change in odds based on a unit change of the
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Table 11
Multinomial Regression Statistics with Variable CI. All Responses

Decision at all HCV VL
levels a
Discontinue therapy
Intercept
Without CI
With CI

95% Confidence Interval for Exp(B)
Odds ratio
Lower
Upper
Bound
Exp (B)
Bound

B

Std. Error

Wald

df

p

1.213
.141

.119
.174

103.157
.654

1
1
0

.000
.419

.818

1.151

1.620

.125
.182

44.968
1.160

1
1
0

.000
.281

.852

1.216

1.738

0b

Continue therapy
Intercept
Without CI
With CI

.841
.196
b

0

a. The reference category is: Repeat test
b. This parameter is set to zero because it is redundant.
VL= Viral Load CI= Confidence Intervals

predictor; or the odds ratio. Numbers greater than one are associated with increasing odds and
numbers less than one are associated with decreasing odds of the outcome. In Table 11, the
analysis shows that the presentation of CI as a variable has no significant strength as a predictor
(p=.419 to Discontinue therapy vs. Repeat test, and p= .281 to Continue therapy vs. Repeat test).
Since CI made no significant impact on the decision outcomes, the variable Viral load level
was added. Predictor variables in this multinomial regression were, Viral load level (VL),
whether the respondents saw results with CI (WCI) and the interaction of the two variables,
(VL* WCI). The final model contained only the VL levels as a significant predictor (model chisquare 792.6, p<0.05, df=8). Addition of the variable CI, or the interaction of the two variables,
CI and VL provided no additional model strength. In fact, the addition of CI as a variable
detracted from model strength (p=.481). Therefore, the presence or absence of CI with the result
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did not impact the decision outcomes in this data set. Table 12 lists the impact of the variable
VL and WCI on the decision outcomes.
Table 12
Multinomial Regression Statistics with Viral Load and the Presence or Absence of CI Variables.
All Responses

Decision at all HCV VLs a

95% Confidence Interval for Exp(B)
Odds Ratio
Lower Bound
Exp (B)
Upper Bound

B

Std. Error

Wald

df

p

21.313

.527

1635.543

1

0.000

100 IU/ml

-21.378

.588

1320.312

1

.000

1.639E-10

5.193E-10

1.645E-09

560 IU/ml

-20.760

.569

1329.446

1

.000

3.158E-10

9.641E-10

2.943E-09

1000 IU/ml

-21.273

.539

1555.018

1

0.000

2.005E-10

5.770E-10

1.661E-09

1950 IU/ml

-19.430

.488

1582.955

1

0.000

1.399E-09

3.644E-09

9.489E-09

31620 IU/ml

b

.196

.513

.474

.784

1.151

1.690

Discontinue therapy
Intercept

Without CI
With CI

0
.141

0
1
0

0b

Continue therapy
Intercept

17.590

.329

2865.757

1

0.000

100 IU/ml

-15.716

.377

1737.393

1

0.000

7.140E-08

1.495E-07

3.130E-07

560 IU/ml

-15.950

.375

1813.406

1

0.000

5.677E-08

1.183E-07

2.465E-07

1000 IU/ml

-18.134

.357

2581.260

1

0.000

6.620E-09

1.332E-08

2.682E-08

1950 IU/ml

-18.269

0.000

1.163E-08

1.163E-08

1.163E-08

31620 IU/ml

b

.861

1.272

1.881

Without CI
With CI

0
.241

1
0

.199

b

0

1.458

1

.227

0

a. The reference category is: "Repeat Test"
b. This parameter is set to zero because it is redundant.
VL= Viral Load level. WCI= With Confidence Intervals

Each VL level was then examined separately using all responses. Chi-square was used to test
the independence of the observed versus expected frequencies of the decisions made at each VL,
using HCV VL results with or without CI. A value of p< 0.05 for the CHISQ.TEST indicates a
very low probability that differences are due to random error, therefore the data sets would be
considered different. As shown in Table 13, no statistically significant probabilities were
obtained for the any of the three possible decisions made from results with CI or without CI at
89

Table 13
All Data: Any Order Seen. Chi-square Analysis at Each VL Level

Discontinue Therapy
Question with
No CI
With CI
Viral Load
IU/ml
# (% resp)
31620
117 (97.5)
1950
99 (82.5)
1000
49 (40.8)
560
25 (20.8)
100
12 (10.0)

# (% resp)
119 (97.5)
98 (81.0)
48 (39.7)
27 (22.1)
14 (11.5)

Continue Therapy
Question with
No CI
With CI
p
1.00
0.99
1.00
1.00
0.99

# (% resp)
3 (2.5)
8 (6.7)
29 (24.2)
85 (70.8)
95 (79.2)

# (% resp)
3 (2.5)
8 (6.6)
28 (23.1)
77 (63.1)
95 (77.9)

Repeat Test
Question with
No CI
With CI
p
1.00
1.00
1.00
0.65
1.00

# (% resp)
0
13 (10.8)
42 (35.0)
10 (8.3)
13 (10.8)

# (% resp)
0
15 (12.4)
45 (37.2)
18 (14.8)
13 (10.7)

p
0.99
0.99
0.49
1.00

NoCI= Without Confidence Intervals. With CI= With Confidence Intervals
any of the viral load levels, indicating no difference in response at any level based on
presentation of HCV VL results with or without CI.
To further verify the paired analyses performed for each single decision, all three decisions at
each VL were further analyzed, utilizing Pearson’s chi-square statistic to test for the
independence of two variables. The variables were: HCV VL results presented with CI, and
HCV VL results presented without CI. With a low significance value (p <0.05) the hypothesis
that the variables are independent would be rejected and the confidence that they are related is
increased. Table 14 contains the output of each of the five analyses. Pearson’s chi-square
statistic was significant at all VLs, indicating a strong relationship between decisions made using
results with CI and those without CI, with little to no impact of the presentation of CI. Cramer’s
V, a measure of association that can be used for nominal variables was greater than 0.8 for each
level tested, supporting the chi-square findings.
Analysis of responses between two groups based on the order of the presentation of results
with and without CI. In practice, HCV VL results are presented to a clinician only once,
currently without the CI. Therefore, respondents were split into two groups based on whether
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Table 14
Results of Pearson’s Chi-square Test. All Three Decisions

Viral Load Contingency Pearson's
2
IU/ml
Table
X
df
31,620
NoCIxWCI*
118
1
1950
NoCIxWCI
174.8
4
1000
NoCIxWCI
162.9
4
560
NoCIxWCI
158.5
4
100
NoCIxWCI
199.9
4
*NoCI= results without CI. WCI= results with CI

p
0.00
0.00
0.00
0.00
0.00

Cramers
V
1
0.86
0.83
0.82
0.921

they saw results with CI first or without CI first. For each respondent, only the decisions
recorded from the first question were analyzed (one answer-set of decisions from each
respondent). Sixty-five respondents (53.4%) saw the results presented with no CI first, and 59
(47.6%) saw results with CI first. The data presented earlier in Table 10 demonstrate that the two
groups were demographically similar.
To determine if there was a significant impact of confidence intervals or viral load level on
the decisions based upon how the respondents saw the results first, multinomial logistic
regression was used with the three decisions as outcomes for the dependent variable. As with the
analysis using all responses, predictor variables were: VL (Viral load level), whether the
respondents saw results with CI (Saw CI) and the interaction of the two variables, (VL* Saw CI).
Again, the final model contained the two predictor variables independently; addition of the
interaction provided no additional model strength (model chi-square 497.4, p< .05, df=8). Viral
load level was the only significant predictor variable. The significance of the Wald statistic for
the variable CI was p= .539 for Discontinue therapy and p= .128 for Continue therapy. The
addition of CI detracted from overall model strength in this analysis (p= .051) but to a lesser
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extent than in the analysis with all responses. Table 15 displays the regression statistics with the
variables viral load level and the presentation of CI.
Table 15
Multinomial Regression Statistics: Two Populations Based on Responses to the First
Presentation of HCV VL Only
Decision at all HCV
VL'sa
B
Std. Error
Wald
Discontinue therapy
Intercept
21.317
.747
814.283
100 IU/ml
-21.506
.837
659.641
560 IU/ml
-20.769
.811
656.122
1000 IU/ml
-21.393
.763
785.394
1950 IU/ml
-19.432
.691
789.913
b
31620 IU/ml
0
Without CI
.173
.281
.378
b
With CI
0
Continue therapy
Intercept
17.898
.463
1495.535
100 IU/ml
-15.626
.535
853.550
560 IU/ml
-15.773
.536
866.571
1000 IU/ml
-18.113
.502
1299.566
1950 IU/ml
-18.261
0.000
b
31620 IU/ml
0
Without CI
-.432
.284
2.315
b
With CI
0
a. The reference category is: Repeat Test
b. This parameter is set to zero because it is redundant.

95% Confidence Interval for Exp(B)
Odds Ratio
Lower Bound
Exp (B)
Upper Bound

df

p

1
1
1
1
1
0
1
0

.000
.000
.000
.000
.000

8.858E-11
1.949E-10
1.146E-10
9.381E-10

4.572E-10
9.548E-10
5.118E-10
3.637E-09

2.360E-09
4.679E-09
2.285E-09
1.410E-08

.539

.685

1.189

2.063

1
1
1
1
1
0
1
0

0.000
.000
.000
.000

5.735E-08
4.940E-08
5.083E-09
1.173E-08

1.636E-07
1.412E-07
1.361E-08
1.173E-08

4.667E-07
4.035E-07
3.643E-08
1.173E-08

.372

.649

1.132

.128

RL= Viral load level. CI = Confidence Intervals
As with the analysis of all responses, chi-square tests were used for this grouping to test for a
probable correlation of decision with the presentation of CI at each VL (Table 16). Though no
statistically significant correlations were found, some interesting observations were made. When
presented with HCV VL with CI just above the decision threshold [1950 (990-3800 IU/ml)], 7%
more respondents chose the decision to continue therapy, and approximately 11% fewer chose to
discontinue therapy than those presented with results without CI. A small percent more (2%)
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Table 16
Respondents’ Decisions Split by Presentation of Results for First Question
Discontinue Therapy
"Survey with"
No CI
With CI
Viral Load
IU/ml
# (% resp) # (% resp)
31620
64 (98.5) 57 (95.0)

Continue Therapy
"Survey with"
No CI
With CI
p
0.93

# (% resp) # (% resp)
1 (1.5)
2 (5.0)

Repeat Test
"Survey with"
No CI
With CI
p
0.93

# (% resp) # (% resp)
0
0

p

1950

56 (86.2)

45 (77.6)

0.67

2 (3.1)

6 (10.3)

0.45

7 (10.8)

7 (12.1)

1.00

1000

28 (43.1)

19 (32.8)

0.71

16 (24.6)

14 (24.1)

1.00

21 (32.3)

25 (43.1)

0.68

560

15 (23.1)

10 (16.9)

0.87

41 (63.1)

45 (76.3)

0.47

9 (13.8)

4 (6.8)

0.65

100

7 (10.8)

5 (8.5)

0.98

48 (73.8)

51 (86.4)

0.38

10 (15.4)

3 (5.1)

0.32

NoCI= Without Confidence Intervals. With CI= With Confidence Intervals
chose the Repeat test option. When presented with results just below the decision point and with
CI [560 (290-1,110) IU/ml], 13% more respondents chose the decision to continue therapy, 5%
less chose to discontinue therapy, and 7% fewer chose to repeat the test. With the exception of
the repeat testing at this level, these decision differences were more pronounced with the
responses split into two groups based on the first presentation seen, than those observed when all
responses were analyzed as one group. At the decision threshold of 1000 IU/ml, 11% fewer who
saw the results with CI (510- 1,970 IU/ml) chose to discontinue therapy than those who saw
results without CI, and 7% more repeated the test. The percentage of respondents who chose to
continue therapy was the same between these two groups at this level. Since the confidence
intervals presented with the HCV VL results immediately above and below the threshold showed
the VL crossing the decision threshold, these results reveal some impact on the decision
outcomes. However the impact was not statistically significant by chi-square tests.
To determine if there were differences in response to CI between VLs, the number and
percent responses for each decision were analyzed by two-tailed T tests. No statistical
significance was found for any of the response differences (p= .66 - .91).
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Analysis based on order of the presentation of results, with or without CI. The order of
presentation of the HCV VL results, with or without CI, was randomized among the survey
participants. Therefore, responses could be analyzed based on the order in which they were seen.
As with prior analyses, chi-square tests were used separately for each VL level. There was only
one decision outcome that was initially observed as statistically significant, the decision to
continue therapy based on HCV VL results of 560 IU/ml with CI [560 (290-1,110) IU/ml]. For
this case, the order in which the HCV VL results were seen, with or without CI, had an impact on
the decision made. If the respondents saw the HCV VL without CI first, fewer decided to
continue therapy than those who saw the result with CI first (p = 0.04). More decided to
discontinue therapy than those who saw the CI first, and more decided to repeat the test than
those who saw the CI first. The latter two comparisons were not statistically significant by the
original criterion of p<0.05. However, even the one statistically significant effect by the original
criterion may be a result of an inflated chance of a type I error due to the multiple tests
performed (Field, 2013). Applying the Bonferroni correction, using 28 as the number of tests, a
more rigorous threshold for significance would be 0.002 (pcrit = α/κ). In this case, no finding is
statistically significant. Table 17 shows all the pair wise chi-square tests for these analyses and
the associated p-values with each pair. The first column labeled “Viral Load” is the item seen by
the participant. The decision choices are in the succeeding columns, but split by the type of
presentation the respondents saw first. For example, for the first viral load presented (31,620
IU/ml without CI), 117 respondents decided to discontinue therapy. Sixty-four of them answered
this seeing this as the first presentation (NoCI), while 53 of the respondents had seen the results
with CI before viewing this result.
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Table 17
Chi-square Test Result Based on Order Seen

Viral Load

Discontinue Therapy
Seen First
No CI
With CI
# (%resp) # (%resp)

p

31620

64 (98.5) 53 (96.4)

0.91

1 (1.5)

2 (3.6)

0.91

0

0

1950

56 (86.2) 43 (78.2)

0.73

2 (3.1)

6 (10.9)

0.40

7 (10.8)

6 (10.9)

1.00

1000

28 (43.1) 21 (38.2)

0.96

16 (24.6) 13 (23.6)

1.00

21 (32.3) 21 (38.2)

0.93

560

15 (23.1) 10 (18.2)

0.93

41 (63.1) 44 (80.0)

0.25

9 (13.8)

1 (1.8)

0.13

7 (10.8)

0.99

48 (73.8) 47 (85.5)

0.49

10 (15.4)

3 (5.5)

0.39

100
31620
(16,060 - 62,230)
1950
(990- 3,800 )
1000
(510 – 1,970 )
560
(290 - 1,110)
100
(50 – 200)

5 (9.1)

Continue Therapy
Seen First
No CI
With CI
# (%resp) # (%resp)

p

Repeat Test
Seen First
No CI
With CI
# (%resp) # (%resp)

p

62 (98.4) 57 (95.0)

0.77

1 (1.6)

3 (5.0)

0.77

0

0

53 (84.1) 45 (77.6)

0.84

2 (3.2)

6 (10.3)

0.47

8 (12.7)

7 (12.1)

1.00

29 (46.0) 19 (32.8)

0.53

14 (22.2) 14 (24.1)

1.00

20 (31.7) 25 (43.1)

0.64

17 (27.0) 10 (16.9)

0.62

32 (50.8) 45 (76.3)

0.04

14 (22.2)

4 (6.8)

0.12

9 (14.3)

0.80

44 (69.8) 51 (86.4)

0.18

10 (15.9)

3 (5.1)

0.29

5 (8.5)

NoCI= Without Confidence Intervals. With CI= With Confidence Intervals
Further analysis of the decision outcomes for a VL of 560 IU/ml with CI. Though there were
no statistically significant findings at the VL of 560 IU/ ml with CI, this result presented some of
the more interesting observations and was used for further analysis. In the survey, respondents
were asked if the results with CI provided relevant information, if it detracted from or confused
the result, or if neither of these applied. This variable (Relevant) was used in a multinomial
logistic regression with all three decisions as outcomes at the VL level of 560 IU/ml presented
with CI. The other predictor variable was which test results were seen first, those without CI or
those with CI. The only outcome having a significant predictor was the decision to continue
therapy. The significant predictor for Continue therapy was the order of the presentation of
results: viewing the HCV VL results with no CI first. The regression model and individual chi-
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square tests had the same outcome. However from the model it could be determined that if
clinicians saw a VL of 560 IU/ml without CI first, they were 7.5 times less likely (odds ratio
0.134) to decide to continue their patients on therapy than to repeat the test. Table 18 displays
the statistical data.
Table 18
Multinomial Regression of Decision Choices at 560 IU/ml

a

560 IU/ml with CI
Discontinue Therapy
Intercept
No CI seen first
With CI seen first

95% Confidence Interval for Exp(B)
Lower Bound
Exp(B)
Upper Bound

B

Std. Error

Wald

df

p

1.441
-.982

.710
.757

4.120
1.682

1
1
0

.042
.195

.085

.375

1.652

b

0

CI added to
information

-.696

.665

1.097

1

.295

.136

.499

1.834

CI detracted from
information

.112

1.305

.007

1

.932

.087

1.118

14.437

CI neither added or
detracted

0b

0

Continue Therapy
Intercept
No CI seen first
With CI seen first

2.418
-2.009

.658
.692

13.523
8.436

1
1
0

.000
.004

.035

.134

.520

b

0

CI added to
information

.169

.600

.079

1

.778

.366

1.184

3.833

CI detracted from
information

2.017

1.132

3.178

1

.075

.818

7.519

69.104

CI neither added or
detracted

0b

0

a. The reference category is: Repeat Test
b. This parameter is set to zero because it is redundant.

Narrowing the analysis further just to the decision to continue therapy with the presentation of
results at 560 IU/ml, binomial logistic regression analyses could be used and other factors could
be examined. Predictor variables were: which test results were seen first, with or without CI
(Seen first), and whether the respondent thought that the results with CI provided relevant
information (Relevant). The predictor variables were added in hierarchical progression: Seen
first, Relevant and the interaction Seen first *Relevant. The chi-square of each new model over
96

the previous was significant at p<0.05. The final model contained both predictors and the
interaction of the two predictor variables. However, the model only correctly predicted 67.8% of
the outcomes. Of the predictor variables, the two parameters most informative (Wald statistic
p<0.5) were: viewing HCV VL without CI first (from Seen first) and, if the CI detracted from or
confused the result (from the variable Relevant). At HCV VL of 560 IU/ml, clinicians who saw
results without CI first were nearly four times less likely to choose to continue therapy (odds
ratio 0.256) than those who saw the results with CI first. However, respondents who answered
that the CIs detracted from the result were seven times more likely to choose the “continue with
therapy” option at this level (odds ratio 7.12), than those who responded that the CI presentation
did not add information or it detracted/ confused the result (the reference). Table 19 lists the
variables with their corresponding statistics.
Table 19
Logistic Regression Statistics for Continue Therapy Decision at HCV VL 560IU/ml with CI

Continue Therapy at 560
IU/ml with CI
No CI seen first
Relevant
CI added to
information
CI detracted
from information
Constant

95% C.I.for EXP(B)
Odds ratio
Lower Exp(B) Upper
.110
.256
.594

B
-1.363

S.E.
.429

Wald
10.073
7.864

df
1
2

p
.002
.020

.598

.442

1.834

1

.176

.765

1.819

4.322

1.963

.715

7.538

1

.006

1.754

7.121

28.915

.794

.364

4.760

1

.029

2.213

Prior analyses suggested that there were no interdependencies between the variables in the
survey; however, to specifically illustrate this, a correlation matrix utilizing Pearson’s chi-square
was developed. Table 20 shows that the only statistically significant correlation is between the
decision to continue therapy when the HCV VL = 560 IU/ml with CI and whether or not the CI
was seen first. This is consistent with the other findings.
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Table 20
Correlation Matrix for the Decision to Continue Therapy at 560 IU/ml

Correlations
560 IU/ml With CI Pearson Correlation
Continue Therapy Sig. (2-tailed)
N
Seen first: With or Pearson Correlation
Without CI
Sig. (2-tailed)

560 IU/ml
With CI
Continue

Seen first:
With or
Without CI

1

.264**
.003
122
1

122

.264**
.003
N
122
CI provided
Pearson Correlation
-.116
relevant
Sig. (2-tailed)
.211
information
N
118
Want to have CI Pearson Correlation
.031
with results
Sig. (2-tailed)
.746
N
114
**. Correlation is significant at the 0.01 level (2-tailed).

124
.042
.648
118
-.034
.718
114

CI provided
relevant
Want to have
information CI with results
-.116

.031

.211
118
.042
.648
118
1

.746
114
-.034
.718
114
-.143
.130
114
1

118
-.143
.130
114

114

Impact of presentation order, with and without CI, on changes in decisions from the first to
the second set of results. Data from the 118 respondents who answered both questions were
included in the data set. Twenty-four (20.3%) gave different decisions for the second question
than they did for the first question. Of those, 18 (75%) saw the test results without CIs first,
while 6 (25%) saw the results with CIs first. By the chi-square test, this difference was not
significant: p= 0.13).
Binomial logistic regression was performed on the dependent variable Changed decision,
using each decision at each level (31 changed decisions out of 588 individual decisions at all
levels). Predictor variables were VL and Seen first (whether the respondent saw the results
without CI first or saw the results with CI first). The predictor variables VL and Seen First were
added in hierarchical progression: VL, Seen first and the interaction of VL*Seen first. In a final
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model, excluding the interaction of the two variables, Seen first was significant (Wald = 3.176,
p=0.001, df=1). For those who viewed results without CIs first, the odds of changing the
response on the next result with CI were approximately five times more likely than the converse
(95% CI of odds ratio: 1.11-13.39). The addition of the interaction of VL*Seen first was not
informative and masked the significance of the variable Seen First.
H1 and H2 null hypothesis findings. The H1 null hypothesis, that the presentation of CIs will
have no impact on the clinicians’ therapy management decisions, cannot be rejected. The
presentation of HCV VL results with 95% confidence intervals had no statistically significant
impact on the treatment decision for HCV genotype 1 patients. There were no statistically
significant findings at a significance threshold that corrected for the multiple analyses performed.
The one finding with a p<.05 did continue to be seen when analyzed further, however, it
describes a scenario that does not reflect clinical practice. At 560 IU/ml, when respondents first
saw results without CI and then were presented with results displaying the CI, they were less
likely to choose to continue therapy than their counterparts who saw the results with CI first.
Conversely, clinicians who stated the presentation of CIs detracted from or confused the results
were more likely to continue therapy. In addition, clinicians seeing results without CI first and
then with CI were more likely to change their decision on the second question. Though these are
interesting findings that could provide some insight to further research, they do not support the
rejection of the null hypothesis.
The H2 null hypothesis is also not rejected. H02, that there is no impact of CIs on the
decisions at different VLs, depended on at least one finding in H01 at one of the VL levels. Viral
load levels themselves, had the greatest impact on decision outcomes irrespective of whether the
results were presented with or without CIs.
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H3 null hypothesis. Clinicians’ experience and demographics will have no impact on
treatment decisions using HCV VL results presented with and without confidence intervals.
Multinomial logistic regression was used to evaluate possible correlations between physician
demographics, clinical experience, practice preferences and the three outcome decisions.
Predictors variables in the analysis were the five viral load levels (VL), presentation of HCV VL
results with or without CI (With CI / NoCI), where the respondents practiced (Where practice),
the respondents’ professions, field of medicine, whether they manage hepatitis C patients, use
AASLD guidelines, the number of years in practice (Years practice), and the number of hepatitis
C patients seen per month (Patients month). Besides VL, only where the clinicians practiced, the
number of years in practice and the number of patients seen per month demonstrated any
significance to the outcome (Wald statistic at p< .05). The first two were significant in the
decision to discontinue therapy and the third was significant in the decision to continue therapy.
To examine the role of clinicians’ practice preferences, the variables Relevant (whether the
respondents thought the presentation of CIs added information to the result) and whether or not
the respondent wanted to see CI with their results (Want CI), were added to the model with the
variables HCV VL levels, With CI, Where practice, Years practice and Patients month. With
addition of these variables, where clinicians practiced was no longer statistically significant in
the overall model. The Wald statistic for practicing in Europe went from p=0.031 to p=0.325
and for practicing in Canada, it went from p=0.043 to p=0.43. The number of respondents in
these categories was small compared to those that practice in the United States (less than 10%
combined).
Across all HCV VL levels, the number of years in practice had a negative influence on the
decision to discontinue therapy (Exp B/ odds ratio 0.974). However, the impact was slight. For
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each increasing year in practice the choice of discontinuing therapy at all VLs is 1.02 times less
likely than repeating the test. Responses indicating a desire to have CIs reported with results and
those indicating the converse both had a negative association with this decision. The odds ratios
for both these responses were less than one and the frequency of these two choices was very
close (42.0% wanted CI and 47.3% did not). The other choices for this variable were “Don’t
know” and “I already receive CI”, and the responses for these two variables together were
approximately 10%. Because there was no distinguishable difference in the responses of those
that did and did not want CI, this variable was not considered useful in predicting the decision to
discontinue therapy.
For the decision to continue therapy, the number of patients seen per month had a small
negative impact. However clinicians who thought the presentation of CI’s detracted from or
confused the result, were 3.2 times more likely to choose this response at all VLs (odds ratio
3.197) than to repeat the test. This was a statistically significant finding and is similar to the
findings at 560 IU/ml in the presentation of results with CI.
The decisions at each VL were further analyzed by multinomial logistic regression. Only the
number of years in practice and the number of hepatitis C patients seen per month were
significantly associated with decisions at specific HCV VL levels (Wald statistics p<0.05), and
those were only at HCV VLs of 1950 IU/ml and 100 IU/ml respectively. The effects were small.
For example, at 1950 IU/ml, with each increasing year of practice, the respondents were 1.07
times less likely to choose the decision to discontinue therapy versus repeating the test. The
significant effect of respondents who stated that the results with CI detracted/ confused the
result, which was seen in the model with all decisions from all VLs, was not significant at any
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single specific VL with or without CI. All variables with statistical significance are listed in
Table 21.
The H3 null hypothesis, that experience and demographics will have no impact on the therapy
management decisions, is rejected. Some respondent demographics and practice preferences did
impact the HCV therapy decision outcomes. Over all decision outcomes at any VL, the
significant demographics and characteristics were: the years in practice, the number of patients
seen per month, and whether or not the presentation of results detracted or confused the results.
At 1950 IU/ml, the number of years in practice was significant in the Discontinue therapy
decision; and at 100 IU/ml, the number of patients seen per month was significant to the
Continue therapy decision. The presentation of results with or without CI made no impact.
Other analyses for clinical utility. The amount of repeat testing was notable at some VL
levels. Repeat testing delays the implementation of results and can add costs to a patient’s care.
Analysis of the data to determine if any of the variables contributed to the likelihood of repeating
the test was performed.
Decision to repeat the test. Respondents chose to repeat the test at all VLs except the highest
one: 31,620 IU/ml. The choice Repeat test was 17.5% of all decisions made at all levels. For
those respondents answering both HCV VL questions, the decision to repeat did not decrease
with the second viewing of the HCV VLs: 8.2% of all first-question response decisions and 8.5%
of all second-question response decisions were Repeat test decisions. The decision to repeat tests
at the therapy decision threshold and the two immediately flanking levels (560, 1000, and 1950
IU/ml) was 19.8% of all decisions made. At the decision threshold (1000 IU/ml) Repeat test was
36.1% of all decisions made.
.
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Table 21
Respondent Demographic, Practice and Preference Variables Demonstrating Significance in Respondent Decision Choices

95% Confidence Interval for Exp(B)

p
0.031
0.325

Lower
bound
0.025
.075

Exp (B)
0.144
.421

Upper
bound
0.838
2.363

0.043
0.433
0.025
0.011
0.001
0.014
0.001
0.026

0.013
0.081
0.952
0.026
0.014
0.991
1.603
0.868

0.112
0.488
0.974
0.127
0.067
0.995
3.197
0.928

0.937
2.932
0.997
0.625
0.332
0.999
6.375
0.991

Decisions at VL 100 IU/ml Decision to Continue Therapy Number of patients per month
Continuous
0.01
0.974
*Statistical significance of parameters in Where_practice were only observed in model without Relevant and Want_CI: top p value for each.

0.985

0.996

Dependant variable
Decisions at all VL

Variable parameter
Decicion to Discontinue Therapy *Where practice: Europe

Variable Type
Categorical
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*Where practice :Canada
Number of years in practice
Want CI with HCV VL results
Do NOT want CI with HCV VL results
Decision to Continue Therapy Number of patients per month
CI's detracted from or confused result
Decisions at VL 1950 IU/ml Decicion to Discontinue Therapy Number of years in practice

Categorical
Continuous
Categorical
Categorical
Categorical
Continuous

Table 22 lists the percent of decisions at all VLs presented with and without CI. In the
previous chi-square analyses of the decisions made at each VL the decision to repeat the test was
not significantly influenced by the presentation of CI. In the multinomial regression analyses,
the repeat decision outcome was the reference and only the variables examined in H3 null
hypothesis analyses showed any significance. Using the Repeat test as the only dependant
variable with a yes/no outcome, binomial logistic regression could be utilized for a specific
analysis of this decision.
Binomial logistic regression analyses were performed on the decision of whether or not to
repeat the test to further examine if there was any effect from viral load levels or the presentation
of results with CI. Data from all responses were used first. Predictor variables were: VL and the
presentation of CI. The model chi-square was significant (p<0.05) and 86.4% of cases could be
correctly classified. The only significant variable however was the HCV VL level (Wald=33.12,
p<0.5, df=4). Whether or not the respondents thought the presentation of CI provided relevant
information (predictor variable-Relevant) was added to the model. There was no significant
correlation (Wald = 3.18, p= 0.204, df=2).
Similarly, logistic regression analysis was performed using only the responses from the first
question. VL and whether the respondent viewed results with CI (Saw CI) were predictor
variables. The presence or absence of CI was not significant in the decision to repeat tests either
alone (p=0.663) or interacting with VL (p=0.196). Viral Load level is the strongest predictor of
the decision to repeat the test. This is consistent with the visual examination of the data.
Summary of survey analyses. From the survey, 138 responses were received. Strong
clinical guideline adherence was demonstrated in self-reported behaviors and in decision choices
recorded. However, up to 37% of decisions were to repeat the test. The impact of knowing the
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Table 22
Decisions Made at Each VL Level

HCV VL
Level
IU/ml
31620 Combined

1950

1000

500

100

Decisions
Continue
Discontinue Therapy
Therapy (%)
(%)
97.5
2.5

Repeat test
(%)
0.0

NoCI

97.5

2.5

0.0

With CI

97.5

2.5

0.0

Combined

81.7

6.6

11.6

NoCI

82.5

6.8

10.8

With CI

81.0

6.6

12.4

Combined

40.2

23.7

36.1

NoCI

40.8

24.2

35.0

With CI

39.7

23.1

37.2

Combined

21.5

67.0

11.6

NoCI

20.8

70.8

8.3

With CI

22.1

63.1

14.8

Combined

10.7

78.5

10.7

NoCI

10.0

79.2

10.8

With CI

11.5

77.9

10.7

Combined: All responses from Q1 and Q2 combined
NoCI: Responses from all results reported without confidence intervals
With CI: Responses from all results reported with confidence intervals

assay imprecision was not statistically significant to clinicians’ decision regarding the therapy
management of the simulated patient. There was no significant impact of clinician
demographics, experience or practice preferences for the decisions made using the results with or
without CI, however those who thought the CIs detracted from or confused the result were more
likely to decide to continue therapy than repeat the test. Those who thought the CIs confused or
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detracted from the result were only 16.9% of responses however. Some associations were
observed between demographics, practice preferences, and decisions regardless of the
presentation of CI at each viral load level. The most impactful variable on the decisions
recorded for repeating the test was the level of viral load being reviewed.
Determining Value and the Impact of Clinicians’ Use of Test Information on that Value
A Markov decision-tree model was developed as described in the Methods section. Changes
from the pilot model were: removal of death as a health state, removal of SVR as a separate
health state from the Response health state, and reduction of the time horizon from 72 to 60
weeks (more appropriately reflecting the time span over which the test has influence; that needed
to evaluate SVR). In addition, the health state “Decompensated cirrhosis” was added and
Quality of Life (QoL) values were accumulated at each state. Transition probabilities, costs and
QoL parameters for health states were populated from literature and older costs were inflation
adjusted where appropriate (Table 7). Decisions made by clinicians’ test use were represented
by the survey data for initial model inputs. The circled boxes in Figure 8 illustrate where in the
decision tree initial inputs were entered.
Analyses to evaluate the economic impact of the clinicians’ decisions. The impact of
decisions made from HCV VL results with and without CI on the value of the test was evaluated
using the model described in the methods and the preceding paragraphs.
Because the clinically prescribed decisions are not identical for all VL levels, data for each
VL in the survey was first evaluated separately, and different inputs and patient flow strategies
were used for each level accordingly. At each VL level, the analysis was run with all patients on
therapy to determine treatment costs without the therapy management information provided by
HCV VL, then with decision inputs according to established guidelines (AASLD, 2011; Vertex
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Figure 8. Decision path showing health states, costs, transition probabilities and QoL. The circled boxes show the entry point for the
three decisions: Continue therapy, Discontinue therapy or Repeat the test.

Pharmaceuticals, 2011), and finally, with decision inputs from the survey described (made with
and without CI). For decision inputs according to AASLD Guidelines, no entries were made to
the Repeat test input, and the Continue and Discontinue therapy inputs were made using the
percent distribution of the population VLs at that level (based on the imprecision used in the
survey of 1SD =0.15 log10). For example, at 560 IU/ml, based on the imprecision of the test,
approximately 4.8% of results would be expected to fall at or above 1000 IU/ml. Therefore for
the guideline- dictated decision, 4.8% were placed in the Discontinue therapy arm. For 31,620
IU/ml, all were placed in the Discontinue therapy arm. For decision inputs according to the
proportions from the survey, only responses from the first presentation of HCV results to the
respondents were used. The data were used in this manner (as opposed to combining all
responses) because the presentation of HCV VL results twice (with and without CI) does not
reflect common clinical practice. When using Repeat test decisions, those proportions were first
combined with the Continue therapy decisions for entry into the model. After an initial step of
“two weeks” the proportion of Repeat test responses was re-distributed among the Discontinue
therapy and Continue therapy arms according to the original proportions of those two decisions,
adjusted for no repeat testing. For example, if the original decision inputs were 40% Discontinue
therapy, 40% Continue therapy and 20% Repeat test, the 20% Repeat test would be combined
with the 40% Continue therapy decisions for initial input. After the first two week cycle, the
20% would be redistributed with half (10%) going to the Discontinue therapy arm and the other
half (10%) remaining in the Continue therapy arm.
The resulting total costs and the average QoL ratio for each of the model inputs were
recorded. The total costs of the survey-guided decisions with and without CI were compared
against the total costs of the decisions according to guidelines at each viral load level. Since the
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survey respondents were primarily specialists, their recorded decisions and the guideline-dictated
decisions were close for most of the viral load levels; with the exception of Repeat test decisions.
This was reflected in the comparisons of the total costs between the guideline decisions, those
made viewing HCV VLs with CI, and those made viewing HCV VLs without CI. For most
comparisons, there was less than a 10% difference in total costs. As expected, the greatest
differences were seen at or near the decision point. For those VLs above the 1000 IU/ml
threshold, deviations from guidelines were associated with higher costs as a result of keeping
patients on therapy. Notably, at 1950 IU/ml the decisions made using results with CI were
associated with 16% greater costs than the guideline-dictated decisions and 12% higher costs
than those decisions made using results without CI. The impact to the QoL values between the
three types of decision inputs was negligible.
Table 23 displays the decision model inputs and outputs for each VL using the 12-week
decision point inputs defined by guidelines and from the survey data. From the survey data the
input decisions are further split to those made with CI and those made without CI presentation.
The first column in the table lists the five viral load levels in IU/ml. For each of the decision
inputs (guideline-directed or survey-directed), the actual percentages of each decision are stated
with the output total costs from the model and the output QoL value. Using the guideline
directed decision percentages as a benchmark, the total cost outputs from decisions made by
respondents in the survey using results without and with precision information are compared
(labeled in the table as “% Change from Guide”). Additionally, total costs outputs from the
survey-directed decision inputs with CI are compared to those made without CI (labeled as
“%Change from NoCI”).
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Table 23
Total Costs / QoL Comparisons from Guideline-Directed Decisions and Survey Decisions Made
with and without CI
Guideline

Survey No CI

Survey with CI

Total
Total
Total
HCV VL Model Inputs
costs $
costs $
%Change Model Inputs
costs $
%Change %Change
Model Inputs
(IU/ml) %R/%DC RX/%ContRX (60 Wks) Av QOL %R/%DC RX/%ContRX (60 Wks) Av QOL from Guide %R/%DC RX/%ContRX (60 Wks) Av QOL from Guide from NoCI

31620
1950
1000
560
100

0/100/0
0/97.3/2.7
0/50/50
0/4.8/95.2
0/0/100

7813
8147
13424
17414
17778

0.82
0.82
0.86
0.97
0.99

0/98.5/1.5
10.8/86.2/3.1
32.3/43.1/24.6
13.8/23.1/63.1
15.4/10.8/73.8

8000
8377
12461
15171
16494

0.82
0.82
0.87
0.94
0.97

2
3
-7
-13
-7

0/95/5
12.1/77.6/10.3
43.1/32.8/24.1
6.8/16.9/76.3
5.1/8.5/86.4

8436
9421
13590
16051
16877

0.82
0.82
0.87
0.95
0.97

8
16
1
-8
-5

5
12
9
6
2

VL= Viral load levels. RX= therapy. NoCI= Without Confidence Intervals. With CI= With
Confidence Intervals.
Using the data from Table 23, the total costs at each VL resulting from guideline-directed
decisions versus decisions made by survey respondents using results with and without CI
presentation are shown in Figure 9.

Figure 9. Total costs resulting from guideline-dictated decisions and survey-guided decisions.
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Figure 10 displays a graphical representation of the percent change in total costs of the
survey-directed decisions made with and without CI from the guideline directed decisions.

Figure 10. Percent change in total costs from survey decisions made with and with CI compared
to guideline-dictated decisions.
The value of HCV VL test information. To determine the value in cost differences per
patient that the HCV test information brings to the 12-week therapy decision, analyses were
performed with 100% of the decisions in the Continue therapy arm for each viral load level.
This provided a base case at each VL level reflecting all patients on therapy regimens without a
test to help manage the decision to remove non-responders. The all-on-therapy analyses were
followed by using inputs to the Discontinue and Continue therapy arms for each VL according
to the AASLD guidelines (guideline-directed). Finally, inputs according to the decisions made
in the survey were used. Since the value of the test at this specific point in the therapy
management course is demonstrated by removing non-responders from inappropriate therapy, it
was measured in the cost differences by subtracting the costs of the decisions made with the test
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information from the costs of continuing all patients on therapy. Table 24 shows the costs of the
base case (all patients continuing therapy) compared to costs using the test according to
guidelines, and according to the combined responses on the survey as well as with those
responses using HCV VL with CI and those using HCV VL without CI. As expected, the
highest cost differences are among those that have high viral load levels. For those at the 100
IU/ml level, any differences seen as “cost savings” that are greater than the decision-directed
savings are inappropriate, as removing a potential responder from therapy is incorrect. (The
calculation of the guideline-directed value at 100 IU/ml is appropriately $95 due to the removal
Table 24
Value of Test Information: Average Differences in Total Costs Realized as Savings per Patient
Guideline Directed

1

VL Result:
HCV RNA
IU/mL

Total Costs $:
All Continue
Therapy

31620
1950
1000
560
100

24976
24900
21424
18726
17873

Value of test
information

Survey - All Responses
Value of test
information

Survey - NoCI only
Value of test
information

Survey - With CI Only
Value of test
information

Total
Costs $ Costs savings $1

Total
Costs $ Costs savings $1

Total
Costs $ Costs savings $1

Total
Costs $ Costs savings $1

7813
8147
13423
17414
17778

8125
8888
12713
15431
16569

8000
8377
12461
15171
16494

8436
9421
13590
16051
16877

17163
16753
8001
1312
95

16851
16012
8711
3295
1304

16976
16523
8963
3555
1379

16540
15479
7834
2675
996

Based on the difference in costs of leaving all patients all on therapy and removing nonresponders per guideline-dictated and survey response decisions.
of the proportion of patients that show the presence of HCV RNA at 12 weeks post dualcombination therapy. This proportion, derived from literature, is coded into the model. At 560
IU/ml, due to the distribution of the population of VLs with the imprecision stated,
approximately 4.8% cross the 1000 IU/ml threshold. Figure 11 shows the cost differences,
realized as savings at each VL level from Table 24.
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Figure 11. Cost differences realized as cost savings per patient at each VL due to the
contribution of the HCV VL test in removing non-responders.
From this evaluation, it was demonstrated that there were some differences in total cost
savings per patient based on clinicians use. When compared to decisions made on the basis of
HCV VL according to the AASLD guidelines, the different decisions by clinicians produced up
to 16% increase in average total costs per patient in VLs at 1000 IU/ml and above. Below 1000
IU/ml, cost differences seen as “savings” greater than those realized by the guidance directed
decisions are not valid as these savings are associated with patients who were inappropriately
removed from therapy. QoL values did decrease in these cases, but only by one to two percent.
The time horizon of the model may be too short to show a more dramatic effect. Interestingly,
decisions made with the presentation of CI’s resulted in an increase of costs per patient at all
viral load levels (from 1 to12%). Since the economic contribution of the HCV VL is to produce
cost savings in the treatment management of non-responders, the presentation of CIs diminished
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the value of the test information. QoL values at each VL were not affected by presentation of CI
when compared within a VL level.
Analysis of a representative population with several VLs. To simulate decisions for a
population of patients having a distribution of VLs at the 12-week test point, initial inputs
designed to produce therapeutic outcomes relatively consistent with the population in the
telaprevir clinical trial were used (Jacobson, et al., 2011). During the trial, all patients were on
therapy throughout the course, unless there was a clinical reason for removal. Seventy-three
percent of patients had an SVR, while 17% relapsed. At the start of triple combination therapy
(12 weeks prior to the starting point of this model), 77% of patients had greater than 800,000
IU/ml HCV RNA. In addition, approximately 6% already had cirrhosis. To represent the
population in the relatively simple model that was developed for this work, 86% were entered
into the Continue therapy arm in the Response health state with 14% in the Discontinue therapy
arm, splitting the Discontinue therapy proportion further with half in the Chronic HCV health
state and half in the Cirrhosis health state. The final response percent at week 60 was 73%,
consistent with the response outcome of the trial.
The output of the model simulating this population was used to determine the total costs of all
patients continuing therapy, a scenario without a test available. Inputs were then adjusted to
enter the proportion of non-responders stated in the trial into the discontinue therapy arm to
assess the cost differences of removing them at week 12 based on their HCV VL. The results
($2633 in average cost savings per patient) are shown in Table 25.
Impact of repeat-testing on test value. The impact of repeat-testing on the costs was
examined using this clinical study population. For this purpose, adjustments were made to the
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Table 25
Average Cost Savings per Patient in Removing Non-responders for Telaprevir Clinical Trial
Population
Total
Costs $
Telaprevir Study "Population"
All patients Continue therapy
19472
Pts who would not have responded: off therapy at 12 and 24 wks
16839
Cost Savings per Patient 2633

Av QoL
Value
0.95
0.96

model to maintain the ratios of responders and non-responders as close to the final outcome as
possible. Table 26 shows the different combination of inputs with repeat testing occurring in
eventual non-responders as well as responders. In this model, changes in repeat testing up to
50% had 6% or less impact on the total costs. This may be due to the fact that repeat-testing was
handled by keeping the patient in the Continue therapy arm for the two weeks while “waiting”
for the test result. Following the two-week step, those who would have been removed from
therapy were sent back to the Discontinue therapy arm of the model. In this situation, where the
response rate is high, at most only 14% of those retested had the extra two weeks of therapy. For
these analyses, the HCV RNA test cost is only $58.88 and two weeks of therapy is $953. Per
patient, this is about $1000 in costs. This small impact on costs, even in high repeat testing
scenarios may give insight to the robustness of the test value.
Analyzing model-outputs’ sensitivity to variation in parameters. The model developed for
this research was not complex and had a short time horizon (60 weeks). Inputs and parameters
were based on literature and on survey data. In the analyses described, several different levels of
inputs were tested with variances based on the data received, and the outputs directly reflected
them. To determine the sensitivity of the model outputs to variances in the cost and QoL
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Table 26
Impact of Repeat Testing on Total Costs

Inputs

Outputs

Repeat
Rate

Discontinue
Therapy

Continue
Therapy

0*

0.14*

0.86*

16831

Index

0.05

0.09

0.86

17166

2

0.1

0.04

0.86

17501

4

0.15

0

0.85

17769

6

0.15

0.05

0.8

17434

4

0.2

0.05

0.75

17434

4

0.2

0.1

0.7

17099

2

0.25

0.1

0.65

17099

2

0.3

0.1

0.6

17099

2

0.35

0.1

0.55

17099

2

0.4

0.05

0.55

17434

4

0.4

0.1

0.5

17099

2

0.45

0.05

0.5

17434

4

0.45

0.1

0.45

17099

2

0.5

0.05

0.45

17434

4

0.5

0.1

0.4

17099

2

0.14

0.36

16781

0

0.5
* Index

% Change
Costs ($) from Index

parameters, those values were varied and the model was run with each change using the
telaprevir clinical trial population inputs. Total costs were changed in 10% increments from
minus 50% of the parameter value used in the analyses to plus 50% of the value. Additionally,
treatment costs and the HCV RNA test costs were tested separately for their contribution to
model output sensitivity. Table 27 and Figure 12 are tabular and graphical representations of the
outputs of this deterministic sensitivity analysis.
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Table 27
Model Output Sensitivity to Costs and QoL Parameter Values

Total Cost Changes

Therapy Cost Changes
Only

HCV VL Test Cost
Changes Only

%Change
%Change
%Change
%Change
from
New Total From New Total From New Total From
Baseline Costs ( $) Baseline Costs ( $) Baseline Costs ( $) Baseline
-50
8420
-50.0
9525
-43.4
16814
-0.1

QoL Ratio Changes
New
Average
QoL
0.48

%Change
From
Baseline
-50.0

0.57

-40.6

0.67

-30.2

-40

10104

-40.0

10988

-34.7

-30

11788

-30.0

12450

-26.1

-20

13471

-20.0

13914

-17.4

0.77

-19.8

-10

15155

-10.0

15372

-8.7

0.86

-10.4

0*

16839*

0*

16839*

0*

0.96*

0*

+10

18523

10.0

18202

8.1

0.97

1.0

+20

20207

20.0

19765

17.4

0.99

3.1

+30

21891

30.0

21228

26.1

1

4.2

+40

23575

40.0

22690

34.7

1

4.2

+50

25259

50.0

24153

43.4

1

4.2

16824

16839*

16854

-0.1

0*

0.1

16864

0.1

+100

16890

0.3

+250

16965

0.7

+500

17090

1.5

+750

17215

2.2

+1000

17341

3.0

+2000

17843

6.0

*Baseline
** QoL values not adjusted beyond 1

For total costs, the increases or decreases resulted in similar changes of magnitude in the
output. Table 27 shows the variation of the parameter values and resulting change in the model
outputs. Treatment costs were about 87% of the total costs, and the model was demonstrated to
be sensitive to them. HCV RNA test costs had very little impact on the model outputs, even
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Figure 12. Model sensitivity to costs and QoL parameters values.
when increased by 2000% (resulting in a test cost of $1237). The base case “cost” used was the
Medicare national limit of $58.88, however the cost of an HCV RNA test does vary widely and
private-pay patients can pay above $1000. The analyses in this research demonstrated that even
at that price, the test maintains its contributory economic value in the decisions being made
regarding therapy management.
QoL ratios were also varied in the manner described for costs, except when each QoL ratio
reached one, or full health, no further adjustments were made. For QoL ratios, the changes
below the base case mirrored the percent change in QoL values.
Section summary: determining value. Through decision-analytic modeling, the economic
contribution of the HCV VL test at week 12 was demonstrated. In this evaluation, changes in the
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use of the information were shown to affect the value of the test. Changes in the use of the
information from that directed by clinical guidelines could be measured in a simulated
population with a representative distribution of viral load levels. Despite variations in use, the
test held value.
Summary of Results.
The analyses and results in this section described two aspects of the clinical utility of a
laboratory test, using HCV VL as a model, the interpretation and use of the test information and
the economic contribution it has to the efficient use of clinical resources. It was found that
among the hepatology specialists who responded to the survey, test information use was close to
clinical guidelines, with the exception of repeat testing. Although differences were observed,
there was no statistically significant impact on the use of the information when CIs were present.
Through the use of a specifically developed decision analytic model, economic contributions
in average cost differences per patient could be demonstrated in simulated scenarios. The HCV
VL test contributed an average of over $2600 in cost differences over all subjects in a
hypothetical population of HCV patients, with savings up to $17,000 at higher VL levels.
Varying the cost of the test up to $1200 had little impact on the value of the information
produced from it.
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Chapter Five: Discussion and Conclusions

Summary of the Study
The goal of this study was to examine the impact of physician awareness of a key
performance characteristic for a pivotal laboratory test utilized in patient management decisions,
and the economic contribution of that test to patient care. Quantitative HCV VL was used as the
model since it is the principal indicator of the success or failure of current anti-HCV therapies.
For HCV genotype 1 patients on triple-combination therapy, the HCV VL assessed at several
time points during the course of therapy determines whether or not the patient should continue
treatment. Since the treatment regimen is costly and can be debilitating, removing nonresponders is appropriate when the HCV VL indicates they will not benefit from further therapy.
Clinicians’ uses of quantitative HCV RNA results to make this decision after 12 weeks of the
triple-combination-therapy part of the HCV-treatment regimen were studied.
The key performance characteristic examined for the HCV VL test was its imprecision, which
in this study was operationally defined as the 95% CI based on an SD of 0.15 log10 IU/ml.
Through a survey, decisions made by clinicians after reviewing HCV VL results with and
without those CIs were compared. Demographics, practice behaviors, and test presentation
preferences were also analyzed to determine if they played a role in their decisions. In addition,
a decision-analytic model was developed to calculate and evaluate how the value of the HCV VL
test information was affected by the clinicians’ utilization of the HCV VL results in their clinical
decision making process. The hypothesis was that the clinical utility (CU) and the value of the
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laboratory test information would change if clinicians were aware of the imprecision of the
results.
Discussion of Survey Findings and Implications
Of the 1491 e-mail invitations to the survey sent, 124 responses were received with usable
data (8.3%). The subset was small, however over 90% of those responding were representative
of the target population, clinicians who manage HCV patients.
In an analysis of all responses, there was less than a 10% difference between decisions made
when viewing quantitative HCV VL results with CIs, and those made without the CIs, at all
HCV VL levels. Analysis of responses based solely on the presentation format of the first
question seen by respondents showed greater differences between the two presentations,
particularly for those HCV VL levels flanking either side of the decision threshold. For the HCV
VL level immediately above the 1000 IU/ml threshold (1950 IU/ml) and immediately below
(560 IU/ml), the presentation of CIs led to a 7-13% increase in the decision to continue therapy.
At the 560 IU/ml HCV VL level, the presentation of CIs was also associated with a decrease in
the decision to repeat the test compared to decisions made without CIs. These differences were
not statistically significant, however. Small response numbers may have had a role: data from
the first question seen provided only 65 responses to the HCV VL results without CI and 59 from
the results with CI.
When the responses were analyzed to examine the impact that the order of presentation had
on decisions, those clinicians who viewed results without CIs, and then saw results with CIs,
were less likely to choose to continue therapy at all VL levels, except the actual threshold level
of 1000 IU/ml (the decisions were the same). The VL level demonstrating the highest difference
between the responses with the two presentations was at 560 IU/ml; just below the threshold. At
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this level, while most of the assay variance was below the threshold (lower bound = 290 IU/ml)
the upper bound of the CI crossed the threshold slightly (upper bound = 1,110 IU/ml). This may
have influenced the decision not to continue treatment or to repeat the test. Repeating the test,
where the greater number of the decisions shifted, delays the decision. These findings, though
interesting, do not reflect current practice, as clinicians are not presented with the same results
twice. However, they could provoke further discussion regarding the presentation of imprecision
information to a community not accustomed to seeing it or instructed how to incorporate it into
their decisions.
The tendency to continue the current course when the information is doubtful was
demonstrated in the decisions made by those respondents who thought the imprecision
information confused or detracted from the result. They were more likely to continue therapy
than even to repeat the test. The decision to continue therapy is one of no action in this scenario.
Patients are already on therapy at the decision point; and the action decision would be to remove
the treatment. In the HCV triple combination therapy regimen, there is another HCV VL testing
point 12 weeks after the one addressed in the survey (Ghany et al., 2011). At that time, the HCV
VL should be undetectable for the patient to continue the last 24 weeks of therapy, giving the
clinician and the patient time to revisit the earlier decision and compare the HCV VL results.
Whether these considerations were part of the thought process for this group of experienced
respondents was not tested.
Behavioral decision research is a field of study having roots in behavioral economics, and has
grown to several applied areas (Medin & Bazerman, 1999; Thaler, 1991). Some of the tenets
discussed in this field may provide insight into the observed tendency to choose no action
(Continue therapy or Repeat the test) over action when faced with risk or uncertainty. It was not
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the aim of this study to explain why clinicians made their choices, but to observe what the
choices were and assess their impact on the value of the test information. Questions regarding
the reason for choices, or the next course of action, might be added in future studies to focus on
the question of continuing a path for patients when guidelines suggest an opposite action.
Repeat testing levels were high, and not surprisingly, most predominately high near the
decision threshold. Repeat test rates were not influenced by the presentation of imprecision
information or the order in which that information was seen. The Repeat test option was 8.2% of
all first question responses and 8.5% of all second question responses, indicating that the second
presentation of results did not fulfill the role of a repeat test for respondents. If the second
viewing did fulfill this role, the repeat rate would be expected to be less for the second response.
The impact that the HCV VL level had on the actual decisions was anticipated. The
therapeutic management of HCV patients hinges on HCV VL testing. The fact that the
presentation of CIs had no statistically significant impact on the responses was unexpected,
especially considering the studies discussed earlier that demonstrated clinicians’ difficulty with
more complex laboratory data (Bachmann et al., 2003; Bramwell et al., 2006; Cahan et al., 2003;
Ghosh & Ghosh, 2004; Heller et al., 2004). The findings in this work could be attributed to
several factors.
The targeted population was one of hepatology specialists; and the returned surveys were
from the AASLD members, which may account for the strong knowledge of, and intended
adherence to the treatment guidelines. It was appropriate to survey this group however, as it
represents the community of specialists primarily managing HCV disease. Experienced
clinicians using quantitative HCV RNA tests in the management of their patients have worked
with quantitative HCV RNA tests as they have evolved, and the discussions surrounding the
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relative imprecision in HCV VL testing have been active among them. An inherent knowledge
of the test imprecision and having to make treatment decisions while considering the variance in
test methods and in individual laboratories may already exist. The presentation of results with
CIs in the survey may have served to substantiate this knowledge. It was notable, though, that
the greatest difference in decisions made with and without CI was for those clinicians that had
made decisions without CI first and then were presented with CI at the HCV VL level of 560
IU/ml, which is very near the decision threshold. If the presentation of CIs with a result that is
near a threshold impacts this experienced and specialized group, surveying a sample of nonspecialists with a relevant diagnostic/ therapeutic combination could possibly demonstrate
greater differences in dealing with the presentation of imprecision.
The CIs defining the imprecision in this study were conservative, particularly at the lower
levels where imprecision is greatest in quantitative viral load assays. Table 2 described
published studies with these relative values. The CIs presented with the HCV VL results in the
in the survey may have illustrated an optimal situation. A larger imprecision range might have
produced different findings. In addition, the decision threshold for telaprevir is 1000 IU/ml,
which is 40 times the limit of detection for quantitative HCV RNA assays used for these
decisions and comfortably within a reproducible part of the reportable range. Another protease
inhibitor (boceprevir), used in a similar manner with interferon and ribavirin, has a decision
threshold of 100 IU/ml (Ghany et al., 2011). The imprecision at this point would be expected to
be much larger, and in some cases cross the lower limits of detection for the tests. Surveying
clinicians using this decision threshold and associated imprecision characteristics may also have
produced greater differences between groups seeing the results with CI and those seeing results
without them, particularly at the threshold.
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An interesting finding was the frequent choice of the decision to repeat the test. Respondents
chose the decision to repeat at all HCV VL levels except the highest (31,620 IU/ml). The Repeat
test decision was 17.5% of all decisions. The decision to repeat tests at the threshold of 1000
IU/ml and the two immediately flanking levels (560 and 1950 IU/ml) was 19.8% of all decisions,
and at the decision threshold (1000 IU/ml) it was 36.1% of all decisions. At these three HCV VL
levels, the decision to repeat was 2-6% higher when the results were presented with CIs. The
presentation of CIs had a consistent and small, but non-statistically significant impact.
Though there were no statistically significant associations with the decision to repeat the
HCV RNA test, the frequency of this decision among respondents is an important consideration.
The Repeat test decision had little impact on the economic value of the test; however, indications
for repeat testing are not part of the labeling for quantitative HCV RNA tests, the therapeutics for
which they are companions, nor is repeat testing considered in the guidance documents. The
inherent imprecision of the quantitative HCV RNA test is already a factor in the establishment of
decision thresholds by means of the therapeutic clinical trials; at least for the specific test used in
those trials. As such, a repeat test may be considered medically unnecessary by reimbursement
policy makers; and the patient or the institution may be required to bear the cost when the
clinician makes this decision. Adding information about the imprecision of the test to the result,
which, in this study, was demonstrated to increase repeat testing behavior, may have
economically adverse consequences.
Repeat testing is not uncommon in clinical laboratory medicine, within the laboratory and at
clinicians’ requests. Several publications discuss the reasons for and the implications of this
practice (Deetz, Nolan, & Scott, 2012; Hawkins, 2005; van Walraven et al., 2003). However, the
tests studied in these publications were typically chemistry and hematology tests, which have
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lower cost, turn-around time and resource impact than molecular tests for viral load. As tests
with more expensive technology, time and resource impact are implemented, examining this
tendency further or outlining in guidelines where repeat testing is appropriate may be necessary.
The manner in which the imprecision information was presented to the clinicians may also
have had an impact on their decisions. In this survey, the imprecision information was presented
numerically and consistent with the visual format of the test result. No additional explanation
accompanied the 95% CI range. Presentation in words, graphically, or with interpretive
language may have led to different decisions. An explanation of how to apply the imprecision
information or a graphical representation of the odds of the value crossing the decision threshold
might have had an impact on the Repeat test decisions or those decisions that were inconsistent
with the clinical guideline recommendations. Bachmann and colleagues noted that among the
different presentation of results they provided to their participants, the most effective way of
presenting complex laboratory information was with an explanatory statement of the odds of the
patient having the disease in question (2003).
Limitations of the survey research. Assessing the impact of a laboratory test in a healthcare
setting necessitates the mitigation of as many variables as possible. One way to accomplish this
is to choose a clinical path where a specific decision employs a prescribed laboratory test, and
then use that in a setting with a single patient. The scenario chosen for this research was based
on professional guidelines of treatment and assessment; and the description of the simulated
patient was intended to present one with an average burden of therapeutic-associated adverse
events. However, a single patient scenario in one specific clinical path limits the ability to
generalize the findings, or to assess if the bias towards patient types exists among respondents.
Since patient-treatment biases were not the focus of this research, the single simulated patient
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scenario provided the opportunity to hold a greater number of variables constant to assess the
effect of the HCV RNA test variables and interpretation. The situation presented in this study
may have a seemingly narrow focus, but the approach used can serve as a basis for research
questions in other disease management areas, or for other questions regarding viral disease
management.
There are no publicly available, validated instruments measuring clinicians’ experiences with
test result imprecision. The survey, through which the hypotheses in this study were tested, was
developed specifically for this work. The questions presented were designed to be consistent
with standard practice guidelines and the HCV VL numbers and imprecision budget used for the
test results were calculated using published studies and recommendations of minimum
performance standards by expert groups. Patient management for HCV disease is evolving
quickly. Even during the development phase of this research, the treatment protocols changed
affecting the patient scenario and the survey design (Ghany, et al., 2009; Ghany et al., 2011).
However the reliance on the clinicians’ interpretations of quantitative HCV RNA results as a
critical component of the therapeutic management of the patient remained constant and will
continue to be used for this purpose for the foreseeable future.
Relying on a survey as a surrogate for clinicians’ decision also has limitations. It is possible
that the participants chose their answers according to how they believed they should answer. A
survey cannot represent the full complexity of the authentic medical situation. Further, there are
no consequences for a wrong decision. A more robust way of gathering data would be to review
patient records. The HCV VL result and the continuance or removal of therapy would be
apparent information in the patient record, and easily extractable. However, a multi-site or
multi-system study would have to be done in order to access a significant number of clinicians.
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Patients would have to be matched by disease severity, viral load, adverse events and
demographics. A small study to verify or dispute the findings in this study may be justified but
the larger one may not be a priority until the use of electronic health records across systems is
more established and easily accessed by legitimate researchers.
Discussion of Economic Model Findings and Implications
A Markov decision-tree model was developed to determine the value of the HCV VL test
information. Transition probabilities, costs, and QoL values for health states were populated
from published literature. Clinicians’ actual use of the HCV VL information was represented by
the survey data and used as inputs to the model. The definition of value for this study was the
potential average differences in costs per patient obtained by removing non-responders from
inappropriate therapy. This would result in potential savings that could be attributed to having
the HCV VL information. The HCV VL test information contributes to an average of over
$2600 in cost savings in a model population of HCV patients, with savings up to $17,000 at
higher HCV VL levels. Presentation of CI with the HCV VL results showed a slight decrease in
the value, as decisions made after reviewing HCV VL with CIs resulted in greater costs than
guideline-directed decisions made without CIs.
Though cost savings of $2,600 to $17,000 may be considered small compared to other health
economic analyses, when the investment made to facilitate those savings ($58.88 Medicare
reimbursement rate) is considered, the HCV VL test in the clinical scenario used for this research
was determined to be economically effective. Even when the cost of the test was mathematically
increased to nearly $1200, there was little impact to its value in the model. The optimal value
does depend on realizing cost savings through the proper use of the test in patient management.
It was shown that when decisions were made according to guidelines, the test was most cost
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effective. This type of analysis might help demonstrate the importance of investing in programs
to assure that clinicians interpret and use testing information properly, in addition to the efforts
spent in the technical considerations of choosing an assay.
Limitations of the health economic research. Mathematical models have advantages as
well as limitations, and are as robust as the assumptions and data built into them. The costs,
disease state transitions, and QoL values in the model developed for this research were sourced
from a rich literature base and conservative choices were made. The sensitivity of the model
outputs to costs was demonstrated; higher or lower treatment or disease associated costs will
have an impact on the outcome of test value. With the small investment needed for the current
HCV laboratory test though, its relative value prevails. For HCV VL testing at the 12-week
decision point, testing costs up to $2600 would still realize a net savings, using the assumptions
made in this model.
A limitation of the decision analytic model developed for this study was seen at the lower VL
levels. Adverse outcomes for inappropriately choosing to remove a patient from therapy exist
due to the patient’s disease progression. However, the full costs of these adverse outcomes could
not be assessed in this study due to the short time horizon of the model. Discontinuing 24 weeks
of therapy for an individual would “save” approximately $11,400 for approximately the first
half-year; however, depending on the rate of disease progression due to therapy discontinuance,
the next four-and-a-half years would incur six month costs of $3090 to $42,600. Liver
transplant, which could happen after this time period, and which would add considerable cost
was not included in the model. Since the proportion of patients that progress through the more
expensive stages of hepatitis C is small, and those costs do not always outweigh the treatment
savings in the short run, QoL ratios were also evaluated. To assess a quality of life penalty, QoL
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values were calculated at each health state and for some inputs having a greater proportion of
decisions to discontinue therapy than was appropriate, the QoL value did decrease. However the
decrease in QoL was less than 2%. Again, the measurable change in health state in 60 months
for the majority of patients is subtle. Attempts to build economic models to appropriately
address the scope of influence of diagnostic tests would benefit from inter-disciplinary
discussions among laboratory professionals, health economists, clinicians and policy makers.
The costs of producing and implementing laboratory reports with CIs on each result were not
considered. It was assumed that they would be minimal in relation to the overall costs of the
treatments and disease management. However they could be significant with respect to the
current cost of generating a billable laboratory result. Costs to be considered are: the cost of
performing studies to determine the imprecision of the results within the laboratory, changes to
the laboratory information systems which generate the reports, education and training of
clinicians, and of laboratory staff to answer clinicians’ questions. The value of the information
in the population of HCV patients was calculated to be an average of $2600 per patient. The cost
of implementing CIs, as well as the true costs of performing the test (instead of the Medicare
reimbursement used in this study), could be used to determine the cost/benefit of including CIs
with laboratory test results for HCV VL.
Conclusions and Recommendations for Future Research
The results of this research led to the following conclusions:


The presentation of test imprecision with HCV VL results had little impact on clinicians’
treatment management choices at the 12-week decision point for HCV patients.



There was a high percent of repeat testing as the HCV VL test result neared the decision
threshold. Presentation of imprecision information did not influence this rate.
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When treatment management decisions changed from viewing results with and without
CIs, they were most often associated with not having imprecision information first,
followed by seeing results with imprecision information.



Most clinicians surveyed preferred not to have imprecision information presented with
HCV VL test results.



The monetary value of HCV VL information at the 12 week decision point for triple
combination therapy could be calculated through a decision analytic model. The
monetary value of the test information prevailed despite knowledge of imprecision and
high rates of repeat testing.

Recommendations for future research in the context of these conclusions are discussed below.
The responses to the survey showed that the presentation of test imprecision with the HCV VL
results had little impact on the clinicians’ treatment management choices. As noted, this was
unexpected and inconsistent with predictions modeled by laboratory professionals (Pisani et al.,
2009). The high percent of the Repeat test choice, though not entirely unexpected, was also
notable. Since many clinical path recommendations are developed without reference to test
specifications, and the conditions for repeat testing are not usually discussed, these findings
underscore the importance of conducting research in the interpretation and employment of
laboratory test results by the actual users of the information.
The clinicians surveyed in this study were an elite group of specialists. By the number of
years in practice, it can be assumed that their professional experience had developed with the
development of the quantitative molecular HCV RNA tests. Their responses provide a
benchmark for appropriate interpretation and use of complex quantitative test information.
Laboratory test results, however, are available to and used by many types of providers: general
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practice physicians, nurses, pharmacists, other non-provider professionals and patients.
Coincidently, with the advances in research and technology, laboratory test information is
becoming more complex.
Future research in test interpretation and clinical use should study test results for complex
specialty areas, which highly impact medical decisions and are used by non-specialists. A
relevant example is cardiac marker testing to determine and predict myocardial events.
Mathematical models demonstrating the impact of test imprecision on those decisions have been
performed and the recommendations of useable assays include a tolerance for imprecision (Wu
& Christensen, 2013). However, the determination of a cardiac event is not always made by a
specialist who is familiar with the latest studies in this field regarding the biological variation
and assay imprecision of standard and ultra sensitive tests. Research presenting emergency
department physicians with results of these tests that include their imprecision could illustrate the
impact of this additional information on high risk, high impact decisions. Another example is
quantitative CMV testing for transplant patients. In this case, specialists from different fields
(transplantation and infectious diseases) use quantitative CMV VL to discriminate between graft
rejection, infection, clearance of infection or viral resistance (Bienek, Kirby, Cheng,
Eichelberger, & Qian, 2011; Perrottet et al., 2010). CMV VL results inform very different
management strategies for each of these indications. Research on the clarity of the result at the
decision point considering the test imprecision could help refine the precision specifications
needed for these tests. A third area is in disease prediction tests, which are being used to
persuade patients to make behavioral and lifestyle changes to avert them. Research in the
interpretation, use and the actual impact of that information on the intended outcome is critically
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important in the current heath care environment where resource prioritization must be supported
by data.
Clinicians’ knowledge and use of imprecision information is also an important topic for
developing clinical laboratory policy. Laboratory guidelines exist that articulate the
determination and reporting of imprecision with laboratory test results (CLSI C51A, 2011& IS0,
2012). In this study, it was shown that most changed decisions occurred when respondents
viewed results with imprecision after having viewed the same results without it. Further, the
most frequent response to the question of whether or not respondents wanted imprecision
information with laboratory test results was negative. It is currently mandated that test
imprecision information be available on request, and it is anticipated that future guidance will
require it. Standardization of how it is to be calculated and portrayed; and an understanding of
how users of the information will respond have not been studied. Further research to help guide
policy in this area is warranted.
Another area for future research is in methods development for the value of laboratory test
information analyses. The value of the HCV VL test information at the 12-week decision point
for triple combination therapy was determined through a decision analytic model evaluating the
monetary value of the information provided for that specific decision. Typically, health
economic analyses examine the extension of life or increased quality of life facilitated though
service or therapeutic interventions where incremental cost effectiveness ratios are measured and
compared. When applied to evaluate diagnostic tests, these methods presume that the primary
intended use of the diagnostic test is to extend life and quality. While those are the ultimate
outcomes, evaluating diagnostic information in this manner and comparing its contribution to
interventions and services with direct impact on them, can obscure the primary contribution of
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the diagnostic test. Examining the value of the test information that directs a decision along that
ultimate path may more clearly represent the contribution of the laboratory test. The analysis
presented in this study demonstrated this strategy and is one way the value of the test result could
be calculated. Development of the decision analytic model revealed several issues to be
considered such as: the required complexity of the model, the aspects of the outcome to be
measured, the appropriate time horizon of the model, the representation of actual decisions made
by users, and the impact of decisions made as a result of incorrect results.
The value of information is a concept already gaining use in clinical trial decisions for
extending or truncating arms of trials, determining the value of additional research, and adding
different indications (Meltzer, Hoomans, Chung, & Basu, 2011). Though the value of
information in a decision path can be calculated, it has not been used as a tool to measure or
compare laboratory tests as was presented here. The field of companion diagnostics is growing,
where more laboratory tests will have direct roles in deciding treatment paths. Further
development and consideration of this type of analysis will be useful to guide investment in the
diagnostic tests that will be necessary to realize personalized medicine. Interdisciplinary work is
critical to define the acceptable perspective and scope of economic analyses specifically relevant
to clinical laboratory diagnostics. Information derived from such analyses may help support
policy decisions needed to make available those diagnostics for which clinical and economic
utility can be demonstrated.
The predicted economic burden of HCV disease has catalyzed a strong pipeline of HCV
therapeutics currently in trials (Cox, 2013). Health economic literature on the cost effectiveness
of new therapeutics is now available shortly after their approval for use (Camma et al., 2012).
However, there are no economic analyses for the laboratory tests which are integral to the

134

clinical trials and which determine the efficacy of the drugs; the same tests that will be used to
triage patients to therapies and manage their therapy for response, compliance and drug
resistance. As new therapies in hepatitis C and hepatitis B are developed, the viral load assays
will be critical in assessing outcomes and then managing patients. Knowing the technical
limitations of the assays only answers part of the question of their clinical utility. Whether or not
clinicians accurately account for those technical limitations when using the information is also
important. To be able to communicate the value that those assays bring to patient management
decisions will also help secure development support and future access to these tests for the
patients who need them.
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Appendix A: HCV VL Survey

Text of Survey: HCV-1 Triple Combination Therapy- Incivek.
Consent
We are conducting a study of laboratory tests and their impact on medical decisions. If you are
willing to participate, we would like you to complete a brief, confidential survey. The principal
investigator on this survey is William Korzun, PhD, Associate Professor, Department of Clinical
Laboratory Sciences, Virginia Commonwealth University.
Time Required: We expect the survey will take less than 10 minutes.
Risks: This is a confidential, individual based survey. There are no reasonably foreseeable risks
or discomforts involved in taking part in this survey.
Compensation: There is no compensation for completing this survey. However if you would like
a summary of the results, please send a separate email with the title “HCV Survey Summary” to
madejrm@mymail.vcu.edu. A summary will be sent to you in 2013.
Confidentiality: Your responses are anonymous and you cannot be identified. Individual
responses to the survey questions will be kept confidential, and the output of the study will be
based on aggregation of the data collected from participants.
Participation: In the event you choose not to participate, you will not be penalized.
Study contact for questions: If you have questions, concerns, or complaints, please feel free to
email Dr. William Korzun:
WJKORZUN@VCU.EDU or Roberta Madej at madejrm@mymail.vcu.edu.
If you have any questions about your rights as a participant in this study, you may contact:
Office for Research
Virginia Commonwealth University
800 East Leigh Street, Suite 113
P.O. Box 980568
Richmond, VA 23298
To proceed with the survey please, choose “I consent and agree to participate”. If you do not
wish to take the survey, please choose “I do not wish to take this survey”.
Thank you for your time.
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Please choose one of the following:
○ I consent and agree to participate
○ I do not wish to take this survey
Introduction: HCV Triple Combination Therapy with Incivek (Telaprevir)
Welcome to the Survey. Thank you for your participation. There are no correct or incorrect
answers. The best estimate of what your decision would be in the following scenario is
requested.
The purpose of this survey is to evaluate responses to quantitative lab test results presented in
different ways by the clinical laboratory, using quantitative HCV RNA (HCV viral load) as a
model. You will be presented with a description of a patient followed by laboratory results and
will be asked to choose the responses closest to what your decisions would be for each result
presented. The results will be presented to you twice – each in a different way.
The decision for this “patient” is the treatment management decision made at Treatment Week
(TW) 12 for patients with HCV genotype 1 disease who have been on triple combination therapy
with Incivek (telaprevir), peginterferon alpha and ribavirin therapy. According to the AASLD
guidelines published in October 2011, the recommended course is to treat with the three drugs
for 12 weeks, then to continue with peginterferon alfa and ribavirin for an additional 12- 36
weeks, or discontinue all therapy. Important to this decision are the results of quantitative HCV
Viral Load (HCV VL) testing at TW 12.
At the 12week decision point, the AASLD guidelines recommend the following:
“Patients without cirrhosis treated with telaprevir, peginterferon, and ribavirin, whose HCV RNA
level at weeks 4 and 12 is undetectable should be considered for a shortened duration of therapy
of 24 weeks (Class 2a, Level A).
Treatment with all three drugs (telaprevir, peginterferon alfa, and ribavirin) should be stopped if
the HCV RNA level is >1,000 IU/mL {3Log10 IU/ml} at treatment weeks 4 or 12 and/or
detectable at treatment week 24 (Class 2a, Level B).”
Ghany et al. (2011) Hepatology, 54, 1433-1444.
Description of case and results – Integers
Patient: middle aged with chronic HCV genotype 1a. No cirrhosis.
Your previously untreated (for HCV) patient has been on triple combination therapy for 12
weeks with: Incivek (telaprevir) 750mg three times a day, together with peg interferon alfa
weekly and weight based ribavirin. Over the 12 weeks your patient has experienced the
following side effects: nausea, moderate to severe fatigue, joint and muscle aches, irritability and
headaches. Hemoglobin has gone from 12.3 to 9.1 gm/dl. The patient is employed fulltime and
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has missed approximately 10 days of work in the last 12 weeks due to the fatigue, nausea and
headaches.
You are reviewing the Treatment Week 12 HCV viral load results in order to make a
decision regarding the continuing management of this patient. The quantitative HCV RNA
test result for this patient performed before the start of therapy (week zero, baseline) was
560,000 IU/ml.
Consider each of the following 12 week HCV RNA results individually with regards to
this patient. For each, please indicate what your most likely decision would be regarding
this patient’s therapy?
Continue Rx with
dual therapy
31,620 IU/ml
1,950 IU/ml
1,000 IU/ml
560 IU/ml
100 IU/ml

Discontinue Rx

○
○
○
○
○

○
○
○
○
○

Repeat the HCV viral
load test
○
○
○
○
○

Description of case and results – Integers with CI
Patient: middle aged with chronic HCV genotype 1a. No cirrhosis.
Your previously untreated (for HCV) patient has been on triple combination therapy for 12
weeks with: Incivek (telaprevir) 750mg three times a day, together with peg interferon alfa
weekly and weight based ribavirin. Over the 12 weeks your patient has experienced the
following side effects: nausea, moderate to severe fatigue, joint and muscle aches, irritability and
headaches. Hemoglobin has gone from 12.3 to 9.1 gm/dl. The patient is employed fulltime and
has missed approximately 10 days of work in the last 12 weeks due to the fatigue, nausea and
headaches.
You are reviewing the Treatment Week 12 HCV viral load results in order to make a
decision regarding the continuing management of this patient. The quantitative HCV RNA
test result for this patient performed before the start of therapy (week zero, baseline) was
560,000 IU/ml (95% CI: 286,000 - 1,107,000 IU/ml).
Consider each of the following 12 week HCV RNA results individually with regards to
this patient. For each, please indicate what your most likely decision would be regarding
this patient’s therapy?
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Continue Rx with
dual therapy
31,620 IU/ml (95% CI: 16,060
- 62,230
IU/ml)
1,950 IU/ml (95% CI: 990 3,800 IU/ml)
1,000 IU/ml (95% CI: 510 1,970 IU/ml)
560 IU/ml (95% CI: 290 1,110
IU/ml)
100 IU/ml (95% CI: 50 – 200
IU/ml)

Discontinue Rx

Repeat the HCV
viral load test

○

○

○

○

○

○

○

○

○

○

○

○

○

○

○

Question regarding the utility of the test results with CI
One set of test results you reviewed contained the measurement uncertainty of the
result expressed as the 95% confidence interval (CI). The test results with the 95%
confidence intervals:
○

Provided relevant added information to the test result.

○

Detracted from or confused the test result.

○

Neither added to nor detracted from the test result.

Participant demographics
Please answer the following questions regarding your professional demographics and practice.
Where do you currently practice/ work?
○

Africa

○

Australia/ New Zealand

○

Canada

○

Europe

○

Latin America/ South America

○

United States
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Do you manage the treatment of Hepatitis C patients?
○

Yes

○

No

HCV patient managing professionals (For those choosing “Yes” to the question “Do you
manage the treatment of HCV patients?)
Which of the following best describes your profession?
○

Physician

○

Physician Assistant

○

Nurse Practitioner

○

Nurse

○

Other (please specify)

How many YEARS have you been practicing medicine? _____
Approximately how many Hepatitis C patients do you see per MONTH? _____
Which most appropriately describes your practice field?
○

General Medicine

○

Internal Medicine

○

Infectious Diseases

○

Hepatology

○

Gastroenterology

○

Urology

○

Pathology

○

Family Medicine

○

Pediatrics
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○

Oncology

○

Other (please specify)

Please select the guidelines that you use when managing Hepatitis C patients (select
all that apply):
○

American Association for the Study of Liver Diseases (AASLD)

○

American College of Gastroenterology (ACG)

○

American Gastroenterological Association (AGA)

○

CDC

○

EASL

○

Information from the pharmaceutical company

○

Institutional guidelines

○

Other (please specify)

Would you like to receive the 95% confidence intervals of laboratory values reported with
patient results?
○

Yes

○

No

○

I already receive 95% confidence intervals from my testing laboratory

○

I don’t know

Do you use quantitative HCV RNA test results (HCV viral load tests) in the treatment
management of your patients with Hepatitis C?
○

Yes

○

No
(For “No”) Why not? ___
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( For “Yes” to the use of quantitative HCV RNA results) Do you send patients / samples to the
same testing laboratory for the pretreatment and 12 week quantitative HCV RNA ?
○

Sometimes,

○

Most of the time,

○

Not at all

○

It is not within my control

( For “Yes” to the use of quantitative HCV RNA results) Do you specify that the identical test
method be used for the pretreatment and 12 week quantitative HCV RNA tests?
○

Sometimes,

○

Most of the time,

○

Not at all

○

It is not within my control

( For “Yes” to the use of quantitative HCV RNA results) Please choose the type of HCV viral
load results that are closest to the test results you receive from your testing laboratory:
○

Integers (i.e. 1,000,000 IU/ml)

○

Log10 (i.e. 6.0 Log10 IU/ml)

○

Both integers and Log10 values are provided

○

I am not sure

Non HCV Managing professionals (For those choosing “No” to the question, “Do you manage
the treatment of HCV patients?)
Which of the following best describes your profession?
○

Physician

○

Pathologist

○

Non-Pathologist Laboratory Director
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○

Laboratory Professional (Non Pathologist/ Non Director)

○

Pharmacist

○

Other (please specify)

Thank you for the time that you have spent in taking this survey. If you would like a copy of
the results please send a separate email with the title “HCV Survey Summary” to
madejrm@mymail.vcu.edu.
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